Sexually Transmitted Infections Treatment Guidelines, 2021

Kimberly A Workowski, Laura H Bachmann, Philip A Chan, Christine M Johnston, Christina A Muzny, Ina Park, Hilary Reno, Jonathan M Zenilman, Gail A Bolan, Kimberly A Workowski, Laura H Bachmann, Philip A Chan, Christine M Johnston, Christina A Muzny, Ina Park, Hilary Reno, Jonathan M Zenilman, Gail A Bolan

Abstract

These guidelines for the treatment of persons who have or are at risk for sexually transmitted infections (STIs) were updated by CDC after consultation with professionals knowledgeable in the field of STIs who met in Atlanta, Georgia, June 11-14, 2019. The information in this report updates the 2015 guidelines. These guidelines discuss 1) updated recommendations for treatment of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis; 2) addition of metronidazole to the recommended treatment regimen for pelvic inflammatory disease; 3) alternative treatment options for bacterial vaginosis; 4) management of Mycoplasma genitalium; 5) human papillomavirus vaccine recommendations and counseling messages; 6) expanded risk factors for syphilis testing among pregnant women; 7) one-time testing for hepatitis C infection; 8) evaluation of men who have sex with men after sexual assault; and 9) two-step testing for serologic diagnosis of genital herpes simplex virus. Physicians and other health care providers can use these guidelines to assist in prevention and treatment of STIs.

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Christina Muzny reports other support from CDC, during the conduct of the study; grants from the National Institutes of Health/National Institute of Allergy and Infectious Diseases and Lupin Pharmaceuticals; personal fees from Lupin Pharmaceuticals, PhagoMed, Cepheid, and Beckton Dickinson; and personal fees and other support from Roche Diagnostics, Abbott Molecular, and BioFire Diagnostics, outside the submitted work. Hilary Reno reports grants from Hologic, outside the submitted work. Christine Johnston reports other support from CDC, during the conduct of the study; received research funding from Sanofi-Pasteur; royalties from UpToDate; and personal fees from MedPace, Gilead, AbbVie, and UpToDate, outside the submitted work.

Figures

FIGURE
FIGURE
Algorithm to evaluate the need for nonoccupational HIV postexposure prophylaxis among adult and adolescent survivors of sexual assault Abbreviation: PEP = postexposure prophylaxis.

References

    1. Workowski KA, Bolan GA; CDC. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015;64(No. RR-3).
    1. Barrow RY, Ahmed F, Bolan GA, Workowski KA. Recommendations for providing quality sexually transmitted diseases clinical services, 2020. MMWR Recomm Rep 2020;68(No. RR-5). 10.15585/mmwr.rr6805a1
    1. CDC. A guide to taking a sexual history. Atlanta, GA: US Department of Health and Human Services, CDC.
    1. Henderson JT, Senger CA, Henninger M, Bean SI, Redmond N, O’Connor EA. Behavioral counseling interventions to prevent sexually transmitted infections: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2020;324:682–99. 10.1001/jama.2020.10371
    1. Kamb ML, Fishbein M, Douglas JM Jr, et al.; Project RESPECT Study Group. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. JAMA 1998;280:1161–7. 10.1001/jama.280.13.1161
    1. Metsch LR, Feaster DJ, Gooden L, et al. Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial. JAMA 2013;310:1701–10. 10.1001/jama.2013.280034
    1. Brookmeyer KA, Hogben M, Kinsey J. The role of behavioral counseling in sexually transmitted disease prevention program settings. Sex Transm Dis 2016;43(Suppl 1):S102–12. 10.1097/OLQ.0000000000000327
    1. Patel P, Bush T, Mayer K, et al.; SUN Study Investigators. Routine brief risk-reduction counseling with biannual STD testing reduces STD incidence among HIV-infected men who have sex with men in care. Sex Transm Dis 2012;39:470–4. 10.1097/OLQ.0b013e31824b3110
    1. Warner L, Klausner JD, Rietmeijer CA, et al.; Safe in the City Study Group. Effect of a brief video intervention on incident infection among patients attending sexually transmitted disease clinics. PLoS Med 2008;5:e135. 10.1371/journal.pmed.0050135
    1. Mustanski B, Parsons JT, Sullivan PS, Madkins K, Rosenberg E, Swann G. Biomedical and behavioral outcomes of Keep It Up!: an ehealth HIV prevention program RCT. Am J Prev Med 2018;55:151–8. 10.1016/j.amepre.2018.04.026
    1. Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019;68:698–702. 10.15585/mmwr.mm6832a3
    1. Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018;67(No. RR-1). 10.15585/mmwr.rr6701a1
    1. Doshani M, Weng M, Moore KL, Romero JR, Nelson NP. Recommendations of the Advisory Committee on Immunization Practices for use of hepatitis A vaccine for persons experiencing homelessness. MMWR Morb Mortal Wkly Rep 2019;68:153–6. 10.15585/mmwr.mm6806a6
    1. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002;(1):CD003255. 10.1002/14651858.CD003255
    1. Giannou FK, Tsiara CG, Nikolopoulos GK, et al. Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples. Expert Rev Pharmacoecon Outcomes Res 2016;16:489–99. 10.1586/14737167.2016.1102635
    1. Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr 2015;68:337–44. 10.1097/QAI.0000000000000461
    1. Johnson WD, O’Leary A, Flores SA. Per-partner condom effectiveness against HIV for men who have sex with men. AIDS 2018;32:1499–505. 10.1097/QAD.0000000000001832
    1. Crosby RA, Charnigo RA, Weathers C, Caliendo AM, Shrier LA. Condom effectiveness against non-viral sexually transmitted infections: a prospective study using electronic daily diaries. Sex Transm Infect 2012;88:484–9. 10.1136/sextrans-2012-050618
    1. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004;82:454–61.
    1. Warner L, Stone KM, Macaluso M, Buehler JW, Austin HD. Condom use and risk of gonorrhea and chlamydia: a systematic review of design and measurement factors assessed in epidemiologic studies. Sex Transm Dis 2006;33:36–51. 10.1097/01.olq.0000187908.42622.fd
    1. Bernabe-Ortiz A, Carcamo CP, Scott JD, Hughes JP, Garcia PJ, Holmes KK. HBV infection in relation to consistent condom use: a population-based study in Peru. PLoS One 2011;6:e24721. 10.1371/journal.pone.0024721
    1. Ness RB, Hillier SL, Kip KE, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol 2004;104:761–9. 10.1097/01.AOG.0000139512.37582.17
    1. Martin IE, Gu W, Yang Y, Tsang RS. Macrolide resistance and molecular types of Treponema pallidum causing primary syphilis in Shanghai, China. Clin Infect Dis 2009;49:515–21. 10.1086/600878
    1. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006;354:2645–54. 10.1056/NEJMoa053284
    1. Bleeker MC, Hogewoning CJ, Voorhorst FJ, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer 2003;107:804–10. 10.1002/ijc.11473
    1. Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003;107:811–6. 10.1002/ijc.11474
    1. Koss CA, Dunne EF, Warner L. A systematic review of epidemiologic studies assessing condom use and risk of syphilis. Sex Transm Dis 2009;36:401–5. 10.1097/OLQ.0b013e3181a396eb
    1. Hernández-Romieu AC, Siegler AJ, Sullivan PS, Crosby R, Rosenberg ES. How often do condoms fail? A cross-sectional study exploring incomplete use of condoms, condom failures and other condom problems among black and white MSM in southern U.S.A. Sex Transm Infect 2014;90:602–7. 10.1136/sextrans-2014-051581
    1. D’Anna LH, Margolis AD, Warner L, et al.; Safe City Study Group. Condom use problems during anal sex among men who have sex with men (MSM): findings from the Safe in the City study. AIDS Care 2012;24:1028–38. 10.1080/09540121.2012.668285
    1. Steiner MJ, Cates W Jr, Warner L. The real problem with male condoms is nonuse. Sex Transm Dis 1999;26:459–62. 10.1097/00007435-199909000-00007
    1. Kowal D, Hatcher RA, Nelson AL, et al., eds. Contraceptive technology. 21st ed. Atlanta, GA: Managing Contraception; 2017.
    1. Gallo MF, Kilbourne-Brook M, Coffey PS. A review of the effectiveness and acceptability of the female condom for dual protection. Sex Health 2012;9:18–26. 10.1071/SH11037
    1. Mantell JE, Kelvin EA, Exner TM, Hoffman S, Needham S, Stein ZA. Anal use of the female condom: does uncertainty justify provider inaction? AIDS Care 2009;21:1185–94. 10.1080/09540120902730005
    1. Rosenberg MJ, Davidson AJ, Chen JH, Judson FN, Douglas JM. Barrier contraceptives and sexually transmitted diseases in women: a comparison of female-dependent methods and condoms. Am J Public Health 1992;82:669–74. 10.2105/AJPH.82.5.669
    1. de Bruyn G, Shiboski S, van der Straten A, et al.; MIRA Team. The effect of the vaginal diaphragm and lubricant gel on acquisition of HSV-2. Sex Transm Infect 2011;87:301–5. 10.1136/sti.2010.047142
    1. Ramjee G, van der Straten A, Chipato T, et al.; MIRA team. The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One 2008;3:e3488. 10.1371/journal.pone.0003488
    1. Lusti-Narasimhan M, Merialdi M, Holt B. Multipurpose prevention technologies: maximising positive synergies. BJOG 2014;121:251. 10.1111/1471-0528.12606
    1. Ahmed K, Baeten JM, Beksinska M, et al.; Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet 2019;394:303–13. 10.1016/S0140-6736(19)31288-7
    1. Young Holt B, Dellplain L, Creinin MD, Peine KJ, Romano J, Hemmerling A. A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV. Eur J Contracept Reprod Health Care 2018;23:326–34. 10.1080/13625187.2018.1508650
    1. Wilkinson D, Tholandi M, Ramjee G, Rutherford GW. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis 2002;2:613–7. 10.1016/S1473-3099(02)00396-1
    1. McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010;376:1329–37. 10.1016/S0140-6736(10)61086-0
    1. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1977–87. 10.1016/S0140-6736(08)61842-5
    1. Van Damme L, Govinden R, Mirembe FM, et al.; CS Study Group. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008;359:463–72. 10.1056/NEJMoa0707957
    1. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008;3:e1474. 10.1371/journal.pone.0001474
    1. Cottrell ML, Kashuba AD. Topical microbicides and HIV prevention in the female genital tract. J Clin Pharmacol 2014;54:603–15. 10.1002/jcph.292
    1. Abdool Karim SS, Abdool Karim Q, Kharsany ABM, et al.; CAPRISA 004 Trial Group. Tenofovir gel for the prevention of herpes simplex virus Type 2 infection. N Engl J Med 2015;373:530–9. 10.1056/NEJMoa1410649
    1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168–74. Erratum in: Science 2011;333:524. 10.1126/science.1193748
    1. Marrazzo JM, Ramjee G, Richardson BA, et al.; VOICE Study Team. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015;372:509–18. 10.1056/NEJMoa1402269
    1. Delany-Moretlwe S, Lombard C, Baron D, et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2018;18:1241–50. 10.1016/S1473-3099(18)30428-6
    1. Baeten JM, Palanee-Phillips T, Brown ER, et al.; MTN-020–ASPIRE Study Team. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med 2016;375:2121–32. 10.1056/NEJMoa1506110
    1. Nel A, van Niekerk N, Kapiga S, et al.; Ring Study Team. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med 2016;375:2133–43. 10.1056/NEJMoa1602046
    1. Cranston RD, Lama JR, Richardson BA, et al.; MTN-017 Protocol Team. MTN-017: a rectal phase 2 extended safety and acceptability study of tenofovir reduced-glycerin 1% gel. Clin Infect Dis 2017;64:614–20.
    1. Hooton TM, Roberts PL, Stamm WE. Effects of recent sexual activity and use of a diaphragm on the vaginal microflora. Clin Infect Dis 1994;19:274–8. 10.1093/clinids/19.2.274
    1. Fihn SD, Boyko EJ, Normand EH, et al. Association between use of spermicide-coated condoms and Escherichia coli urinary tract infection in young women. Am J Epidemiol 1996;144:512–20. 10.1093/oxfordjournals.aje.a008958
    1. Polis CB, Curtis KM, Hannaford PC, et al. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS 2016;30:2665–83. 10.1097/QAD.0000000000001228
    1. Kiweewa FM, Brown E, Mishra A, et al.; MTN-020/ASPIRE Study Team. Acquisition of sexually transmitted infections among women using a variety of contraceptive options: a prospective study among high-risk African women. J Int AIDS Soc 2019;22:e25257. 10.1002/jia2.25257
    1. McCarthy KJ, Gollub EL, Ralph L, van de Wijgert J, Jones HE. Hormonal contraceptives and the acquisition of sexually transmitted infections: an updated systematic review. Sex Transm Dis 2019;46:290–6. 10.1097/OLQ.0000000000000975
    1. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 2016;65(No. RR-3). 10.15585/mmwr.rr6503a1
    1. Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep 2016;65(No. RR-4). 10.15585/mmwr.rr6504a1
    1. Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod 2012;27:1994–2000. 10.1093/humrep/des140
    1. Shen J, Che Y, Showell E, Chen K, Cheng L. Interventions for emergency contraception. Cochrane Database Syst Rev 2019;1:CD001324.
    1. Marcell AV, Waks AB, Rutkow L, McKenna R, Rompalo A, Hogan MT. What do we know about males and emergency contraception? A synthesis of the literature. Perspect Sex Reprod Health 2012;44:184–93. 10.1363/4418412
    1. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007;369:657–66. 10.1016/S0140-6736(07)60313-4
    1. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007;369:643–56. 10.1016/S0140-6736(07)60312-2
    1. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005;2:e298. Erratum in: PLoS Med 2006;3:298. 10.1371/journal.pmed.0020298
    1. Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009;360:1298–309. 10.1056/NEJMoa0802556
    1. Auvert B, Sobngwi-Tambekou J, Cutler E, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 2009;199:14–9. 10.1086/595566
    1. Sobngwi-Tambekou J, Taljaard D, Lissouba P, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis 2009;199:958–64. 10.1086/597208
    1. Gray R, Kigozi G, Kong X, et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. AIDS 2012;26:609–15. 10.1097/QAD.0b013e3283504a3f
    1. Mehta SD, Moses S, Parker CB, Agot K, Maclean I, Bailey RC. Circumcision status and incident herpes simplex virus type 2 infection, genital ulcer disease, and HIV infection. AIDS 2012;26:1141–9. 10.1097/QAD.0b013e328352d116
    1. World Health Organization/UNAIDS. New data on male circumcision and HIV prevention: policy and programme implications [Internet]. Geneva, Switzerland: WHO/UNAIDS Technical Consultation on Male Circumcision and HIV Prevention: Research Implications for Policy and Programming; 2007.
    1. American Urological Association. Circumcision policy statement [Internet]. Linthicum, MD: American Urological Association; 2017.
    1. Yuan T, Fitzpatrick T, Ko NY, et al. Circumcision to prevent HIV and other sexually transmitted infections in men who have sex with men: a systematic review and meta-analysis of global data. Lancet Glob Health 2019;7:e436–47. 10.1016/S2214-109X(18)30567-9
    1. Grohskopf LA, Chillag KL, Gvetadze R, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr 2013;64:79–86. 10.1097/QAI.0b013e31828ece33
    1. Grant RM, Lama JR, Anderson PL, et al.; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587–99. 10.1056/NEJMoa1011205
    1. Baeten JM, Donnell D, Ndase P, et al.; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399–410. 10.1056/NEJMoa1108524
    1. Thigpen MC, Kebaabetswe PM, Paxton LA, et al.; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423–34. 10.1056/NEJMoa1110711
    1. Choopanya K, Martin M, Suntharasamai P, et al.; Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381:2083–90. 10.1016/S0140-6736(13)61127-7
    1. Molina JM, Charreau I, Spire B, et al.; ANRS IPERGAY Study Group. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV 2017;4:e402–10. 10.1016/S2352-3018(17)30089-9
    1. CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update: a clinical practice guideline. Atlanta, GA: US Department of Health and Human Services, CDC; 2018.
    1. Jones J, Weiss K, Mermin J, et al. Proportion of incident human immunodeficiency virus cases among men who have sex with men attributable to gonorrhea and chlamydia: a modeling analysis. Sex Transm Dis 2019;46:357–63. 10.1097/OLQ.0000000000000980
    1. Pathela P, Braunstein SL, Blank S, Schillinger JA. HIV incidence among men with and those without sexually transmitted rectal infections: estimates from matching against an HIV case registry. Clin Infect Dis 2013;57:1203–9. 10.1093/cid/cit437
    1. Pathela P, Braunstein SL, Blank S, Shepard C, Schillinger JA. The high risk of an HIV diagnosis following a diagnosis of syphilis: a population-level analysis of New York City men. Clin Infect Dis 2015;61:281–7. 10.1093/cid/civ289
    1. Chou R, Evans C, Hoverman A, et al. Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2019;321:2214–30. 10.1001/jama.2019.2591
    1. Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med 2016;176:75–84. 10.1001/jamainternmed.2015.4683
    1. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016;387:53–60. 10.1016/S0140-6736(15)00056-2
    1. Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis 2015;61:1601–3. 10.1093/cid/civ778
    1. Celum C, Wald A, Lingappa JR, et al.; Partners in Prevention HSV/HIV Transmission Study Team. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010;362:427–39. 10.1056/NEJMoa0904849
    1. Celum C, Wald A, Hughes J, et al.; HPTN 039 Protocol Team. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:2109–19. 10.1016/S0140-6736(08)60920-4
    1. Bolan RK, Beymer MR, Weiss RE, Flynn RP, Leibowitz AA, Klausner JD. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. Sex Transm Dis 2015;42:98–103. 10.1097/OLQ.0000000000000216
    1. Grant JS, Stafylis C, Celum C, et al. Doxycycline prophylaxis for bacterial sexually transmitted infections. Clin Infect Dis 2020;70:1247–53. 10.1093/cid/ciz866
    1. Myer L, Kuhn L, Stein ZA, Wright TC Jr, Denny L. Intravaginal practices, bacterial vaginosis, and women’s susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis 2005;5:786–94. 10.1016/S1473-3099(05)70298-X
    1. Molina JM, Charreau I, Chidiac C, et al.; ANRS IPERGAY Study Group. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis 2018;18:308–17. 10.1016/S1473-3099(17)30725-9
    1. Cohen MS, Chen YQ, McCauley M, et al.; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493–505. 10.1056/NEJMoa1105243
    1. Rodger AJ, Cambiano V, Bruun T, et al.; PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 2016;316:171–81. 10.1001/jama.2016.5148
    1. Bavinton BR, Pinto AN, Phanuphak N, et al.; Opposites Attract Study Group. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV 2018;5:e438–47. 10.1016/S2352-3018(18)30132-2
    1. Rodger AJ, Cambiano V, Bruun T, et al.; PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet 2019;393:2428–38. 10.1016/S0140-6736(19)30418-0
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, AIDSinfo.
    1. Golden MR, Kerani RP, Stenger M, et al. Effect of expedited partner therapy (EPT) on chlamydial prevalence: the Washington State Community-Level Trial. Presented at the STD Prevention Conference, Minneapolis, MN; March 12–15, 2012.
    1. Philip SS, Yu X, Donnell D, Vittinghoff E, Buchbinder S. Serosorting is associated with a decreased risk of HIV seroconversion in the EXPLORE Study Cohort. PLoS One 2010;5:e12662. 10.1371/journal.pone.0012662
    1. Vallabhaneni S, Li X, Vittinghoff E, Donnell D, Pilcher CD, Buchbinder SP. Seroadaptive practices: association with HIV acquisition among HIV-negative men who have sex with men. PLoS One 2012;7:e45718. 10.1371/journal.pone.0045718
    1. Jin F, Prestage GP, Templeton DJ, et al. The impact of HIV seroadaptive behaviors on sexually transmissible infections in HIV-negative homosexual men in Sydney, Australia. Sex Transm Dis 2012;39:191–4. 10.1097/OLQ.0b013e3182401a2f
    1. Hotton AL, Gratzer B, Mehta SD. Association between serosorting and bacterial sexually transmitted infection among HIV-negative men who have sex with men at an urban lesbian, gay, bisexual, and transgender health center. Sex Transm Dis 2012;39:959–64. 10.1097/OLQ.0b013e31826e870d
    1. Anderson C, Gallo MF, Hylton-Kong T, et al. Randomized controlled trial on the effectiveness of counseling messages for avoiding unprotected sexual intercourse during sexually transmitted infection and reproductive tract infection treatment among female sexually transmitted infection clinic patients. Sex Transm Dis 2013;40:105–10. 10.1097/OLQ.0b013e31827938a1
    1. Golden MR, Hogben M, Handsfield HH, St Lawrence JS, Potterat JJ, Holmes KK. Partner notification for HIV and STD in the United States: low coverage for gonorrhea, chlamydial infection, and HIV. Sex Transm Dis 2003;30:490–6. 10.1097/00007435-200306000-00004
    1. Katz DA, Dombrowski JC, Kerani RP, et al. Integrating HIV testing as an outcome of STD partner services for men who have sex with men. AIDS Patient Care STDS 2016;30:208–14. 10.1089/apc.2016.0027
    1. Katz DA, Dombrowski JC, Barry M, Spellman D, Bell TR, Golden MR. STD partner services to monitor and promote HIV pre-exposure prophylaxis use among men who have sex with men. J Acquir Immune Defic Syndr 2019;80:533–41. 10.1097/QAI.0000000000001952
    1. Bocour A, Renaud TC, Udeagu CC, Shepard CW. HIV partner services are associated with timely linkage to HIV medical care. AIDS 2013;27:2961–3. 10.1097/QAD.0000000000000031
    1. Tesoriero JM, Johnson BL, Hart-Malloy R, et al. Improving retention in HIV care through New York’s expanded partner services Data-to-Care pilot. J Public Health Manag Pract 2017;23:255–63. 10.1097/PHH.0000000000000483
    1. Trelle S, Shang A, Nartey L, Cassell JA, Low N. Improved effectiveness of partner notification for patients with sexually transmitted infections: systematic review. BMJ 2007;334:354. 10.1136/bmj.39079.460741.7C
    1. CDC. Recommendations for partner services programs for HIV infection, syphilis, gonorrhea, and chlamydial infection. MMWR Recomm Rep 2008;57(No. RR-9).
    1. Thurman AR, Shain RN, Holden AE, Champion JD, Perdue ST, Piper JM. Partner notification of sexually transmitted infections: a large cohort of Mexican American and African American women. Sex Transm Dis 2008;35:136–40. 10.1097/OLQ.0b013e318151498f
    1. Kissinger PJ, Niccolai LM, Magnus M, et al. Partner notification for HIV and syphilis: effects on sexual behaviors and relationship stability. Sex Transm Dis 2003;30:75–82. 10.1097/00007435-200301000-00015
    1. Smith SG, Zhang X, Basile KC, et al. The National Intimate Partner and Sexual Violence Survey: 2015 data brief—updated release. Atlanta GA: US Department of Health and Human Services, CDC, National Center for Injury Prevention and Control; 2018.
    1. Wilson TE, Hogben M, Malka ES, et al. A randomized controlled trial for reducing risks for sexually transmitted infections through enhanced patient-based partner notification. Am J Public Health 2009;99(Suppl 1):S104–10. 10.2105/AJPH.2007.112128
    1. Yu YY, Frasure-Williams JA, Dunne EF, Bolan G, Markowitz L, Bauer HM. Chlamydia partner services for females in California family planning clinics. Sex Transm Dis 2011;38:913–8. 10.1097/OLQ.0b013e3182240366
    1. Mickiewicz T, Al-Tayyib A, Thrun M, Rietmeijer C. Implementation and effectiveness of an expedited partner therapy program in an urban clinic. Sex Transm Dis 2012;39:923–9. 10.1097/OLQ.0b013e3182756f20
    1. Kachur R, Strona FV, Kinsey J, Collins D. Introducing technology into partner services: a toolkit for programs. Atlanta, GA: US Department of Health and Human Services, CDC; 2015.
    1. Kachur R, Hall W, Coor A, Kinsey J, Collins D, Strona FV. The use of technology for sexually transmitted disease partner services in the United States: a structured review. Sex Transm Dis 2018;45:707–12. 10.1097/OLQ.0000000000000864
    1. Pellowski J, Mathews C, Kalichman MO, Dewing S, Lurie MN, Kalichman SC. Advancing partner notification through electronic communication technology: a review of acceptability and utilization research. J Health Commun 2016;21:629–37. 10.1080/10810730.2015.1128020
    1. Borchardt LN, Pickett ML, Tan KT, Visotcky AM, Drendel AL. Expedited partner therapy: pharmacist refusal of legal prescriptions. Sex Transm Dis 2018;45:350–3. 10.1097/OLQ.0000000000000751
    1. Qin JZ, Diniz CP, Coleman JS. Pharmacy-level barriers to implementing expedited partner therapy in Baltimore, Maryland. Am J Obstet Gynecol 2018;218:504.e1–6. 10.1016/j.ajog.2018.01.036
    1. Schillinger J, Slutsker J, Tsang L, et al. Do prescriptions for expedited partner therapy get filled? Findings from a multi-jurisdictional evaluation, US, 2017–2018. Sex Transm Infect 2019;95(Suppl 1):A107.
    1. Slutsker JS, Tsang LB, Schillinger JA. Do prescriptions for expedited partner therapy for chlamydia get filled? Findings from a multi-jurisdictional evaluation, United States, 2017–2019. Sex Transm Dis 2020;47:376–82. 10.1097/OLQ.0000000000001163
    1. Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005;352:676–85. 10.1056/NEJMoa041681
    1. Schillinger JA, Kissinger P, Calvet H, et al. Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial. Sex Transm Dis 2003;30:49–56. 10.1097/00007435-200301000-00011
    1. Kissinger P, Mohammed H, Richardson-Alston G, et al. Patient-delivered partner treatment for male urethritis: a randomized, controlled trial. Clin Infect Dis 2005;41:623–9. 10.1086/432476
    1. Cameron ST, Glasier A, Scott G, et al. Novel interventions to reduce re-infection in women with chlamydia: a randomized controlled trial. Hum Reprod 2009;24:888–95. 10.1093/humrep/den475
    1. Kissinger P, Schmidt N, Mohammed H, et al. Patient-delivered partner treatment for Trichomonas vaginalis infection: a randomized controlled trial. Sex Transm Dis 2006;33:445–50. 10.1097/01.olq.0000204511.84485.4c
    1. Schwebke JR, Desmond RA. A randomized controlled trial of partner notification methods for prevention of trichomoniasis in women. Sex Transm Dis 2010;37:392–6. 10.1097/OLQ.0b013e3181dd1691
    1. Stephens SC, Bernstein KT, Katz MH, Philip SS, Klausner JD. The effectiveness of patient-delivered partner therapy and chlamydial and gonococcal reinfection in San Francisco. Sex Transm Dis 2010;37:525–9. 10.1097/OLQ.0b013e3181d8920f
    1. Kerani RP, Fleming M, DeYoung B, Golden MR. A randomized, controlled trial of inSPOT and patient-delivered partner therapy for gonorrhea and chlamydial infection among men who have sex with men. Sex Transm Dis 2011;38:941–6. 10.1097/OLQ.0b013e318223fcbc
    1. Stekler J, Bachmann L, Brotman RM, et al. Concurrent sexually transmitted infections (STIs) in sex partners of patients with selected STIs: implications for patient-delivered partner therapy. Clin Infect Dis 2005;40:787–93. 10.1086/428043
    1. McNulty A, Teh MF, Freedman E. Patient delivered partner therapy for chlamydial infection—what would be missed? Sex Transm Dis 2008;35:834–6. 10.1097/OLQ.0b013e3181761993
    1. Schillinger J, Jamison K, Slutsker J, et al. STI and HIV infections among MSM reporting exposure to gonorrhea or chlamydia: implications for expedited partner therapy. Sex Transm Infect 2019;95(Suppl 1):A107. 10.1136/sextrans-2019-sti.272
    1. Turner AN, Feldblum PJ, Hoke TH. Baseline infection with a sexually transmitted disease is highly predictive of reinfection during follow-up in Malagasy sex workers. Sex Transm Dis 2010;37:559–62. 10.1097/OLQ.0b013e3181d70a03
    1. Peterman TA, Tian LH, Metcalf CA, et al.; RESPECT-2 Study Group. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: a case for rescreening. Ann Intern Med 2006;145:564–72. 10.7326/0003-4819-145-8-200610170-00005
    1. Owens DK, Davidson KW, Krist AH, et al.; US Preventive Services Task Force. Screening for HIV infection: US Preventive Services Task Force recommendation statement. JAMA 2019;321:2326–36. 10.1001/jama.2019.6587
    1. Health and Human Services Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, AIDSinfo; 2014.
    1. Committee on Obstetric Practice HIV Expert Work Group. ACOG Committee opinion no. 752: prenatal and perinatal human immunodeficiency virus testing. Obstet Gynecol 2018;132:e138–42. 10.1097/AOG.0000000000002825
    1. CDC. Sexually transmitted disease surveillance 2019 [Internet]. Atlanta GA: US Department of Health and Human Services, CDC; 2021.
    1. Warren HP, Cramer R, Kidd S, Leichliter JS. State requirements for prenatal syphilis screening in the United States, 2016. Matern Child Health J 2018;22:1227–32. 10.1007/s10995-018-2592-0
    1. Lin JS, Eder M, Bean S. Screening for syphilis infection in pregnant women: a reaffirmation evidence update for the U.S. Preventive Services Task Force. Evidence Synthesis No. 167. AHRQ Publication No. 18-05238-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2018.
    1. Neblett Fanfair R, Tao G, Owusu-Edusei K, Gift TL, Bernstein KT. Suboptimal prenatal syphilis testing among commercially insured women in the United States, 2013. Sex Transm Dis 2017;44:219–21. 10.1097/OLQ.0000000000000569
    1. Patel CG, Huppert JS, Tao G. Provider adherence to syphilis testing recommendations for women delivering a stillbirth. Sex Transm Dis 2017;44:685–90. 10.1097/OLQ.0000000000000656
    1. Matthias JM, Rahman MM, Newman DR, Peterman TA. Effectiveness of prenatal screening and treatment to prevent congenital syphilis, Louisiana and Florida, 2013–2014. Sex Transm Dis 2017;44:498–502. 10.1097/OLQ.0000000000000638
    1. Albright CM, Emerson JB, Werner EF, Hughes BL. Third-trimester prenatal syphilis screening: a cost-effectiveness analysis. Obstet Gynecol 2015;126:479–85. 10.1097/AOG.0000000000000997
    1. Owens DK, Davidson KW, Krist AH, et al.; US Preventive Services Task Force. Screening for hepatitis B virus infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. JAMA 2019;322:349–54. 10.1001/jama.2019.9365
    1. LeFevre ML; US Preventive Services Task Force. Screening for chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161:902–10. 10.7326/M14-1981
    1. Watts T, Stockman L, Martin J, Guilfoyle S, Vergeront JM. Increased risk for mother-to-infant transmission of hepatitis C virus among Medicaid recipients—Wisconsin, 2011–2015. MMWR Morb Mortal Wkly Rep 2017;66:1136–9. 10.15585/mmwr.mm6642a3
    1. Patrick SW, Bauer AM, Warren MD, Jones TF, Wester C. Hepatitis C virus infection among women giving birth—Tennessee and United States, 2009–2014. MMWR Morb Mortal Wkly Rep 2017;66:470–3. 10.15585/mmwr.mm6618a3
    1. Chappell CA, Hillier SL, Crowe D, Meyn LA, Bogen DL, Krans EE. Hepatitis C virus screening among children exposed during pregnancy. Pediatrics 2018;141:e20173273. 10.1542/peds.2017-3273
    1. Gowda C, Kennedy S, Glover C, Prasad MR, Wang L, Honegger JR. Enhanced identification of maternal hepatitis C virus infection using existing public health surveillance systems. Paediatr Perinat Epidemiol 2018;32:401–10. 10.1111/ppe.12481
    1. Waruingi W, Mhanna MJ, Kumar D, Abughali N. Hepatitis C virus universal screening versus risk based selective screening during pregnancy. J Neonatal Perinatal Med 2015;8:371–8. 10.3233/NPM-15915024
    1. Boudova S, Mark K, El-Kamary SS. Risk-based hepatitis C screening in pregnancy is less reliable than universal screening: a retrospective chart review. Open Forum Infect Dis 2018;5:ofy043. 10.1093/ofid/ofy043
    1. Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC recommendations for hepatitis C screening among adults—United States, 2020. MMWR Recomm Rep 2020;69(No. RR-2). 10.15585/mmwr.rr6902a1
    1. Moyer VA; US Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159:349–57. 10.7326/0003-4819-159-5-201309030-00672
    1. Perkins RB, Guido RS, Castle PE, et al.; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2020;24:102–31. 10.1097/LGT.0000000000000525
    1. Owens DK, Davidson KW, Krist AH, et al.; US Preventive Services Task Force. Screening for bacterial vaginosis in pregnant persons to prevent preterm delivery: US Preventive Services Task Force recommendation statement. JAMA 2020;323:1286–92. 10.1001/jama.2020.2684
    1. American Academy of Pediatrics Committee on Fetus and Newborn; American College of Obstetrics and Gynecology Committee on Obstetric Practice. Guidelines for perinatal care. Kilpatrick SJ, Papile LA, eds. 8th ed. Itasca, IL: American Academy of Pediatrics and Washington, DC: American College of Obstetrics and Gynecology; 2017.
    1. Curry SJ, Krist AH, Owens DK, et al.; US Preventive Services Task Force. Screening for syphilis infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. JAMA 2018;320:911–7. 10.1001/jama.2018.11785
    1. Bibbins-Domingo K, Grossman DC, Curry SJ, et al.; US Preventive Services Task Force. Serologic screening for genital herpes infection: US Preventive Services Task Force recommendation statement. JAMA 2016;316:2525–30. 10.1001/jama.2016.16776
    1. Selph SS, Bougatsos C, Dana T, Grusing S, Chou R. Screening for HIV infection in pregnant women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2019;321:2349–60. 10.1001/jama.2019.2593
    1. Henderson JT, Webber EM, Bean SI. Screening for Hepatitis B infection in pregnant women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2019;322:360–2. 10.1001/jama.2019.1655
    1. Leichliter JS, Dittus PJ, Copen CE, Aral SO. Trends in factors indicating increased risk for STI among key subpopulations in the United States, 2002–2015. Sex Transm Infect 2020;96:121–3. 10.1136/sextrans-2019-054045
    1. Committee on Adolescence; Council on Clinical and Information Technology; Blythe MJ, Del Beccaro MA. Standards for health information technology to ensure adolescent privacy. Pediatrics 2012;130:987–90. 10.1542/peds.2012-2580
    1. ACOG Committee Opinion no. 599: Committee on Adolescent Health Care: adolescent confidentiality and electronic health records. Obstet Gynecol 2014;123:1148–50. 10.1097/01.AOG.0000446825.08715.98
    1. Thompson LA, Martinko T, Budd P, Mercado R, Schentrup AM. Meaningful use of a confidential adolescent patient portal. J Adolesc Health 2016;58:134–40. 10.1016/j.jadohealth.2015.10.015
    1. Society for Adolescent Health and Medicine; American Academy of Pediatrics. Confidentiality protections for adolescents and young adults in the health care billing and insurance claims process. J Adolesc Health 2016;58:374–7. 10.1016/j.jadohealth.2015.12.009
    1. Bamberger DM, Graham G, Dennis L, Gerkovich MM. Extragenital gonorrhea and chlamydia among men and women according to type of sexual exposure. Sex Transm Dis 2019;46:329–34. 10.1097/OLQ.0000000000000967
    1. Chan PA, Robinette A, Montgomery M, et al. Extragenital infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae: a review of the literature. Infect Dis Obstet Gynecol 2016;2016:5758387. 10.1155/2016/5758387
    1. Owusu-Edusei K Jr, Hoover KW, Gift TL. Cost-effectiveness of opt-out chlamydia testing for high-risk young women in the U.S. Am J Prev Med 2016;51:216–24. 10.1016/j.amepre.2016.01.007
    1. DiClemente RJ, Sales JM, Danner F, Crosby RA. Association between sexually transmitted diseases and young adults’ self-reported abstinence. Pediatrics 2011;127:208–13. 10.1542/peds.2009-0892
    1. Curry SJ, Krist AH, Owens DK, et al.; US Preventive Services Task Force. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA 2018;320:674–86. 10.1001/jama.2018.10897
    1. Committee on Practice Bulletins—Gynecology. Practice bulletin no. 157: cervical cancer screening and prevention. Obstet Gynecol 2016;127:e1–20. 10.1097/AOG.0000000000001263
    1. Benard VB, Watson M, Castle PE, Saraiya M. Cervical carcinoma rates among young females in the United States. Obstet Gynecol 2012;120:1117–23. 10.1097/AOG.0b013e31826e4609
    1. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin 2020;70:321–46. 10.3322/caac.21628
    1. Owens DK, Davidson KW, Krist AH, et al.; US Preventive Services Task Force. Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement. JAMA 2019;321:2203–13. 10.1001/jama.2019.6390
    1. Mayer KH, Bekker LG, Stall R, Grulich AE, Colfax G, Lama JR. Comprehensive clinical care for men who have sex with men: an integrated approach. Lancet 2012;380:378–87. 10.1016/S0140-6736(12)60835-6
    1. Buchbinder SP, Vittinghoff E, Heagerty PJ, et al. Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr 2005;39:82–9. 10.1097/01.qai.0000134740.41585.f4
    1. Paz-Bailey G, Mendoza MC, Finlayson T, et al.; NHBS Study Group. Trends in condom use among MSM in the United States: the role of antiretroviral therapy and seroadaptive strategies. AIDS 2016;30:1985–90. 10.1097/QAD.0000000000001139
    1. Spicknall IH, Gift TL, Bernstein KT, Aral SO. Sexual networks and infection transmission networks among men who have sex with men as causes of disparity and targets of prevention. Sex Transm Infect 2017;93:307–8. 10.1136/sextrans-2016-052676
    1. Glick SN, Morris M, Foxman B, et al. A comparison of sexual behavior patterns among men who have sex with men and heterosexual men and women. J Acquir Immune Defic Syndr 2012;60:83–90. 10.1097/QAI.0b013e318247925e
    1. Goodreau SM, Golden MR. Biological and demographic causes of high HIV and sexually transmitted disease prevalence in men who have sex with men. Sex Transm Infect 2007;83:458–62. 10.1136/sti.2007.025627
    1. Chew Ng RA, Samuel MC, Lo T, et al. Sex, drugs (methamphetamines), and the Internet: increasing syphilis among men who have sex with men in California, 2004–2008. Am J Public Health 2013;103:1450–6. 10.2105/AJPH.2012.300808
    1. Bernstein KT, Stephens SC, Strona FV, Kohn RP, Philip SS. Epidemiologic characteristics of an ongoing syphilis epidemic among men who have sex with men, San Francisco. Sex Transm Dis 2013;40:11–7. 10.1097/OLQ.0b013e31827763ea
    1. Cohen SE, Chew Ng RA, Katz KA, et al. Repeat syphilis among men who have sex with men in California, 2002–2006: implications for syphilis elimination efforts. Am J Public Health 2012;102:e1–8. 10.2105/AJPH.2011.300383
    1. Kirkcaldy RD, Harvey A, Papp JR, et al. Neisseria gonorrhoeae antimicrobial susceptibility surveillance—The Gonococcal Isolate Surveillance Project, 27 sites, United States, 2014. MMWR Surveill Summ 2016;65(No. SS-7). 10.15585/mmwr.ss6507a1
    1. Kirkcaldy RD, Zaidi A, Hook EW 3rd, et al. Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005–2010. Ann Intern Med 2013;158:321–8. 10.7326/0003-4819-158-5-201303050-00004
    1. Newman LM, Dowell D, Bernstein K, et al. A tale of two gonorrhea epidemics: results from the STD Surveillance Network. Public Health Rep 2012;127:282–92. 10.1177/003335491212700308
    1. Hess KL, Hu X, Lansky A, Mermin J, Hall HI. Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol 2017;27:238–43. 10.1016/j.annepidem.2017.02.003
    1. Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: a systematic review. AIDS 2014;28:1509–19. 10.1097/QAD.0000000000000298
    1. Koblin BA, Husnik MJ, Colfax G, et al. Risk factors for HIV infection among men who have sex with men. AIDS 2006;20:731–9. 10.1097/01.aids.0000216374.61442.55
    1. Ackers ML, Greenberg AE, Lin CY, et al. High and persistent HIV seroincidence in men who have sex with men across 47 U.S. cities. PLoS One 2012;7:e34972. 10.1371/journal.pone.0034972
    1. Zetola NM, Bernstein KT, Wong E, Louie B, Klausner JD. Exploring the relationship between sexually transmitted diseases and HIV acquisition by using different study designs. J Acquir Immune Defic Syndr 2009;50:546–51. 10.1097/QAI.0b013e318195bd2b
    1. Solomon MM, Mayer KH, Glidden DV, et al.; iPrEx Study Team. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial. Clin Infect Dis 2014;59:1020–6. 10.1093/cid/ciu450
    1. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999;75:3–17. 10.1136/sti.75.1.3
    1. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006;20:73–83. 10.1097/01.aids.0000198081.09337.a7
    1. Reynolds SJ, Risbud AR, Shepherd ME, et al. High rates of syphilis among STI patients are contributing to the spread of HIV-1 in India. Sex Transm Infect 2006;82:121–6. 10.1136/sti.2005.015040
    1. Hoots BE, Wejnert C, Martin A, et al.; NHBS Study Group. Undisclosed HIV infection among MSM in a behavioral surveillance study. AIDS 2019;33:913–8. 10.1097/QAD.0000000000002147
    1. Dolling DI, Desai M, McOwan A, et al.; PROUD Study Group. An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis. Trials 2016;17:163. 10.1186/s13063-016-1286-4
    1. Oldenburg CE, Nunn AS, Montgomery M, et al. Behavioral changes following uptake of HIV pre-exposure prophylaxis among men who have sex with men in a clinical setting. AIDS Behav 2018;22:1075–9. 10.1007/s10461-017-1701-1
    1. Montaño MA, Dombrowski JC, Dasgupta S, et al. Changes in sexual behavior and STI diagnoses among MSM initiating PrEP in a clinic setting. AIDS Behav 2019;23:548–55. 10.1007/s10461-018-2252-9
    1. Traeger MW, Schroeder SE, Wright EJ, et al. Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis. Clin Infect Dis 2018;67:676–86. 10.1093/cid/ciy182
    1. Jenness SM, Weiss KM, Goodreau SM, et al. Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study. Clin Infect Dis 2017;65:712–8. 10.1093/cid/cix439
    1. Tang EC, Vittinghoff E, Philip SS, et al. Quarterly screening optimizes detection of sexually transmitted infections when prescribing HIV preexposure prophylaxis. AIDS 2020;34:1181–6. 10.1097/QAD.0000000000002522
    1. Barbee LA, Khosropour CM, Dombrowksi JC, Golden MR. New human immunodeficiency virus diagnosis independently associated with rectal gonorrhea and chlamydia in men who have sex with men. Sex Transm Dis 2017;44:385–9. 10.1097/OLQ.0000000000000614
    1. Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. J Acquir Immune Defic Syndr 2010;53:537–43. 10.1097/QAI.0b013e3181c3ef29
    1. Barbee LA, Khosropour CM, Dombrowski JC, Manhart LE, Golden MR. An estimate of the proportion of symptomatic gonococcal, chlamydial and non-gonococcal non-chlamydial urethritis attributable to oral sex among men who have sex with men: a case-control study. Sex Transm Infect 2016;92:155–60. 10.1136/sextrans-2015-052214
    1. Lafferty WE, Hughes JP, Handsfield HH. Sexually transmitted diseases in men who have sex with men. Acquisition of gonorrhea and nongonococcal urethritis by fellatio and implications for STD/HIV prevention. Sex Transm Dis 1997;24:272–8. 10.1097/00007435-199705000-00007
    1. Bernstein KT, Stephens SC, Barry PM, et al. Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the oropharynx to the urethra among men who have sex with men. Clin Infect Dis 2009;49:1793–7. 10.1086/648427
    1. Patton ME, Kidd S, Llata E, et al. Extragenital gonorrhea and chlamydia testing and infection among men who have sex with men—STD Surveillance Network, United States, 2010–2012. Clin Infect Dis 2014;58:1564–70. 10.1093/cid/ciu184
    1. Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis 2005;41:67–74. 10.1086/430704
    1. Koedijk FD, van Bergen JE, Dukers-Muijrers NH, van Leeuwen AP, Hoebe CJ, van der Sande MA; Dutch STI centres. The value of testing multiple anatomic sites for gonorrhoea and chlamydia in sexually transmitted infection centres in the Netherlands, 2006–2010. Int J STD AIDS 2012;23:626–31. 10.1258/ijsa.2012.011378
    1. Barbee LA, Dombrowski JC, Kerani R, Golden MR. Effect of nucleic acid amplification testing on detection of extragenital gonorrhea and chlamydial infections in men who have sex with men sexually transmitted disease clinic patients. Sex Transm Dis 2014;41:168–72. 10.1097/OLQ.0000000000000093
    1. Danby CS, Cosentino LA, Rabe LK, et al. Patterns of extragenital chlamydia and gonorrhea in women and men who have sex with men reporting a history of receptive anal intercourse. Sex Transm Dis 2016;43:105–9. 10.1097/OLQ.0000000000000384
    1. van der Helm JJ, Hoebe CJ, van Rooijen MS, et al. High performance and acceptability of self-collected rectal swabs for diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men and women. Sex Transm Dis 2009;36:493–7. 10.1097/OLQ.0b013e3181a44b8c
    1. Alexander S, Ison C, Parry J, et al.; Brighton Home Sampling Kits Steering Group. Self-taken pharyngeal and rectal swabs are appropriate for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in asymptomatic men who have sex with men. Sex Transm Infect 2008;84:488–92. 10.1136/sti.2008.031443
    1. Freeman AH, Bernstein KT, Kohn RP, Philip S, Rauch LM, Klausner JD. Evaluation of self-collected versus clinician-collected swabs for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae pharyngeal infection among men who have sex with men. Sex Transm Dis 2011;38:1036–9. 10.1097/OLQ.0b013e318227713e
    1. Chesson HW, Bernstein KT, Gift TL, Marcus JL, Pipkin S, Kent CK. The cost-effectiveness of screening men who have sex with men for rectal chlamydial and gonococcal infection to prevent HIV Infection. Sex Transm Dis 2013;40:366–71. 10.1097/OLQ.0b013e318284e544
    1. Jenness SM, Weiss KM, Prasad P, Zlotorzynska M, Sanchez T. Bacterial sexually transmitted infection screening rates by symptomatic status among men who have sex with men in the United States: a hierarchical Bayesian analysis. Sex Transm Dis 2019;46:25–30. 10.1097/OLQ.0000000000000896
    1. Hoover KW, Butler M, Workowski K, et al.; Evaluation Group for Adherence to STD and Hepatitis Screening. STD screening of HIV-infected MSM in HIV clinics. Sex Transm Dis 2010;37:771–6. 10.1097/OLQ.0b013e3181e50058
    1. de Voux A, Bernstein KT, Bradley H, Kirkcaldy RD, Tie Y, Shouse RL; Medical Monitoring Project. Syphilis testing among sexually active men who have sex with men and who are receiving medical care for human immunodeficiency virus in the United States: Medical Monitoring Project, 2013–2014. Clin Infect Dis 2019;68:934–9. 10.1093/cid/ciy571
    1. Gray RT, Hoare A, Prestage GP, Donovan B, Kaldor JM, Wilson DP. Frequent testing of highly sexually active gay men is required to control syphilis. Sex Transm Dis 2010;37:298–305. 10.1097/OLQ.0b013e3181ca3c0a
    1. Tuite AR, Fisman DN, Mishra S. Screen more or screen more often? Using mathematical models to inform syphilis control strategies. BMC Public Health 2013;13:606. 10.1186/1471-2458-13-606
    1. Tuite A, Fisman D. Go big or go home: impact of screening coverage on syphilis infection dynamics. Sex Transm Infect 2016;92:49–54. 10.1136/sextrans-2014-052001
    1. Tuite AR, Shaw S, Reimer JN, Ross CP, Fisman DN, Mishra S. Can enhanced screening of men with a history of prior syphilis infection stem the epidemic in men who have sex with men? A mathematical modelling study. Sex Transm Infect 2018;94:105–10. 10.1136/sextrans-2017-053201
    1. Raifman JR, Gebo KA, Mathews WC, et al.; HIV Research Network. Gonorrhea and chlamydia case detection increased when testing increased in a multisite US HIV cohort, 2004–2014. J Acquir Immune Defic Syndr 2017;76:409–16. 10.1097/QAI.0000000000001514
    1. Barbee LA, Dhanireddy S, Tat SA, Marrazzo JM. Barriers to bacterial sexually transmitted infection testing of HIV-infected men who have sex with men engaged in HIV primary care. Sex Transm Dis 2015;42:590–4. 10.1097/OLQ.0000000000000320
    1. McMillan A, Young H, Moyes A. Rectal gonorrhoea in homosexual men: source of infection. Int J STD AIDS 2000;11:284–7. 10.1177/095646240001100502
    1. Chow EP, Cornelisse VJ, Read TR, Chen MY, Bradshaw CS, Fairley CK. Saliva use in sex: associations with use of smartphone dating applications in men who have sex with men. Int J STD AIDS 2018;29:362–6. 10.1177/0956462417727669
    1. Cornelisse VJ, Priest D, Fairley CK, et al. The frequency of kissing as part of sexual activity differs depending on how men meet their male casual sexual partners. Int J STD AIDS 2018;29:598–602. 10.1177/0956462417748717
    1. Krist AH, Davidson KW, Mangione CM, et al.; US Preventive Services Task Force. Screening for hepatitis B virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA 2020;324:2415–22. 10.1001/jama.2020.22980
    1. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 2010;52:1497–505. 10.1002/hep.23808
    1. Wandeler G, Gsponer T, Bregenzer A, et al.; Swiss HIV Cohort Study. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis 2012;55:1408–16. 10.1093/cid/cis694
    1. Garg S, Taylor LE, Grasso C, Mayer KH. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. Clin Infect Dis 2013;56:1480–7. 10.1093/cid/cit054
    1. Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009;23:F1–7. 10.1097/QAD.0b013e32832e5631
    1. Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis 2012;55:279–90. 10.1093/cid/cis382
    1. Taylor LE, DeLong AK, Maynard MA, et al. Acute hepatitis C virus in an HIV clinic: a screening strategy, risk factors, and perception of risk. AIDS Patient Care STDS 2011;25:571–7. 10.1089/apc.2011.0106
    1. Kaul R, Kimani J, Nagelkerke NJ, et al.; Kibera HIV Study Group. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 2004;291:2555–62. 10.1001/jama.291.21.2555
    1. Ong JJ, Baggaley RC, Wi TE, et al. Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure prophylaxis for the prevention of HIV infection: a systematic review and meta-analysis. JAMA Netw Open 2019;2:e1917134. 10.1001/jamanetworkopen.2019.17134
    1. Paz-Bailey G, Hoots BE, Xia M, Finlayson T, Prejean J, Purcell DW; NHBS Study Group. Trends in Internet use among men who have sex with men in the United States. J Acquir Immune Defic Syndr 2017;75(Suppl 3):S288–95. 10.1097/QAI.0000000000001404
    1. Badal HJ, Stryker JE, DeLuca N, Purcell DW. Swipe right: dating website and app use among men who have sex with men. AIDS Behav 2018;22:1265–72. 10.1007/s10461-017-1882-7
    1. Chan PA, Crowley C, Rose JS, et al. A network analysis of sexually transmitted diseases and online hookup sites among men who have sex with men. Sex Transm Dis 2018;45:462–8. 10.1097/OLQ.0000000000000784
    1. Beymer MR, Weiss RE, Bolan RK, et al. Sex on demand: geosocial networking phone apps and risk of sexually transmitted infections among a cross-sectional sample of men who have sex with men in Los Angeles County. Sex Transm Infect 2014;90:567–72. 10.1136/sextrans-2013-051494
    1. Medina MM, Crowley C, Montgomery MC, et al. Disclosure of HIV serostatus and pre-exposure prophylaxis use on internet hookup sites among men who have sex with men. AIDS Behav 2019;23:1681–8. 10.1007/s10461-018-2286-z
    1. Chan PA, Towey C, Poceta J, et al. Online hookup sites for meeting sexual partners among men who have sex with men in Rhode Island, 2013: a call for public health action. Public Health Rep 2016;131:264–71. 10.1177/003335491613100210
    1. Lampkin D, Crawley A, Lopez TP, Mejia CM, Yuen W, Levy V. Reaching suburban men who have sex with men for STD and HIV services through online social networking outreach: a public health approach. J Acquir Immune Defic Syndr 2016;72:73–8. 10.1097/QAI.0000000000000930
    1. Sun CJ, Stowers J, Miller C, Bachmann LH, Rhodes SD. Acceptability and feasibility of using established geosocial and sexual networking mobile applications to promote HIV and STD testing among men who have sex with men. AIDS Behav 2015;19:543–52. 10.1007/s10461-014-0942-5
    1. Dritz SK, Back AF. Letter: Shigella enteritis venereally transmitted. N Engl J Med 1974;291:1194. 10.1056/NEJM197411282912223
    1. Aragón TJ, Vugia DJ, Shallow S, et al. Case-control study of shigellosis in San Francisco: the role of sexual transmission and HIV infection. Clin Infect Dis 2007;44:327–34. 10.1086/510593
    1. Simms I, Field N, Jenkins C, et al. Intensified shigellosis epidemic associated with sexual transmission in men who have sex with men—Shigella flexneri and S. sonnei in England, 2004 to end of February 2015. Euro Surveill 2015;20:21097. 10.2807/1560-7917.ES2015.20.15.21097
    1. Gilbart VL, Simms I, Jenkins C, et al. Sex, drugs and smart phone applications: findings from semistructured interviews with men who have sex with men diagnosed with Shigella flexneri 3a in England and Wales. Sex Transm Infect 2015;91:598–602. 10.1136/sextrans-2015-052014
    1. Narayan S, Galanis E; BC STEI Group. Are enteric infections sexually transmitted in British Columbia? Can Commun Dis Rep 2016;42:24–9. 10.14745/ccdr.v42i02a01
    1. Mohan K, Hibbert M, Rooney G, et al. What is the overlap between HIV and shigellosis epidemics in England: further evidence of MSM transmission? Sex Transm Infect 2018;94:67–71. 10.1136/sextrans-2016-052962
    1. Hughes G, Silalang P, Were J, et al. Prevalence and characteristics of gastrointestinal infections in men who have sex with men diagnosed with rectal chlamydia infection in the UK: an ‘unlinked anonymous’ cross-sectional study. Sex Transm Infect 2018;94:518–21. 10.1136/sextrans-2016-053057
    1. O’Sullivan B, Delpech V, Pontivivo G, et al. Shigellosis linked to sex venues, Australia. Emerg Infect Dis 2002;8:862–4. 10.3201/eid0808.010534
    1. Marcus U, Zucs P, Bremer V, et al. Shigellosis—a re-emerging sexually transmitted infection: outbreak in men having sex with men in Berlin. Int J STD AIDS 2004;15:533–7. 10.1258/0956462041558221
    1. Danila RN, Eikmeier DL, Robinson TJ, La Pointe A, DeVries AS. Two concurrent enteric disease outbreaks among men who have sex with men, Minneapolis-St Paul area. Clin Infect Dis 2014;59:987–9. 10.1093/cid/ciu478
    1. Okame M, Adachi E, Sato H, et al. Shigella sonnei outbreak among men who have sex with men in Tokyo. Jpn J Infect Dis 2012;65:277–8. 10.7883/yoken.65.277
    1. Wilmer A, Romney MG, Gustafson R, et al. Shigella flexneri serotype 1 infections in men who have sex with men in Vancouver, Canada. HIV Med 2015;16:168–75. 10.1111/hiv.12191
    1. CDC. Shigella sonnei outbreak among men who have sex with men—San Francisco, California, 2000–2001. MMWR Morb Mortal Wkly Rep 2001;50:922–6.
    1. Baer JT, Vugia DJ, Reingold AL, Aragon T, Angulo FJ, Bradford WZ. HIV infection as a risk factor for shigellosis. Emerg Infect Dis 1999;5:820–3. 10.3201/eid0506.990614
    1. Simms I, Gilbart VL, Byrne L, et al. Identification of verocytotoxin-producing Escherichia coli O117:H7 in men who have sex with men, England, November 2013 to August 2014. Euro Surveill 2014;19:20946. 10.2807/1560-7917.ES2014.19.43.20946
    1. Quinn TC, Goodell SE, Fennell C, et al. Infections with Campylobacter jejuni and Campylobacter-like organisms in homosexual men. Ann Intern Med 1984;101:187–92. 10.7326/0003-4819-101-2-187
    1. Gaudreau C, Pilon PA, Sylvestre J-L, Boucher F, Bekal S. Multidrug-resistant Campylobacter coli in men who have sex with men, Quebec, Canada, 2015. Emerg Infect Dis 2016;22:1661–3. 10.3201/eid2209.151695
    1. Chen GJ, Lin KY, Hung CC, Chang SC. Hepatitis A outbreak among men who have sex with men in a country of low endemicity of hepatitis A infection. J Infect Dis 2017;215:1339–40. 10.1093/infdis/jix123
    1. Lo YC, Ji DD, Hung CC. Prevalent and incident HIV diagnoses among Entamoeba histolytica-infected adult males: a changing epidemiology associated with sexual transmission—Taiwan, 2006–2013. PLoS Negl Trop Dis 2014;8:e3222. 10.1371/journal.pntd.0003222
    1. Stark D, van Hal SJ, Matthews G, Harkness J, Marriott D. Invasive amebiasis in men who have sex with men, Australia. Emerg Infect Dis 2008;14:1141–3. 10.3201/eid1407.080017
    1. Mitchell H, Hughes G. Recent epidemiology of sexually transmissible enteric infections in men who have sex with men. Curr Opin Infect Dis 2018;31:50–6. 10.1097/QCO.0000000000000423
    1. Weatherburn P, Hickson F, Reid D, Torres-Rueda S, Bourne A. Motivations and values associated with combining sex and illicit drugs (‘chemsex’) among gay men in South London: findings from a qualitative study. Sex Transm Infect 2017;93:203–6. 10.1136/sextrans-2016-052695
    1. Baker KS, Dallman TJ, Ashton PM, et al. Intercontinental dissemination of azithromycin-resistant shigellosis through sexual transmission: a cross-sectional study. Lancet Infect Dis 2015;15:913–21. 10.1016/S1473-3099(15)00002-X
    1. Bowen A, Grass J, Bicknese A, Campbell D, Hurd J, Kirkcaldy RD. Elevated risk for antimicrobial drug-resistant Shigella infection among men who have sex with men, United States, 2011–2015. Emerg Infect Dis 2016;22:1613–6. 10.3201/eid2209.160624
    1. Gaudreau C, Rodrigues-Coutlée S, Pilon PA, Coutlée F, Bekal S. Long-lasting outbreak of erythromycin- and ciprofloxacin-resistant Campylobacter jejuni subspecies jejuni from 2003 to 2013 in men who have sex with men, Quebec, Canada. Clin Infect Dis 2015;61:1549–52. 10.1093/cid/civ570
    1. Muzny CA, Sunesara IR, Martin DH, Mena LA. Sexually transmitted infections and risk behaviors among African American women who have sex with women: does sex with men make a difference? Sex Transm Dis 2011;38:1118–25. 10.1097/OLQ.0b013e31822e6179
    1. Eisenberg M. Differences in sexual risk behaviors between college students with same-sex and opposite-sex experience: results from a national survey. Arch Sex Behav 2001;30:575–89. 10.1023/A:1011958816438
    1. Koh AS, Gómez CA, Shade S, Rowley E. Sexual risk factors among self-identified lesbians, bisexual women, and heterosexual women accessing primary care settings. Sex Transm Dis 2005;32:563–9. 10.1097/01.olq.0000175417.17078.21
    1. Goodenow C, Szalacha LA, Robin LE, Westheimer K. Dimensions of sexual orientation and HIV-related risk among adolescent females: evidence from a statewide survey. Am J Public Health 2008;98:1051–8. 10.2105/AJPH.2005.080531
    1. Muzny CA, Austin EL, Harbison HS, Hook EW 3rd. Sexual partnership characteristics of African American women who have sex with women; impact on sexually transmitted infection risk. Sex Transm Dis 2014;41:611–7. 10.1097/OLQ.0000000000000194
    1. Riskind RG, Tornello SL, Younger BC, Patterson CJ. Sexual identity, partner gender, and sexual health among adolescent girls in the United States. Am J Public Health 2014;104:1957–63. 10.2105/AJPH.2014.302037
    1. Schick V, Rosenberger JG, Herbenick D, Reece M. Sexual behaviour and risk reduction strategies among a multinational sample of women who have sex with women. Sex Transm Infect 2012;88:407–12. 10.1136/sextrans-2011-050404
    1. Richters J, Prestage G, Schneider K, Clayton S. Do women use dental dams? Safer sex practices of lesbians and other women who have sex with women. Sex Health 2010;7:165–9. 10.1071/SH09072
    1. Rowen TS, Breyer BN, Lin TC, Li CS, Robertson PA, Shindel AW. Use of barrier protection for sexual activity among women who have sex with women. Int J Gynaecol Obstet 2013;120:42–5. 10.1016/j.ijgo.2012.08.011
    1. Lindley LL, Friedman DB, Struble C. Becoming visible: assessing the availability of online sexual health information for lesbians. Health Promot Pract 2012;13:472–80. 10.1177/1524839910390314
    1. Chetcuti N, Beltzer N, Methy N, Laborde C, Velter A, Bajos N; CSF Group. Preventive care’s forgotten women: life course, sexuality, and sexual health among homosexually and bisexually active women in France. J Sex Res 2013;50:587–97. 10.1080/00224499.2012.657264
    1. Logie CH, Navia D, Loutfy MR. Correlates of a lifetime history of sexually transmitted infections among women who have sex with women in Toronto, Canada: results from a cross-sectional internet-based survey. Sex Transm Infect 2015;91:278–83. 10.1136/sextrans-2014-051745
    1. 287. Muzny CA, Kapil R, Austin EL, Hook EW, Geisler WM. Lower sexually transmissible infection prevalence among lifetime exclusive women who have sex with women compared with women who have sex with women and men. Sex Health 2014;11:592–3. 10.1071/SH14181
    1. Muzny CA, Harbison HS, Pembleton ES, Austin EL. Sexual behaviors, perception of sexually transmitted infection risk, and practice of safe sex among southern African American women who have sex with women. Sex Transm Dis 2013;40:395–400. 10.1097/OLQ.0b013e31828caf34
    1. Przedworski JM, McAlpine DD, Karaca-Mandic P, VanKim NA. Health and health risks among sexual minority women: an examination of 3 subgroups. Am J Public Health 2014;104:1045–7. 10.2105/AJPH.2013.301733
    1. Brenick A, Romano K, Kegler C, Eaton LA. Understanding the influence of stigma and medical mistrust on engagement in routine healthcare among Black women who have sex with women. LGBT Health 2017;4:4–10. 10.1089/lgbt.2016.0083
    1. Fethers K, Marks C, Mindel A, Estcourt CS. Sexually transmitted infections and risk behaviours in women who have sex with women. Sex Transm Infect 2000;76:345–9. 10.1136/sti.76.5.345
    1. Marrazzo JM, Koutsky LA, Eschenbach DA, Agnew K, Stine K, Hillier SL. Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis 2002;185:1307–13. 10.1086/339884
    1. Kellock D, O’Mahony CP. Sexually acquired metronidazole-resistant trichomoniasis in a lesbian couple. Genitourin Med 1996;72:60–1. 10.1136/sti.72.1.60
    1. Muzny CA, Rivers CA, Mena LA, Schwebke JR. Genotypic characterization of Trichomonas vaginalis isolates among women who have sex with women in sexual partnerships. Sex Transm Dis 2012;39:556–8. 10.1097/OLQ.0b013e31824f1c49
    1. Chan SK, Thornton LR, Chronister KJ, et al.; CDC. Likely female-to-female sexual transmission of HIV—Texas, 2012. MMWR Morb Mortal Wkly Rep 2014;63:209–12.
    1. Kwakwa HA, Ghobrial MW. Female-to-female transmission of human immunodeficiency virus. Clin Infect Dis 2003;36:e40–1. 10.1086/345462
    1. Marrazzo JM, Handsfield HH, Whittington WL. Predicting chlamydial and gonococcal cervical infection: implications for management of cervicitis. Obstet Gynecol 2002;100:579–84. 10.1097/00006250-200209000-00029
    1. Diamant AL, Schuster MA, McGuigan K, Lever J. Lesbians’ sexual history with men: implications for taking a sexual history. Arch Intern Med 1999;159:2730–6. 10.1001/archinte.159.22.2730
    1. Xu F, Sternberg MR, Markowitz LE. Women who have sex with women in the United States: prevalence, sexual behavior and prevalence of herpes simplex virus type 2 infection—results from national health and nutrition examination survey 2001–2006. Sex Transm Dis 2010;37:407–13. 10.1097/OLQ.0b013e3181db2e18
    1. Everett BG, Higgins JA, Haider S, Carpenter E. Do sexual minorities receive appropriate sexual and reproductive health care and counseling? J Womens Health (Larchmt) 2019;28:53–62. 10.1089/jwh.2017.6866
    1. Marrazzo JM, Koutsky LA, Stine KL, et al. Genital human papillomavirus infection in women who have sex with women. J Infect Dis 1998;178:1604–9. 10.1086/314494
    1. Marrazzo JM, Koutsky LA, Kiviat NB, Kuypers JM, Stine K. Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women. Am J Public Health 2001;91:947–52. 10.2105/AJPH.91.6.947
    1. Bailey JV, Kavanagh J, Owen C, McLean KA, Skinner CJ. Lesbians and cervical screening. Br J Gen Pract 2000;50:481–2.
    1. Anderson TA, Schick V, Herbenick D, Dodge B, Fortenberry JD. A study of human papillomavirus on vaginally inserted sex toys, before and after cleaning, among women who have sex with women and men. Sex Transm Infect 2014;90:529–31. 10.1136/sextrans-2014-051558
    1. Marrazzo JM, Stine K, Wald A. Prevalence and risk factors for infection with herpes simplex virus type-1 and -2 among lesbians. Sex Transm Dis 2003;30:890–5. 10.1097/01.OLQ.0000091151.52656.E5
    1. Muzny CA, Schwebke JR. The clinical spectrum of Trichomonas vaginalis infection and challenges to management. Sex Transm Infect 2013;89:423–5. 10.1136/sextrans-2012-050893
    1. Muzny CA, Blackburn RJ, Sinsky RJ, Austin EL, Schwebke JR. Added benefit of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among men and women attending a sexually transmitted diseases clinic. Clin Infect Dis 2014;59:834–41. 10.1093/cid/ciu446
    1. Singh D, Fine DN, Marrazzo JM. Chlamydia trachomatis infection among women reporting sexual activity with women screened in family planning clinics in the Pacific Northwest, 1997 to 2005. Am J Public Health 2011;101:1284–90. 10.2105/AJPH.2009.169631
    1. Muzny CA, Kapil R, Austin EL, Brown L, Hook EW 3rd, Geisler WM. Chlamydia trachomatis infection in African American women who exclusively have sex with women. Int J STD AIDS 2016;27:978–83. 10.1177/0956462415604092
    1. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 2007;34:864–9. 10.1097/OLQ.0b013e318074e565
    1. Evans AL, Scally AJ, Wellard SJ, Wilson JD. Prevalence of bacterial vaginosis in lesbians and heterosexual women in a community setting. Sex Transm Infect 2007;83:470–5. 10.1136/sti.2006.022277
    1. Olson KM, Boohaker LJ, Schwebke JR, Aslibekyan S, Muzny CA. Comparisons of vaginal flora patterns among sexual behaviour groups of women: implications for the pathogenesis of bacterial vaginosis. Sex Health 2018;15:61–7. 10.1071/SH17087
    1. Muzny CA, Lensing SY, Aaron KJ, Schwebke JR. Incubation period and risk factors support sexual transmission of bacterial vaginosis in women who have sex with women. Sex Transm Infect 2019;95:511–5. 10.1136/sextrans-2018-053824
    1. Bradshaw CS, Walker SM, Vodstrcil LA, et al. The influence of behaviors and relationships on the vaginal microbiota of women and their female partners: the WOW Health Study. J Infect Dis 2014;209:1562–72. 10.1093/infdis/jit664
    1. Marrazzo JM, Antonio M, Agnew K, Hillier SL. Distribution of genital Lactobacillus strains shared by female sex partners. J Infect Dis 2009;199:680–3. 10.1086/596632
    1. Marrazzo JM, Fiedler TL, Srinivasan S, et al. Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis 2012;205:1580–8. 10.1093/infdis/jis242
    1. Mitchell C, Manhart LE, Thomas K, Fiedler T, Fredricks DN, Marrazzo J. Behavioral predictors of colonization with Lactobacillus crispatus or Lactobacillus jensenii after treatment for bacterial vaginosis: a cohort study. Infect Dis Obstet Gynecol 2012;2012:706540. Epub May 30, 2012. 10.1155/2012/706540
    1. Mitchell C, Manhart LE, Thomas KK, Agnew K, Marrazzo JM. Effect of sexual activity on vaginal colonization with hydrogen peroxide-producing Lactobacilli and Gardnerella vaginalis. Sex Transm Dis 2011;38:1137–44. 10.1097/OLQ.0b013e31822e6121
    1. Fethers K, Twin J, Fairley CK, et al. Bacterial vaginosis (BV) candidate bacteria: associations with BV and behavioural practices in sexually-experienced and inexperienced women. PLoS One 2012;7:e30633. 10.1371/journal.pone.0030633
    1. Bradshaw CS, Vodstrcil LA, Hocking JS, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis 2013;56:777–86. 10.1093/cid/cis1030
    1. Marrazzo JM, Thomas KK, Fiedler TL, Ringwood K, Fredricks DN. Risks for acquisition of bacterial vaginosis among women who report sex with women: a cohort study. PLoS One 2010;5:e11139. 10.1371/journal.pone.0011139
    1. Vodstrcil LA, Walker SM, Hocking JS, et al. Incident bacterial vaginosis (BV) in women who have sex with women is associated with behaviors that suggest sexual transmission of BV. Clin Infect Dis 2015;60:1042–53. 10.1093/cid/ciu1130
    1. Muzny CA, Blanchard E, Taylor CM, et al. Identification of key bacteria involved in the induction of incident bacterial vaginosis: a prospective study. J Infect Dis 2018;218:966–78. 10.1093/infdis/jiy243
    1. Marrazzo JM, Thomas KK, Ringwood K. A behavioural intervention to reduce persistence of bacterial vaginosis among women who report sex with women: results of a randomised trial. Sex Transm Infect 2011;87:399–405. 10.1136/sti.2011.049213
    1. Bradshaw CS, Walker J, Fairley CK, et al. Prevalent and incident bacterial vaginosis are associated with sexual and contraceptive behaviours in young Australian women. PLoS One 2013;8:e57688. 10.1371/journal.pone.0057688
    1. Poteat T, Reisner SL, Radix A. HIV epidemics among transgender women. Curr Opin HIV AIDS 2014;9:168–73. 10.1097/COH.0000000000000030
    1. White Hughto JM, Reisner SL, Pachankis JE. Transgender stigma and health: a critical review of stigma determinants, mechanisms, and interventions. Soc Sci Med 2015;147:222–31. 10.1016/j.socscimed.2015.11.010
    1. Radix AE, Lelutiu-Weinberger C, Gamarel KE. Satisfaction and healthcare utilization of transgender and gender non-conforming individuals in NYC: a community-based participatory study. LGBT Health 2014;1:302–8. 10.1089/lgbt.2013.0042
    1. Rapues J, Wilson EC, Packer T, Colfax GN, Raymond HF. Correlates of HIV infection among transfemales, San Francisco, 2010: results from a respondent-driven sampling study. Am J Public Health 2013;103:1485–92. 10.2105/AJPH.2012.301109
    1. Sevelius JM, Patouhas E, Keatley JG, Johnson MO. Barriers and facilitators to engagement and retention in care among transgender women living with human immunodeficiency virus. Ann Behav Med 2014;47:5–16. 10.1007/s12160-013-9565-8
    1. Sevelius JM. Gender affirmation: a framework for conceptualizing risk behavior among transgender women of color. Sex Roles 2013;68:675–89. 10.1007/s11199-012-0216-5
    1. Reisner SL, White Hughto JM, Pardee D, Sevelius J. Syndemics and gender affirmation: HIV sexual risk in female-to-male trans masculine adults reporting sexual contact with cisgender males. Int J STD AIDS 2016;27:955–66. 10.1177/0956462415602418
    1. Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgenderism 2012;13:165–232. 10.1080/15532739.2011.700873
    1. Winter S, Diamond M, Green J, et al. Transgender people: health at the margins of society. Lancet 2016;388:390–400. 10.1016/S0140-6736(16)00683-8
    1. Cahill S, Singal R, Grasso C, et al. Do ask, do tell: high levels of acceptability by patients of routine collection of sexual orientation and gender identity data in four diverse American community health centers. PLoS One 2014;9:e107104. 10.1371/journal.pone.0107104
    1. Cahill SR, Baker K, Deutsch MB, Keatley J, Makadon HJ. Inclusion of sexual orientation and gender identity in Stage 3 Meaningful Use Guidelines: a huge step forward for LGBT health. LGBT Health 2016;3:100–2. 10.1089/lgbt.2015.0136
    1. Tordoff DM, Morgan J, Dombrowski JC, Golden MR, Barbee LA. Increased ascertainment of transgender and non-binary patients using a 2-step versus 1-step gender identity intake question in an STD clinic setting. Sex Transm Dis 2019;46:254–9. 10.1097/OLQ.0000000000000952
    1. Grant JM, Mottet LA, Tanis J. National transgender discrimination survey report on health and health care. Washington, DC: National Center for Transgender Equality and the National Gay and Lesbian Task Force; 2010.
    1. Jaffee KD, Shires DA, Stroumsa D. Discrimination and delayed health care among transgender women and men: implications for improving medical education and health care delivery. Med Care 2016;54:1010–6. 10.1097/MLR.0000000000000583
    1. Glick JL, Theall KP, Andrinopoulos KM, Kendall C. The role of discrimination in care postponement among trans-feminine individuals in the U.S. National Transgender Discrimination Survey. LGBT Health 2018;5:171–9. 10.1089/lgbt.2017.0093
    1. Callander D, Cook T, Cornelisse V, et al. Trans and gender diverse people’s experiences of sexual health care are associated with sexual health screening uptake. Sex Transm Infect 2019;95(Suppl 1):A64.
    1. Casey LS, Reisner SL, Findling MG, et al. Discrimination in the United States: experiences of lesbian, gay, bisexual, transgender, and queer Americans. Health Serv Res 2019;54(Suppl 2):1454–66. 10.1111/1475-6773.13229
    1. Potter J, Peitzmeier SM, Bernstein I, et al. Cervical cancer screening for patients on the female-to-male spectrum: a narrative review and guide for clinicians. J Gen Intern Med 2015;30:1857–64. 10.1007/s11606-015-3462-8
    1. Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006–2017. Am J Public Health 2019;109:e1–8. 10.2105/AJPH.2018.304727
    1. Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis 2013;13:214–22. 10.1016/S1473-3099(12)70315-8
    1. Allan-Blitz LT, Konda KA, Calvo GM, et al. High incidence of extra-genital gonorrheal and chlamydial infections among high-risk men who have sex with men and transgender women in Peru. Int J STD AIDS 2018;29:568–76. 10.1177/0956462417744098
    1. Hiransuthikul A, Janamnuaysook R, Sungsing T, et al. High burden of chlamydia and gonorrhoea in pharyngeal, rectal and urethral sites among Thai transgender women: implications for anatomical site selection for the screening of STI. Sex Transm Infect 2019;95:534–9. 10.1136/sextrans-2018-053835
    1. Kojima N, Park H, Konda KA, et al. The PICASSO Cohort: baseline characteristics of a cohort of men who have sex with men and male-to-female transgender women at high risk for syphilis infection in Lima, Peru. BMC Infect Dis 2017;17:255. 10.1186/s12879-017-2332-x
    1. Pitasi MA, Kerani RP, Kohn R, et al. Chlamydia, gonorrhea, and human immunodeficiency virus infection among transgender women and transgender men attending clinics that provide sexually transmitted disease services in six US cities: results from the Sexually Transmitted Disease Surveillance Network. Sex Transm Dis 2019;46:112–7. 10.1097/OLQ.0000000000000917
    1. James S, Herman JL, Rankin S, Keisling M, Mottet L, Anafi M. The report of the 2015 US transgender survey. Washington, DC: National Center for Transgender Equality; 2016.
    1. Hadj-Moussa M, Ohl DA, Kuzon WM Jr. Feminizing genital gender-confirmation surgery. Sex Med Rev 2018;6:457–468.e2. 10.1016/j.sxmr.2017.11.005
    1. Salgado CJ, Nugent A, Kuhn J, Janette M, Bahna H. Primary sigmoid vaginoplasty in transwomen: technique and outcomes. BioMed Res Int 2018;2018:4907208. 10.1155/2018/4907208
    1. Radix AE, Harris AB, Belkind U, Ting J, Goldstein ZG. Chlamydia trachomatis infection of the neovagina in transgender women. Open Forum Infect Dis 2019;6:ofz470. 10.1093/ofid/ofz470
    1. Elfering L, van der Sluis WB, Mermans JF, Buncamper ME. Herpes neolabialis: herpes simplex virus type 1 infection of the neolabia in a transgender woman. Int J STD AIDS 2017;28:841–3. 10.1177/0956462416685658
    1. van der Sluis WB, Buncamper ME, Bouman MB, et al. Prevalence of neovaginal high-risk human papillomavirus among transgender women in the Netherlands. Sex Transm Dis 2016;43:503–5. 10.1097/OLQ.0000000000000476
    1. Yang C, Liu S, Xu K, Xiang Q, Yang S, Zhang X. Condylomata gigantea in a male transsexual. Int J STD AIDS 2009;20:211–2. 10.1258/ijsa.2008.008213
    1. Matsuki S, Kusatake K, Hein KZ, Anraku K, Morita E. Condylomata acuminata in the neovagina after male-to-female reassignment treated with CO2 laser and imiquimod. Int J STD AIDS 2015;26:509–11. 10.1177/0956462414542476
    1. Bodsworth NJ, Price R, Davies SC. Gonococcal infection of the neovagina in a male-to-female transsexual. Sex Transm Dis 1994;21:211–2. 10.1097/00007435-199407000-00005
    1. Haustein UF. Pruritus of the artificial vagina of a transsexual patient caused by gonococcal infection [German]. Hautarzt 1995;46:858–9. 10.1007/s001050050354
    1. Yamada K, Shida D, Kato T, Yoshida H, Yoshinaga S, Kanemitsu Y. Adenocarcinoma arising in sigmoid colon neovagina 53 years after construction. World J Surg Oncol 2018;16:88. 10.1186/s12957-018-1372-z
    1. Hiroi H, Yasugi T, Matsumoto K, et al. Mucinous adenocarcinoma arising in a neovagina using the sigmoid colon thirty years after operation: a case report. J Surg Oncol 2001;77:61–4. 10.1002/jso.1067
    1. Heller DS. Lesions of the neovagina—a review. J Low Genit Tract Dis 2015;19:267–70. 10.1097/LGT.0000000000000110
    1. Scheim AI, Bauer GR, Travers R. HIV-related sexual risk among transgender men who are gay, bisexual, or have sex with men. J Acquir Immune Defic Syndr 2017;74:e89–96. 10.1097/QAI.0000000000001222
    1. Sevelius J. “There’s no pamphlet for the kind of sex I have”: HIV-related risk factors and protective behaviors among transgender men who have sex with nontransgender men. J Assoc Nurses AIDS Care 2009;20:398–410. 10.1016/j.jana.2009.06.001
    1. Pitasi MA, Oraka E, Clark H, Town M, DiNenno EA. HIV testing among transgender women and men—27 states and Guam, 2014–2015. MMWR Morb Mortal Wkly Rep 2017;66:883–7. 10.15585/mmwr.mm6633a3
    1. Reisner SL, Perkovich B, Mimiaga MJ. A mixed methods study of the sexual health needs of New England transmen who have sex with nontransgender men. AIDS Patient Care STDS 2010;24:501–13. 10.1089/apc.2010.0059
    1. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017;102:3869–903. 10.1210/jc.2017-01658
    1. Deutsch M, ed. Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people. San Francisco, CA: University of California San Francisco, Department of Family and Community Medicine, Center of Excellence for Transgender Care; 2016.
    1. Peitzmeier SM, Reisner SL, Harigopal P, Potter J. Female-to-male patients have high prevalence of unsatisfactory Paps compared to non-transgender females: implications for cervical cancer screening. J Gen Intern Med 2014;29:778–84. 10.1007/s11606-013-2753-1
    1. Peitzmeier SM, Khullar K, Reisner SL, Potter J. Pap test use is lower among female-to-male patients than non-transgender women. Am J Prev Med 2014;47:808–12. 10.1016/j.amepre.2014.07.031
    1. Reisner SL, Deutsch MB, Peitzmeier SM, et al. Test performance and acceptability of self- versus provider-collected swabs for high-risk HPV DNA testing in female-to-male trans masculine patients. PLoS One 2018;13:e0190172. 10.1371/journal.pone.0190172
    1. CDC. Surveillance for viral hepatitis—United States, 2017. Atlanta, GA: US Department of Health and Human Services, CDC; 2019.
    1. Kouyoumdjian FG, Leto D, John S, Henein H, Bondy S. A systematic review and meta-analysis of the prevalence of chlamydia, gonorrhoea and syphilis in incarcerated persons. Int J STD AIDS 2012;23:248–54. 10.1258/ijsa.2011.011194
    1. CDC. Evaluation of large jail STD screening programs, 2008–2009. Atlanta, GA: US Department of Health and Human Services, CDC; 2011.
    1. Pathela P, Hennessy RR, Blank S, Parvez F, Franklin W, Schillinger JA. The contribution of a urine-based jail screening program to citywide male chlamydia and gonorrhea case rates in New York City. Sex Transm Dis 2009;36(Suppl):S58–61. 10.1097/OLQ.0b013e31815615bb
    1. Joesoef MR, Weinstock HS, Kent CK, et al.; Corrections STD Prevalence Monitoring Group. Sex and age correlates of chlamydia prevalence in adolescents and adults entering correctional facilities, 2005: implications for screening policy. Sex Transm Dis 2009;36(Suppl):S67–71. 10.1097/OLQ.0b013e31815d6de8
    1. Blank S, McDonnell DD, Rubin SR, et al. New approaches to syphilis control. Finding opportunities for syphilis treatment and congenital syphilis prevention in a women’s correctional setting. Sex Transm Dis 1997;24:218–26. 10.1097/00007435-199704000-00006
    1. Owusu-Edusei K Jr, Gift TL, Chesson HW, Kent CK. Investigating the potential public health benefit of jail-based screening and treatment programs for chlamydia. Am J Epidemiol 2013;177:463–73. 10.1093/aje/kws240
    1. Spaulding AC, Miller J, Trigg BG, et al. Screening for sexually transmitted diseases in short-term correctional institutions: summary of evidence reviewed for the 2010 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Sex Transm Dis 2013;40:679–84. 10.1097/01.olq.0000431353.88464.ab
    1. CDC. Male chlamydia screening consultation, March 28–29, 2006, meeting report. Atlanta, GA: US Department of Health and Human Services, CDC; 2007.
    1. Cole J, Hotton A, Zawitz C, Kessler H. Opt-out screening for Chlamydia trachomatis and Neisseria gonorrhoeae in female detainees at Cook County jail in Chicago, IL. Sex Transm Dis 2014;41:161–5. 10.1097/OLQ.0000000000000106
    1. Shaikh RA, Simonsen KA, O’Keefe A, et al. Comparison of opt-in versus opt-out testing for sexually transmitted infections among inmates in a county jail. J Correct Health Care 2015;21:408–16. 10.1177/1078345815600447
    1. Spaulding AC, Kim MJ, Corpening KT, Carpenter T, Watlington P, Bowden CJ. Establishing an HIV screening program led by staff nurses in a county jail. J Public Health Manag Pract 2015;21:538–45. 10.1097/PHH.0000000000000183
    1. Rosen DL, Wohl DA, Golin CE, et al. Comparing HIV case detection in prison during opt-in vs. opt-out testing policies. J Acquir Immune Defic Syndr 2016;71:e85–8. 10.1097/QAI.0000000000000889
    1. Gratrix J, Smyczek P, Bertholet L, et al. A cross-sectional evaluation of opt-in testing for sexually transmitted and blood-borne infections in three Canadian provincial correctional facilities: a missed opportunity for public health? Int J Prison Health 2019;15:273–81. 10.1108/IJPH-07-2018-0043
    1. Sutcliffe S, Newman SB, Hardick A, Gaydos CA. Prevalence and correlates of Trichomonas vaginalis infection among female US federal prison inmates. Sex Transm Dis 2010;37:585–90. 10.1097/OLQ.0b013e3181de4113
    1. Freeman AH, Katz KA, Pandori MW, et al. Prevalence and correlates of Trichomonas vaginalis among incarcerated persons assessed using a highly sensitive molecular assay. Sex Transm Dis 2010;37:165–8. 10.1097/OLQ.0b013e3181bcd3fc
    1. Sosman J, Macgowan R, Margolis A, et al.; Project START Biologics Study Group. Sexually transmitted infections and hepatitis in men with a history of incarceration. Sex Transm Dis 2011;38:634–9. 10.1097/OLQ.0b013e31820bc86c
    1. Javanbakht M, Stirland A, Stahlman S, et al. Prevalence and factors associated with Trichomonas vaginalis infection among high-risk women in Los Angeles. Sex Transm Dis 2013;40:804–7. 10.1097/OLQ.0000000000000026
    1. Nijhawan AE, Chapin KC, Salloway R, et al. Prevalence and predictors of Trichomonas infection in newly incarcerated women. Sex Transm Dis 2012;39:973–8. 10.1097/OLQ.0b013e31826e8847
    1. Nijhawan AE, DeLong AK, Celentano DD, et al. The association between Trichomonas infection and incarceration in HIV-seropositive and at-risk HIV-seronegative women. Sex Transm Dis 2011;38:1094–100. 10.1097/OLQ.0b013e31822ea147
    1. Willers DM, Peipert JF, Allsworth JE, Stein MD, Rose JS, Clarke JG. Prevalence and predictors of sexually transmitted infection among newly incarcerated females. Sex Transm Dis 2008;35:68–72. 10.1097/OLQ.0b013e318154bdb2
    1. Nijhawan AE, Salloway R, Nunn AS, Poshkus M, Clarke JG. Preventive healthcare for underserved women: results of a prison survey. J Womens Health (Larchmt) 2010;19:17–22. 10.1089/jwh.2009.1469
    1. Binswanger IA, White MC, Pérez-Stable EJ, Goldenson J, Tulsky JP. Cancer screening among jail inmates: frequency, knowledge, and willingness. Am J Public Health 2005;95:1781–7. 10.2105/AJPH.2004.052498
    1. Brinkley-Rubinstein L, Peterson M, Arnold T, et al. Knowledge, interest, and anticipated barriers of pre-exposure prophylaxis uptake and adherence among gay, bisexual, and men who have sex with men who are incarcerated. PLoS One 2018;13:e0205593. 10.1371/journal.pone.0205593
    1. Brinkley-Rubinstein L, Dauria E, Tolou-Shams M, et al. The path to implementation of HIV pre-exposure prophylaxis for people involved in criminal justice systems. Curr HIV/AIDS Rep 2018;15:93–5. 10.1007/s11904-018-0389-9
    1. Morrow KM; Project START Study Group. HIV, STD, and hepatitis risk behaviors of young men before and after incarceration. AIDS Care 2009;21:235–43. 10.1080/09540120802017586
    1. Bryan AD, Magnan RE, Gillman AS, et al. Effect of including alcohol and cannabis content in a sexual risk-reduction intervention on the incidence of sexually transmitted infections in adolescents: a cluster randomized clinical trial. JAMA Pediatr 2018;172:e175621. 10.1001/jamapediatrics.2017.5621
    1. DiClemente RJ, Davis TL, Swartzendruber A, et al. Efficacy of an HIV/STI sexual risk-reduction intervention for African American adolescent girls in juvenile detention centers: a randomized controlled trial. Women Health 2014;54:726–49. 10.1080/03630242.2014.932893
    1. Fogel CI, Crandell JL, Neevel AM, et al. Efficacy of an adapted HIV and sexually transmitted infection prevention intervention for incarcerated women: a randomized controlled trial. Am J Public Health 2015;105:802–9. 10.2105/AJPH.2014.302105
    1. Son J, Miller WM, Tossone K, Butcher F, Kuo K. The effect of interprofessional student-led reproductive health education on youths in juvenile detention. J Pediatr Adolesc Gynecol 2017;30:370–5. 10.1016/j.jpag.2016.11.002
    1. Costumbrado J, Stirland A, Cox G, et al. Implementation of a hepatitis A/B vaccination program using an accelerated schedule among high-risk inmates, Los Angeles County Jail, 2007–2010. Vaccine 2012;30:6878–82. 10.1016/j.vaccine.2012.09.006
    1. Allison M, Musser B, Satterwhite C, Ault K, Kelly P, Ramaswamy M. Human papillomavirus vaccine knowledge and intention among adult inmates in Kansas, 2016–2017. Am J Public Health 2018;108:1000–2. 10.2105/AJPH.2018.304499
    1. Lucas KD, Miller JL, Eckert V, Horne RL, Samuel MC, Mohle-Boetani JC. Risk, feasibility, and cost evaluation of a prisoner condom access pilot program in one California state prison. J Correct Health Care 2014;20:184–94. 10.1177/1078345814530869
    1. Scott N, McBryde E, Kirwan A, Stoové M. Modelling the impact of condom distribution on the incidence and prevalence of sexually transmitted infections in an adult male prison system. PLoS One 2015;10:e0144869. 10.1371/journal.pone.0144869
    1. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996;125:257–64. 10.7326/0003-4819-125-4-199608150-00001
    1. Henn A, Flateau C, Gallien S. Primary HIV infection: clinical presentation, testing, and treatment. Curr Infect Dis Rep 2017;19:37. 10.1007/s11908-017-0588-3
    1. Robb ML, Eller LA, Kibuuka H, et al.; RV 217 Study Team. Prospective study of acute HIV-1 infection in adults in East Africa and Thailand. N Engl J Med 2016;374:2120–30. 10.1056/NEJMoa1508952
    1. Hoenigl M, Green N, Camacho M, et al. Signs or symptoms of acute HIV infection in a cohort undergoing community-based screening. Emerg Infect Dis 2016;22:532–4. 10.3201/eid2203.151607
    1. Legarth RA, Ahlström MG, Kronborg G, et al. Long-term mortality in HIV-infected individuals 50 years or older: a nationwide, population-based cohort study. J Acquir Immune Defic Syndr 2016;71:213–8. 10.1097/QAI.0000000000000825
    1. Marcus JL, Chao CR, Leyden WA, et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr 2016;73:39–46. 10.1097/QAI.0000000000001014
    1. Cohen MS, Chen YQ, McCauley M, et al.; HPTN 052 Study Team. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016;375:830–9. 10.1056/NEJMoa1600693
    1. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA 2018;320:379–96. 10.1001/jama.2018.8431
    1. Seth P, Wang G, Sizemore E, Hogben M. HIV testing and HIV service delivery to populations at high risk attending sexually transmitted disease clinics in the United States, 2011–2013. Am J Public Health 2015;105:2374–81. 10.2105/AJPH.2015.302778
    1. Benton S, Smith J, Wang F, Heitgerd J, Belcher L, Patel H. HIV testing, diagnosis, and linkage to care among persons tested in select CDC-funded health care and non-health care settings, 2012–2017. Presented at the National HIV Prevention Conference, Atlanta, GA: March 18–21, 2019.
    1. Pathela P, Braunstein SL, Schillinger JA, Shepard C, Sweeney M, Blank S. Men who have sex with men have a 140-fold higher risk for newly diagnosed HIV and syphilis compared with heterosexual men in New York City. J Acquir Immune Defic Syndr 2011;58:408–16. 10.1097/QAI.0b013e318230e1ca
    1. Chou R, Selph S, Dana T, et al. Screening for HIV: systematic review to update the 2005 U.S. Preventive Services Task Force recommendation. Ann Intern Med 2012;157:706–18. 10.7326/0003-4819-157-10-201211200-00007
    1. Branson BM, Handsfield HH, Lampe MA, et al.; CDC. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55(No. RR-14).
    1. DiNenno EA, Prejean J, Irwin K, et al. Recommendations for HIV screening of gay, bisexual, and other men who have sex with men—United States, 2017. MMWR Morb Mortal Wkly Rep 2017;66:830–2. 10.15585/mmwr.mm6631a3
    1. CDC. HIV-2 infection surveillance—United States, 1987–2009. MMWR Morb Mortal Wkly Rep 2011;60:985–8.
    1. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005;191:1403–9. 10.1086/429411
    1. Pilcher CD, Eron JJ Jr, Vemazza PL, et al. Sexual transmission during the incubation period of primary HIV infection. JAMA 2001;286:1713–4. 10.1001/jama.286.14.1713
    1. Calabrese SK, Mayer KH. Providers should discuss U=U with all patients living with HIV. Lancet HIV 2019;6:e211–3. 10.1016/S2352-3018(19)30030-X
    1. Gilbert P, Ciccarone D, Gansky SA, et al. Interactive “Video Doctor” counseling reduces drug and sexual risk behaviors among HIV-positive patients in diverse outpatient settings. PLoS One 2008;3:e1988. 10.1371/journal.pone.0001988
    1. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA; Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis 2014;58:e1–34. 10.1093/cid/cit665
    1. DiCarlo RP, Martin DH. The clinical diagnosis of genital ulcer disease in men. Clin Infect Dis 1997;25:292–8. 10.1086/514548
    1. Lockett AE, Dance DA, Mabey DC, Drasar BS. Serum-free media for isolation of Haemophilus ducreyi. Lancet 1991;338:326. 10.1016/0140-6736(91)90473-3
    1. Lewis DA, Mitjà O. Haemophilus ducreyi: from sexually transmitted infection to skin ulcer pathogen. Curr Opin Infect Dis 2016;29:52–7. 10.1097/QCO.0000000000000226
    1. Romero L, Huerfano C, Grillo-Ardila CF. Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults. Cochrane Database Syst Rev 2017;12:CD012492. 10.1002/14651858.CD012492.pub2
    1. Jessamine PG, Plummer FA, Ndinya Achola JO, et al. Human immunodeficiency virus, genital ulcers and the male foreskin: synergism in HIV-1 transmission. Scand J Infect Dis Suppl 1990;69:181–6.
    1. Briggs GC. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 11th ed. Philadelphia, PA: Wolters Kluwer; 2017.
    1. Lewis DA. Epidemiology, clinical features, diagnosis and treatment of Haemophilus ducreyi—a disappearing pathogen? Expert Rev Anti Infect Ther 2014;12:687–96. 10.1586/14787210.2014.892414
    1. Mitjà O, Lukehart SA, Pokowas G, et al. Haemophilus ducreyi as a cause of skin ulcers in children from a yaws-endemic area of Papua New Guinea: a prospective cohort study. Lancet Glob Health 2014;2:e235–41. 10.1016/S2214-109X(14)70019-1
    1. Marks M, Chi KH, Vahi V, et al. Haemophilus ducreyi associated with skin ulcers among children, Solomon Islands. Emerg Infect Dis 2014;20:1705–7. 10.3201/eid2010.140573
    1. Ghinai R, El-Duah P, Chi KH, et al. A cross-sectional study of ‘yaws’ in districts of Ghana which have previously undertaken azithromycin mass drug administration for trachoma control. PLoS Negl Trop Dis 2015;9:e0003496. 10.1371/journal.pntd.0003496
    1. McQuillan G, Kruszon-Moran D, Flagg EW, Paulose-Ram R. Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14–49: United States, 2015–2016. NCHS Data Brief 2018;304:1–8.
    1. Ryder N, Jin F, McNulty AM, Grulich AE, Donovan B. Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992–2006. Sex Transm Infect 2009;85:416–9. 10.1136/sti.2008.033902
    1. Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003;30:797–800. 10.1097/01.OLQ.0000092387.58746.C7
    1. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994;121:847–54. 10.7326/0003-4819-121-11-199412010-00004
    1. Engelberg R, Carrell D, Krantz E, Corey L, Wald A. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis 2003;30:174–7. 10.1097/00007435-200302000-00015
    1. Masese L, Baeten JM, Richardson BA, et al. Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012. AIDS 2015;29:1077–85. 10.1097/QAD.0000000000000646
    1. Sam SS, Caliendo AM, Ingersoll J, Abdul-Ali D, Kraft CS. Performance evaluation of the Aptima HSV-1 and 2 assay for the detection of HSV in cutaneous and mucocutaneous lesion specimens. J Clin Virol 2018;99-100:1–4. 10.1016/j.jcv.2017.12.006
    1. Wald A, Huang ML, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 2003;188:1345–51. 10.1086/379043
    1. Van Der Pol B, Warren T, Taylor SN, et al. Type-specific identification of anogenital herpes simplex virus infections by use of a commercially available nucleic acid amplification test. J Clin Microbiol 2012;50:3466–71. 10.1128/JCM.01685-12
    1. Binnicker MJ, Espy MJ, Duresko B, Irish C, Mandrekar J. Automated processing, extraction and detection of herpes simplex virus types 1 and 2: a comparative evaluation of three commercial platforms using clinical specimens. J Clin Virol 2017;89:30–3. 10.1016/j.jcv.2017.02.006
    1. Teo JW, Chiang D, Jureen R, Lin RT. Clinical evaluation of a helicase-dependant amplification (HDA)-based commercial assay for the simultaneous detection of HSV-1 and HSV-2. Diagn Microbiol Infect Dis 2015;83:261–2. 10.1016/j.diagmicrobio.2015.07.018
    1. Gitman MR, Ferguson D, Landry ML. Comparison of Simplexa HSV 1 & 2 PCR with culture, immunofluorescence, and laboratory-developed TaqMan PCR for detection of herpes simplex virus in swab specimens. J Clin Microbiol 2013;51:3765–9. 10.1128/JCM.01413-13
    1. Corey L, Holmes KK. Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention. Ann Intern Med 1983;98:973–83. 10.7326/0003-4819-98-6-958
    1. Caviness AC, Oelze LL, Saz UE, Greer JM, Demmler-Harrison GJ. Direct immunofluorescence assay compared to cell culture for the diagnosis of mucocutaneous herpes simplex virus infections in children. J Clin Virol 2010;49:58–60. 10.1016/j.jcv.2010.06.006
    1. Song B, Dwyer DE, Mindel A. HSV type specific serology in sexual health clinics: use, benefits, and who gets tested. Sex Transm Infect 2004;80:113–7. 10.1136/sti.2003.006783
    1. Whittington WL, Celum CL, Cent A, Ashley RL. Use of a glycoprotein G-based type-specific assay to detect antibodies to herpes simplex virus type 2 among persons attending sexually transmitted disease clinics. Sex Transm Dis 2001;28:99–104. 10.1097/00007435-200102000-00007
    1. Zimet GD, Rosenthal SL, Fortenberry JD, et al. Factors predicting the acceptance of herpes simplex virus type 2 antibody testing among adolescents and young adults. Sex Transm Dis 2004;31:665–9. 10.1097/01.olq.0000143089.77493.c2
    1. Turner KR, Wong EH, Kent CK, Klausner JD. Serologic herpes testing in the real world: validation of new type-specific serologic herpes simplex virus tests in a public health laboratory. Sex Transm Dis 2002;29:422–5. 10.1097/00007435-200207000-00011
    1. Eing BR, Lippelt L, Lorentzen EU, et al. Evaluation of confirmatory strategies for detection of type-specific antibodies against herpes simplex virus type 2. J Clin Microbiol 2002;40:407–13. 10.1128/JCM.40.2.407-413.2002
    1. Golden MR, Ashley-Morrow R, Swenson P, Hogrefe WR, Handsfield HH, Wald A. Herpes simplex virus type 2 (HSV-2) Western blot confirmatory testing among men testing positive for HSV-2 using the focus enzyme-linked immunosorbent assay in a sexually transmitted disease clinic. Sex Transm Dis 2005;32:771–7. 10.1097/01.olq.0000175377.88358.f3
    1. Morrow RA, Friedrich D, Meier A, Corey L. Use of “biokit HSV-2 Rapid Assay” to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA. BMC Infect Dis 2005;5:84. 10.1186/1471-2334-5-84
    1. Ngo TD, Laeyendecker O, La H, Hogrefe W, Morrow RA, Quinn TC. Use of commercial enzyme immunoassays to detect antibodies to the herpes simplex virus type 2 glycoprotein G in a low-risk population in Hanoi, Vietnam. Clin Vaccine Immunol 2008;15:382–4. 10.1128/CVI.00437-06
    1. Agyemang E, Le QA, Warren T, et al. Performance of commercial enzyme-linked immunoassays for diagnosis of herpes simplex virus-1 and herpes simplex virus-2 infection in a clinical setting. Sex Transm Dis 2017;44:763–7. 10.1097/OLQ.0000000000000689
    1. Morrow R, Friedrich D. Performance of a novel test for IgM and IgG antibodies in subjects with culture-documented genital herpes simplex virus-1 or -2 infection. Clin Microbiol Infect 2006;12:463–9. 10.1111/j.1469-0691.2006.01370.x
    1. Ameli N, Bacchetti P, Morrow RA, et al. Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS 2006;20:1051–8. 10.1097/01.aids.0000222078.75867.77
    1. Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2—United States, 1999–2010. J Infect Dis 2014;209:325–33. 10.1093/infdis/jit458
    1. Bernstein DI, Bellamy AR, Hook EW 3rd, et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis 2013;56:344–51. 10.1093/cid/cis891
    1. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 2002;34:958–62. 10.1086/339326
    1. Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002;34:944–8. 10.1086/339325
    1. Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2006;42:8–13. 10.1086/498521
    1. Chosidow O, Drouault Y, Leconte-Veyriac F, et al. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br J Dermatol 2001;144:818–24. 10.1046/j.1365-2133.2001.04139.x
    1. Bodsworth NJ, Crooks RJ, Borelli S, et al.; International Valaciclovir HSV Study Group. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. Genitourin Med 1997;73:110–6.
    1. Fife KH, Barbarash RA, Rudolph T, Degregorio B, Roth R; The Valaciclovir International Herpes Simplex Virus Study Group. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. Sex Transm Dis 1997;24:481–6. 10.1097/00007435-199709000-00007
    1. Diaz-Mitoma F, Sibbald RG, Shafran SD, Boon R, Saltzman RL; Collaborative Famciclovir Genital Herpes Research Group. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA 1998;280:887–92. 10.1001/jama.280.10.887
    1. Mertz GJ, Loveless MO, Levin MJ, et al.Collaborative Famciclovir Genital Herpes Research Group. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Arch Intern Med 1997;157:343–9. 10.1001/archinte.1997.00440240109016
    1. Reitano M, Tyring S, Lang W, et al.; International Valaciclovir HSV Study Group. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998;178:603–10. 10.1086/515385
    1. Romanowski B, Marina RB, Roberts JN; Valtrex HS230017 Study Group. Patients’ preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex Transm Dis 2003;30:226–31. 10.1097/00007435-200303000-00010
    1. Corey L, Wald A, Patel R, et al.; Valacyclovir HSV Transmission Study Group. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11–20. 10.1056/NEJMoa035144
    1. Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years’ experience with acyclovir. J Infect Dis 2002;186(Suppl 1):S40–6. 10.1086/342966
    1. Bartlett BL, Tyring SK, Fife K, et al. Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial. J Clin Virol 2008;43:190–5. 10.1016/j.jcv.2008.06.004
    1. Tronstein E, Johnston C, Huang ML, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 2011;305:1441–9. 10.1001/jama.2011.420
    1. Bender Ignacio RA, Perti T, Magaret AS, et al. Oral and vaginal tenofovir for genital herpes simplex virus type 2 shedding in immunocompetent women: a double-blind, randomized, cross-over trial. J Infect Dis 2015;212:1949–56. 10.1093/infdis/jiv317
    1. Wald A, Selke S, Warren T, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis 2006;33:529–33. 10.1097/01.olq.0000204723.15765.91
    1. Johnston C, Magaret A, Stern M, et al. Natural history of genital and oral herpes simplex virus-1 (HSV-1) shedding after first episode genital HSV-1 infection. Sex Transm Infect 2019;95:A42.
    1. Tang YW, Cleavinger PJ, Li H, Mitchell PS, Smith TF, Persing DH. Analysis of candidate-host immunogenetic determinants in herpes simplex virus-associated Mollaret’s meningitis. Clin Infect Dis 2000;30:176–8. 10.1086/313616
    1. Shalabi M, Whitley RJ. Recurrent benign lymphocytic meningitis. Clin Infect Dis 2006;43:1194–7. 10.1086/508281
    1. Landry ML, Greenwold J, Vikram HR. Herpes simplex type-2 meningitis: presentation and lack of standardized therapy. Am J Med 2009;122:688–91. 10.1016/j.amjmed.2009.02.017
    1. Aurelius E, Franzen-Röhl E, Glimåker M, et al.; HSV-2 Meningitis Study Group. Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial. Clin Infect Dis 2012;54:1304–13. 10.1093/cid/cis031
    1. Magawa S, Tanaka H, Furuhashi F, et al. A literature review of herpes simplex virus hepatitis in pregnancy. J Matern Fetal Neonatal Med 2020;33:1774–9. 10.1080/14767058.2018.1527311
    1. Masadeh M, Shen H, Lee Y, et al. A fatal case of herpes simplex virus hepatitis in a pregnant patient. Intractable Rare Dis Res 2017;6:124–7. 10.5582/irdr.2017.01013
    1. Martin ET, Krantz E, Gottlieb SL, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med 2009;169:1233–40. 10.1001/archinternmed.2009.177
    1. Wald A, Langenberg AG, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005;143:707–13. 10.7326/0003-4819-143-10-200511150-00007
    1. Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001;285:3100–6. 10.1001/jama.285.24.3100
    1. Magaret AS, Mujugira A, Hughes JP, et al.; Partners in Prevention HSV/HIV Transmission Study Team. Effect of condom use on per-act HSV-2 transmission risk in HIV-1, HSV-2-discordant couples. Clin Infect Dis 2016;62:456–61.
    1. Mehta SD, Moses S, Agot K, et al. Medical male circumcision and herpes simplex virus 2 acquisition: posttrial surveillance in Kisumu, Kenya. J Infect Dis 2013;208:1869–76. 10.1093/infdis/jit371
    1. Grund JM, Bryant TS, Jackson I, et al. Association between male circumcision and women’s biomedical health outcomes: a systematic review. Lancet Glob Health 2017;5:e1113–22. 10.1016/S2214-109X(17)30369-8
    1. Celum C, Morrow RA, Donnell D, et al.; Partners PrEP Study Team. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann Intern Med 2014;161:11–9. 10.7326/M13-2471
    1. Abdool Karim SS, Abdool Karim Q, Gengiah TN. Tenofovir gel to prevent HSV-2 infection. N Engl J Med 2015;373:1980–1. 10.1056/NEJMoa1410649
    1. Marcus JL, Glidden DV, McMahan V, et al. Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS One 2014;9:e91513. 10.1371/journal.pone.0091513
    1. Celum C, Hong T, Cent A, et al.; ACTG PEARLS/A5175 Team. Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS Study. J Infect Dis 2017;215:907–10. 10.1093/infdis/jix029
    1. Gilbert LK, Wyand F. Genital herpes education and counselling: testing a one-page ‘FAQ’ intervention. Herpes 2009;15:51–6.
    1. Rosenthal SL, Zimet GD, Leichliter JS, et al. The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection. Sex Transm Infect 2006;82:154–7, discussion 157–8. 10.1136/sti.2005.016311
    1. Miyai T, Turner KR, Kent CK, Klausner J. The psychosocial impact of testing individuals with no history of genital herpes for herpes simplex virus type 2. Sex Transm Dis 2004;31:517–21. 10.1097/01.olq.0000137901.71284.6b
    1. Ross K, Johnston C, Wald A. Herpes simplex virus type 2 serological testing and psychosocial harm: a systematic review. Sex Transm Infect 2011;87:594–600. 10.1136/sextrans-2011-050099
    1. Henry RE, Wegmann JA, Hartle JE, Christopher GW. Successful oral acyclovir desensitization. Ann Allergy 1993;70:386–8.
    1. Leeyaphan C, Surawan TM, Chirachanakul P, et al. Clinical characteristics of hypertrophic herpes simplex genitalis and treatment outcomes of imiquimod: a retrospective observational study. Int J Infect Dis 2015;33:165–70. 10.1016/j.ijid.2015.02.002
    1. Keller MJ, Huber A, Espinoza L, et al. Impact of herpes simplex virus type 2 and human immunodeficiency virus dual infection on female genital tract mucosal immunity and the vaginal microbiome. J Infect Dis 2019;220:852–61. 10.1093/infdis/jiz203
    1. Posavad CM, Wald A, Kuntz S, et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004;190:693–6. 10.1086/422755
    1. Tobian AA, Grabowski MK, Serwadda D, et al.; Rakai Health Sciences Program. Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy. J Infect Dis 2013;208:839–46. 10.1093/infdis/jit252
    1. Mujugira A, Magaret AS, Celum C, et al.; Partners in Prevention HSV/HIV Transmission Study Team. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial. J Infect Dis 2013;208:1366–74. 10.1093/infdis/jit333
    1. Van Wagoner N, Geisler WM, Bachmann LH, Hook EW. The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2. Int J STD AIDS 2015;26:574–81. 10.1177/0956462414546504
    1. Reyes M, Shaik NS, Graber JM, et al.; Task Force on Herpes Simplex Virus Resistance. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003;163:76–80. 10.1001/archinte.163.1.76
    1. Safrin S, Crumpacker C, Chatis P, et al.; The AIDS Clinical Trials Group. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991;325:551–5. 10.1056/NEJM199108223250805
    1. Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004;39(Suppl 5):S248–57. 10.1086/422364
    1. Tandon S, Singh J, Sinha S, Sharma DP. Recalcitrant hypertrophic herpes genitalis in HIV-infected patient successfully treated with topical imiquimod. Dermatol Ther (Heidelb) 2017;30:e12479. 10.1111/dth.12479
    1. Perkins N, Nisbet M, Thomas M. Topical imiquimod treatment of aciclovir-resistant herpes simplex disease: case series and literature review. Sex Transm Infect 2011;87:292–5. 10.1136/sti.2010.047431
    1. McElhiney LF. Topical cidofovir for treatment of resistant viral infections. Int J Pharm Compd 2006;10:324–8.
    1. Erard V, Wald A, Corey L, Leisenring WM, Boeckh M. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007;196:266–70. 10.1086/518938
    1. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997;337:509–15. 10.1056/NEJM199708213370801
    1. Pinninti SG, Kimberlin DW. Maternal and neonatal herpes simplex virus infections. Am J Perinatol 2013;30:113–9. 10.1055/s-0032-1332802
    1. Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 1991;324:1247–52. 10.1056/NEJM199105023241804
    1. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003;289:203–9. 10.1001/jama.289.2.203
    1. Ahrens KA, Anderka MT, Feldkamp ML, Canfield MA, Mitchell AA, Werler MM; National Birth Defects Prevention Study. Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997–2007. Paediatr Perinat Epidemiol 2013;27:340–5. 10.1111/ppe.12064
    1. Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984–1999. Birth Defects Res A Clin Mol Teratol 2004;70:201–7. 10.1002/bdra.20013
    1. Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 2010;304:859–66. 10.1001/jama.2010.1206
    1. Sheffield JS, Sánchez PJ, Wendel GD Jr, et al. Placental histopathology of congenital syphilis. Obstet Gynecol 2002;100:126–33.
    1. Watts DH, Brown ZA, Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol 2003;188:836–43. 10.1067/mob.2003.185
    1. Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD Jr. Acyclovir suppression to prevent recurrent genital herpes at delivery. Infect Dis Obstet Gynecol 2002;10:71–7. 10.1155/S1064744902000054
    1. Pinninti SG, Angara R, Feja KN, et al. Neonatal herpes disease following maternal antenatal antiviral suppressive therapy: a multicenter case series. J Pediatr 2012;161:134–8.e1-3. 10.1016/j.jpeds.2011.12.053
    1. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. No. 82 June 2007. Management of herpes in pregnancy. Obstet Gynecol 2007;109:1489–98. 10.1097/01.AOG.0000263902.31953.3e
    1. Winer RL, Hughes JP, Feng Q, et al. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 2011;20:699–707. 10.1158/1055-9965.EPI-10-1108
    1. Ahmed N, Pillay A, Lawler M, Bobat R, Archary M. Donovanosis causing lymphadenitis, mastoiditis, and meningitis in a child. Lancet 2015;385:2644. 10.1016/S0140-6736(15)60992-8
    1. Arora AK, Kumaran MS, Narang T, Saikia UN, Handa S. Donovanosis and squamous cell carcinoma: the relationship conundrum! Int J STD AIDS 2017;28:411–4. 10.1177/0956462416665996
    1. Liverani CA, Lattuada D, Mangano S, et al. Hypertrophic donavanosis in a young pregnant woman. J Pediatr Adolesc Gynecol 2012;25:e81–3. 10.1016/j.jpag.2011.10.002
    1. Magalhães BM, Veasey JV, Mayor SAS, Lellis RF. Donovanosis in a child victim of sexual abuse: response to doxycycline treatment. An Bras Dermatol 2018;93:592–4. 10.1590/abd1806-4841.20187948
    1. Marfatia YS, Menon DS, Jose S, Patel BK. Nonhealing genital ulcer in AIDS: a diagnostic dilemma! Indian J Sex Transm Dis AIDS 2016;37:197–200. 10.4103/0253-7184.192130
    1. Narang T, Kanwar AJ. Genital elephantiasis due to donovanosis: forgotten but not gone yet. Int J STD AIDS 2012;23:835–6. 10.1258/ijsa.2012.012096
    1. Pilani A, Vora R, Anjaneyan G. Granuloma inguinale mimicking as squamous cell carcinoma of penis. Indian J Sex Transm Dis AIDS 2014;35:56–8. 10.4103/0253-7184.132433
    1. Ramdial PK, Sing Y, Ramburan A, et al. Infantile donovanosis presenting as external auditory canal polyps: a diagnostic trap. Am J Dermatopathol 2012;34:818–21. 10.1097/DAD.0b013e3182540ccb
    1. Wahal SP, Tuli D. Donovanosis: an incidental finding on Pap test. J Cytol 2013;30:217–8. 10.4103/0970-9371.117638
    1. Bowden FJ; National Donovanosis Eradication Advisory Committee. Donovanosis in Australia: going, going. Sex Transm Infect 2005;81:365–6. 10.1136/sti.2004.013227
    1. Bright A. National Notifiable Diseases Surveillance System surveillance report: sexually transmissible infections in Aboriginal and Torres Strait Islander people. Commun Dis Intell Q Rep 2015;39:E584–9.
    1. O’Farrell N. Donovanosis. Sex Transm Infect 2002;78:452–7. 10.1136/sti.78.6.452
    1. Mabey D, Peeling RW. Lymphogranuloma venereum. Sex Transm Infect 2002;78:90–2. 10.1136/sti.78.2.90
    1. White JA. Manifestations and management of lymphogranuloma venereum. Curr Opin Infect Dis 2009;22:57–66. 10.1097/QCO.0b013e328320a8ae
    1. de Vries HJ, Zingoni A, White JA, Ross JD, Kreuter A. 2013 European Guideline on the management of proctitis, proctocolitis and enteritis caused by sexually transmissible pathogens. Int J STD AIDS 2014;25:465–74. 10.1177/0956462413516100
    1. Ward H, Martin I, Macdonald N, et al. Lymphogranuloma venereum in the United kingdom. Clin Infect Dis 2007;44:26–32. 10.1086/509922
    1. Martin-Iguacel R, Llibre JM, Nielsen H, et al. Lymphogranuloma venereum proctocolitis: a silent endemic disease in men who have sex with men in industrialised countries. Eur J Clin Microbiol Infect Dis 2010;29:917–25. 10.1007/s10096-010-0959-2
    1. de Voux A, Kent JB, Macomber K, et al. Notes from the field: cluster of lymphogranuloma venereum cases among men who have sex with men—Michigan, August 2015–April 2016. MMWR Morb Mortal Wkly Rep 2016;65:920–1. 10.15585/mmwr.mm6534a6
    1. Pallawela SN, Sullivan AK, Macdonald N, et al. Clinical predictors of rectal lymphogranuloma venereum infection: results from a multicentre case-control study in the U.K. Sex Transm Infect 2014;90:269–74. 10.1136/sextrans-2013-051401
    1. de Vrieze NH, de Vries HJ. Lymphogranuloma venereum among men who have sex with men. An epidemiological and clinical review. Expert Rev Anti Infect Ther 2014;12:697–704. 10.1586/14787210.2014.901169
    1. Koper NE, van der Sande MA, Gotz HM, Koedijk FD; Dutch STI Clinics. Lymphogranuloma venereum among men who have sex with men in the Netherlands: regional differences in testing rates lead to underestimation of the incidence, 2006–2012. Euro Surveill 2013;18:20561. 10.2807/1560-7917.ES2013.18.34.20561
    1. Haar K, Dudareva-Vizule S, Wisplinghoff H, et al. Lymphogranuloma venereum in men screened for pharyngeal and rectal infection, Germany. Emerg Infect Dis 2013;19:488–92. 10.3201/eid1903.121028
    1. Riera-Monroig J, Fuertes de Vega I. Lymphogranuloma venereum presenting as an ulcer on the tongue. Sex Transm Infect 2019;95:169–70. 10.1136/sextrans-2018-053787
    1. Andrada MT, Dhar JK, Wilde H. Oral lymphogranuloma venereum and cervical lymphadenopathy. Case report. Mil Med 1974;139:99–101. 10.1093/milmed/139.2.99
    1. Ilyas S, Richmond D, Burns G, et al. Orolabial lymphogranuloma venereum, Michigan, USA. Emerg Infect Dis 2019;25:2112–4. 10.3201/eid2511.190819
    1. Kersh EN, Pillay A, de Voux A, Chen C. Laboratory processes for confirmation of lymphogranuloma venereum infection during a 2015 investigation of a cluster of cases in the United States. Sex Transm Dis 2017;44:691–4. 10.1097/OLQ.0000000000000667
    1. CDC. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae—2014. MMWR Recomm Rep 2014;63(No. RR-2).
    1. Pathela P, Jamison K, Kornblum J, Quinlan T, Halse TA, Schillinger JA. Lymphogranuloma venereum: an increasingly common anorectal infection among men who have sex with men attending New York City sexual health clinics. Sex Transm Dis 2019;46:e14–7. 10.1097/OLQ.0000000000000921
    1. Cohen S, Brosnan H, Kohn R, et al. P494 Diagnosis and management of lymphogranuloma venereum (LGV) in a municipal STD clinic, San Francisco, 2016–18. Sex Transm Infect 2019;95(Suppl 1):A229.
    1. Leeyaphan C, Ong JJ, Chow EP, et al. Systematic review and meta-analysis of doxycycline efficacy for rectal lymphogranuloma venereum in men who have sex with men. Emerg Infect Dis 2016;22:1778–84. 10.3201/eid2210.160986
    1. Cabello Úbeda A, Fernández Roblas R, García Delgado R, et al. Anorectal lymphogranuloma venereum in Madrid: a persistent emerging problem in men who have sex with men. Sex Transm Dis 2016;43:414–9. 10.1097/OLQ.0000000000000459
    1. Simons R, Candfield S, French P, White JA. Observed treatment responses to short-course doxycycline therapy for rectal lymphogranuloma venereum in men who have sex with men. Sex Transm Dis 2018;45:406–8. 10.1097/OLQ.0000000000000772
    1. Vall-Mayans M, Isaksson J, Caballero E, Sallés B, Herrmann B. Bubonic lymphogranuloma venereum with multidrug treatment failure. Int J STD AIDS 2014;25:306–8. 10.1177/0956462413501158
    1. Blanco JL, Fuertes I, Bosch J, et al. Effective treatment of lymphogranuloma venereum (LGV) with 1g azithormycin administered weekly for 3 weeks in HIV-infected population. Presented at the Conference on Retroviruses and Opportunist Infections, Seattle, WA; February 23–26, 2015.
    1. Kong FY, Rupasinghe TW, Simpson JA, et al. Pharmacokinetics of a single 1g dose of azithromycin in rectal tissue in men. PLoS One 2017;12:e0174372. 10.1371/journal.pone.0174372
    1. Elgalib A, Alexander S, Tong CY, White JA. Seven days of doxycycline is an effective treatment for asymptomatic rectal Chlamydia trachomatis infection. Int J STD AIDS 2011;22:474–7. 10.1258/ijsa.2011.011134
    1. Wormser GP, Wormser RP, Strle F, Myers R, Cunha BA. How safe is doxycycline for young children or for pregnant or breastfeeding women? Diagn Microbiol Infect Dis 2019;93:238–42. 10.1016/j.diagmicrobio.2018.09.015
    1. Towns JM, Leslie DE, Denham I, Azzato F, Fairley CK, Chen M. Painful and multiple anogenital lesions are common in men with Treponema pallidum PCR-positive primary syphilis without herpes simplex virus coinfection: a cross-sectional clinic-based study. Sex Transm Infect 2016;92:110–5. 10.1136/sextrans-2015-052219
    1. Theel ES, Katz SS, Pillay A. Molecular and direct detection tests for Treponema pallidum subspecies pallidum: a review of the literature, 1964–2017. Clin Infect Dis 2020;71(Suppl 1):S4–12. 10.1093/cid/ciaa176
    1. Tuddenham S, Katz SS, Ghanem KG. Syphilis laboratory guidelines: performance characteristics of nontreponemal antibody tests. Clin Infect Dis 2020;71(Suppl 1):S21–42. 10.1093/cid/ciaa306
    1. Park IU, Tran A, Pereira L, Fakile Y. Sensitivity and specificity of treponemal-specific tests for the diagnosis of syphilis. Clin Infect Dis 2020;71(Suppl 1):S13–20. 10.1093/cid/ciaa349
    1. Bristow CC, Klausner JD, Tran A. Clinical test performance of a rapid point-of-care syphilis treponemal antibody test: a systematic review and meta-analysis. Clin Infect Dis 2020;71(Suppl 1):S52–7. 10.1093/cid/ciaa350
    1. Nandwani R, Evans DT. Are you sure it’s syphilis? A review of false positive serology. Int J STD AIDS 1995;6:241–8. 10.1177/095646249500600404
    1. Romanowski B, Sutherland R, Fick GH, Mooney D, Love EJ. Serologic response to treatment of infectious syphilis. Ann Intern Med 1991;114:1005–9. 10.7326/0003-4819-114-12-1005
    1. CDC. Syphilis testing algorithms using treponemal tests for initial screening—four laboratories, New York City, 2005–2006. MMWR Morb Mortal Wkly Rep 2008;57:872–5.
    1. CDC. Discordant results from reverse sequence syphilis screening—five laboratories, United States, 2006–2010. MMWR Morb Mortal Wkly Rep 2011;60:133–7.
    1. Ortiz-Lopez N, Diez M, Diaz O, Simon F, Diaz A. Epidemiological surveillance of congenital syphilis in Spain, 2000–2010. Pediatr Infect Dis J 2012;31:988–90. 10.1097/INF.0b013e31825d3152
    1. Ortiz DA, Shukla MR, Loeffelholz MJ. The traditional or reverse algorithm for diagnosis of syphilis: pros and cons. Clin Infect Dis 2020;71(Suppl 1):S43–51. 10.1093/cid/ciaa307
    1. Berry GJ, Loeffelholz MJ. Use of treponemal screening assay strength of signal to avoid unnecessary confirmatory testing. Sex Transm Dis 2016;43:737–40. 10.1097/OLQ.0000000000000524
    1. Park IU, Chow JM, Bolan G, Stanley M, Shieh J, Schapiro JM. Screening for syphilis with the treponemal immunoassay: analysis of discordant serology results and implications for clinical management. J Infect Dis 2011;204:1297–304. 10.1093/infdis/jir524
    1. Loeffelholz MJ, Wen T, Patel JA. Analysis of bioplex syphilis IgG quantitative results in different patient populations. Clin Vaccine Immunol 2011;18:2005–6. 10.1128/CVI.05335-11
    1. Fakile YF, Jost H, Hoover KW, et al. Correlation of treponemal immunoassay signal strength values with reactivity of confirmatory treponemal testing. J Clin Microbiol 2017;56:e01165-17. 10.1128/JCM.01165-17
    1. Wong EH, Klausner JD, Caguin-Grygiel G, et al. Evaluation of an IgM/IgG sensitive enzyme immunoassay and the utility of index values for the screening of syphilis infection in a high-risk population. Sex Transm Dis 2011;38:528–32. 10.1097/OLQ.0b013e318205491a
    1. Dai S, Chi P, Lin Y, et al. Improved reverse screening algorithm for Treponema pallidum antibody using signal-to-cutoff ratios from chemiluminescence microparticle immunoassay. Sex Transm Dis 2014;41:29–34. 10.1097/OLQ.0000000000000066
    1. Li Z, Feng Z, Liu P, Yan C. Screening for antibodies against Treponema pallidum with chemiluminescent microparticle immunoassay: analysis of discordant serology results and clinical characterization. Ann Clin Biochem 2016;53:588–92. 10.1177/0004563215623806
    1. Yen-Lieberman B, Daniel J, Means C, Waletzky J, Daly TM. Identification of false-positive syphilis antibody results using a semiquantitative algorithm. Clin Vaccine Immunol 2011;18:1038–40. 10.1128/CVI.05066-11
    1. Yimtae K, Srirompotong S, Lertsukprasert K. Otosyphilis: a review of 85 cases. Otolaryngol Head Neck Surg 2007;136:67–71. 10.1016/j.otohns.2006.08.026
    1. Gleich LL, Linstrom CJ, Kimmelman CP. Otosyphilis: a diagnostic and therapeutic dilemma. Laryngoscope 1992;102:1255–9. 10.1288/00005537-199211000-00010
    1. Lukehart SA, Hook EW 3rd, Baker-Zander SA, Collier AC, Critchlow CW, Handsfield HH. Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med 1988;109:855–62. 10.7326/0003-4819-109-11-855
    1. Harding AS, Ghanem KG. The performance of cerebrospinal fluid treponemal-specific antibody tests in neurosyphilis: a systematic review. Sex Transm Dis 2012;39:291–7. 10.1097/OLQ.0b013e31824c0e62
    1. Jaffe HW, Larsen SA, Peters M, Jove DF, Lopez B, Schroeter AL. Tests for treponemal antibody in CSF. Arch Intern Med 1978;138:252–5. 10.1001/archinte.1978.03630260050016
    1. Marra CM, Maxwell CL, Smith SL, et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis 2004;189:369–76. 10.1086/381227
    1. CDC. Inadvertent use of Bicillin C-R to treat syphilis infection—Los Angeles, California, 1999–2004. MMWR Morb Mortal Wkly Rep 2005;54:217–9.
    1. Butler T. The Jarisch-Herxheimer reaction after antibiotic treatment of spirochetal infections: a review of recent cases and our understanding of pathogenesis. Am J Trop Med Hyg 2017;96:46–52. 10.4269/ajtmh.16-0434
    1. Rolfs RT, Joesoef MR, Hendershot EF, et al.; The Syphilis and HIV Study Group. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. N Engl J Med 1997;337:307–14. 10.1056/NEJM199707313370504
    1. Yang CJ, Lee NY, Chen TC, et al. One dose versus three weekly doses of benzathine penicillin G for patients co-infected with HIV and early syphilis: a multicenter, prospective observational study. PLoS One 2014;9:e109667. 10.1371/journal.pone.0109667
    1. Ganesan A, Mesner O, Okulicz JF, et al.; Infectious Disease Clinical Research Program HIV/STI Working Group. A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis. Clin Infect Dis 2015;60:653–60. 10.1093/cid/ciu888
    1. Ghanem KG, Erbelding EJ, Wiener ZS, Rompalo AM. Serological response to syphilis treatment in HIV-positive and HIV-negative patients attending sexually transmitted diseases clinics. Sex Transm Infect 2007;83:97–101. 10.1136/sti.2006.021402
    1. Seña AC, Wolff M, Martin DH, et al. Predictors of serological cure and serofast state after treatment in HIV-negative persons with early syphilis. Clin Infect Dis 2011;53:1092–9. 10.1093/cid/cir671
    1. Zhang RL, Wang QQ, Zhang JP, Yang LJ. Molecular subtyping of Treponema pallidum and associated factors of serofast status in early syphilis patients: identified novel genotype and cytokine marker. PLoS One 2017;12:e0175477. 10.1371/journal.pone.0175477
    1. Seña AC, Zhang XH, Li T, et al. A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. BMC Infect Dis 2015;15:479. 10.1186/s12879-015-1209-0
    1. Tong ML, Lin LR, Liu GL, et al. Factors associated with serological cure and the serofast state of HIV-negative patients with primary, secondary, latent, and tertiary syphilis. PLoS One 2013;8:e70102. 10.1371/journal.pone.0070102
    1. Seña AC, Wolff M, Behets F, et al. Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin. Clin Infect Dis 2013;56:420–2. 10.1093/cid/cis918
    1. Ghanem KG, Erbelding EJ, Cheng WW, Rompalo AM. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. Clin Infect Dis 2006;42:e45–9. 10.1086/500406
    1. Wong T, Singh AE, De P. Primary syphilis: serological treatment response to doxycycline/tetracycline versus benzathine penicillin. Am J Med 2008;121:903–8. 10.1016/j.amjmed.2008.04.042
    1. Hook EW 3rd, Martin DH, Stephens J, Smith BS, Smith K. A randomized, comparative pilot study of azithromycin versus benzathine penicillin G for treatment of early syphilis. Sex Transm Dis 2002;29:486–90. 10.1097/00007435-200208000-00010
    1. Cao Y, Su X, Wang Q, et al. A multicenter study evaluating ceftriaxone and benzathine penicillin G as treatment agents for early syphilis in Jiangsu, China. Clin Infect Dis 2017;65:1683–8. 10.1093/cid/cix611
    1. Riedner G, Rusizoka M, Todd J, et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med 2005;353:1236–44. 10.1056/NEJMoa044284
    1. Hook EW 3rd, Behets F, Van Damme K, et al. A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis. J Infect Dis 2010;201:1729–35. 10.1086/652239
    1. Lukehart SA, Godornes C, Molini BJ, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med 2004;351:154–8. 10.1056/NEJMoa040216
    1. Mitchell SJ, Engelman J, Kent CK, Lukehart SA, Godornes C, Klausner JD. Azithromycin-resistant syphilis infection: San Francisco, California, 2000–2004. Clin Infect Dis 2006;42:337–45. 10.1086/498899
    1. A2058G Prevalence Workgroup. Prevalence of the 23S rRNA A2058G point mutation and molecular subtypes in Treponema pallidum in the United States, 2007 to 2009. Sex Transm Dis 2012;39:794–8.
    1. Rolfs RT, Joesoef MR, Hendershot EF, et al.; The Syphilis and HIV Study Group. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. N Engl J Med 1997;337:307–14. 10.1056/NEJM199707313370504
    1. Collart P, Poitevin M, Milovanovic A, Herlin A, Durel J. Kinetic study of serum penicillin concentrations after single doses of benzathine and benethamine penicillins in young and old people. Br J Vener Dis 1980;56:355–62. 10.1136/sti.56.6.355
    1. Hagdrup HK, Lange Wantzin G, Secher L, Rosdahl VT. Penicillin concentrations in serum following weekly injections of benzathine penicillin G. Chemotherapy 1986;32:99–101. 10.1159/000238397
    1. Frentz G, Nielsen PB, Espersen F, Czartoryski A, Aastrup H. Penicillin concentrations in blood and spinal fluid after a single intramuscular injection of penicillin G benzathine. Eur J Clin Microbiol 1984;3:147–9. 10.1007/BF02014334
    1. Nathan L, Bawdon RE, Sidawi JE, Stettler RW, McIntire DM, Wendel GD Jr. Penicillin levels following the administration of benzathine penicillin G in pregnancy. Obstet Gynecol 1993;82:338–42.
    1. Marra CM, Maxwell CL, Tantalo LC, Sahi SK, Lukehart SA. Normalization of serum rapid plasma reagin titer predicts normalization of cerebrospinal fluid and clinical abnormalities after treatment of neurosyphilis. Clin Infect Dis 2008;47:893–9. 10.1086/591534
    1. Xiao Y, Tong ML, Lin LR, et al. Serological response predicts normalization of cerebrospinal fluid abnormalities at six months after treatment in HIV-negative neurosyphilis patients. Sci Rep 2017;7:9911. 10.1038/s41598-017-10387-x
    1. Hook EW 3rd, Baker-Zander SA, Moskovitz BL, Lukehart SA, Handsfield HH. Ceftriaxone therapy for asymptomatic neurosyphilis. Case report and Western blot analysis of serum and cerebrospinal fluid IgG response to therapy. Sex Transm Dis 1986;13(Suppl):185–8. 10.1097/00007435-198607000-00018
    1. Shann S, Wilson J. Treatment of neurosyphilis with ceftriaxone. Sex Transm Infect 2003;79:415–6. 10.1136/sti.79.5.415
    1. Ahmed KA, Fox SJ, Frigas E, Park MA. Clinical outcome in the use of cephalosporins in pediatric patients with a history of penicillin allergy. Int Arch Allergy Immunol 2012;158:405–10. 10.1159/000333553
    1. Park MA, Koch CA, Klemawesch P, Joshi A, Li JT. Increased adverse drug reactions to cephalosporins in penicillin allergy patients with positive penicillin skin test. Int Arch Allergy Immunol 2010;153:268–73. 10.1159/000314367
    1. Novalbos A, Sastre J, Cuesta J, et al. Lack of allergic cross-reactivity to cephalosporins among patients allergic to penicillins. Clin Exp Allergy 2001;31:438–43. 10.1046/j.1365-2222.2001.00992.x
    1. Pichichero ME, Casey JR. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol Head Neck Surg 2007;136:340–7. 10.1016/j.otohns.2006.10.007
    1. Kingston AA, Vujevich J, Shapiro M, et al. Seronegative secondary syphilis in 2 patients coinfected with human immunodeficiency virus. Arch Dermatol 2005;141:431–3. 10.1001/archderm.141.4.431
    1. CDC. Symptomatic early neurosyphilis among HIV-positive men who have sex with men—four cities, United States, January 2002–June 2004. MMWR Morb Mortal Wkly Rep 2007;56:625–8.
    1. Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Neurosyphilis in a clinical cohort of HIV-1-infected patients. AIDS 2008;22:1145–51. 10.1097/QAD.0b013e32830184df
    1. Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Antiretroviral therapy is associated with reduced serologic failure rates for syphilis among HIV-infected patients. Clin Infect Dis 2008;47:258–65. 10.1086/589295
    1. Tomkins A, Ahmad S, Cousins DE, Thng CM, Vilar FJ, Higgins SP. Screening for asymptomatic neurosyphilis in HIV patients after treatment of early syphilis: an observational study. Sex Transm Infect 2018;94:337–9. 10.1136/sextrans-2016-052938
    1. Yang CJ, Chang SY, Hung CC. Sensitivity and specificity of lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms. Clin Infect Dis 2009;49:162–3, author reply 162–3. 10.1086/599616
    1. Marra CM, Boutin P, McArthur JC, et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus-infected individuals. Clin Infect Dis 2000;30:540–4. 10.1086/313725
    1. Dowell ME, Ross PG, Musher DM, Cate TR, Baughn RE. Response of latent syphilis or neurosyphilis to ceftriaxone therapy in persons infected with human immunodeficiency virus. Am J Med 1992;93:481–8. 10.1016/0002-9343(92)90574-U
    1. Smith NH, Musher DM, Huang DB, et al. Response of HIV-infected patients with asymptomatic syphilis to intensive intramuscular therapy with ceftriaxone or procaine penicillin. Int J STD AIDS 2004;15:328–32. 10.1177/095646240401500511
    1. Ahmed KA, Fox SJ, Frigas E, Park MA. Clinical outcome in the use of cephalosporins in pediatric patients with a history of penicillin allergy. Int Arch Allergy Immunol 2012;158:405–10. 10.1159/000333553
    1. Trivedi S, Williams C, Torrone E, Kidd S. National trends and reported risk factors among pregnant women with syphilis in the United States, 2012–2016. Obstet Gynecol 2019;133:27–32. 10.1097/AOG.0000000000003000
    1. Biswas HH, Chew Ng RA, Murray EL, et al. Characteristics associated with delivery of an infant with congenital syphilis and missed opportunities for prevention—California, 2012 to 2014. Sex Transm Dis 2018;45:435–41. 10.1097/OLQ.0000000000000782
    1. Slutsker JS, Hennessy RR, Schillinger JA. Factors contributing to congenital syphilis cases—New York City, 2010–2016. MMWR Morb Mortal Wkly Rep 2018;67:1088–93. 10.15585/mmwr.mm6739a3
    1. DiOrio D, Kroeger K, Ross A. Social vulnerability in congenital syphilis case mothers: qualitative assessment of cases in Indiana, 2014 to 2016. Sex Transm Dis 2018;45:447–51. 10.1097/OLQ.0000000000000783
    1. Kimball A, Torrone E, Miele K, et al. Missed opportunities for prevention of congenital syphilis—United States, 2018. MMWR Morb Mortal Wkly Rep 2020;69:661–5. 10.15585/mmwr.mm6922a1
    1. Park IU, Chow JM, Bolan G, Stanley M, Shieh J, Schapiro JM. Screening for syphilis with the treponemal immunoassay: analysis of discordant serology results and implications for clinical management. J Infect Dis 2011;204:1297–304. 10.1093/infdis/jir524
    1. Mmeje O, Chow JM, Davidson L, Shieh J, Schapiro JM, Park IU. Discordant syphilis immunoassays in pregnancy: perinatal outcomes and implications for clinical management. Clin Infect Dis 2015;61:1049–53. 10.1093/cid/civ445
    1. Alexander JM, Sheffield JS, Sanchez PJ, Mayfield J, Wendel GD Jr. Efficacy of treatment for syphilis in pregnancy. Obstet Gynecol 1999;93:5–8.
    1. Walker GJ. Antibiotics for syphilis diagnosed during pregnancy. Cochrane Database Syst Rev 2001;(3):CD001143.
    1. Wendel GD Jr, Sheffield JS, Hollier LM, Hill JB, Ramsey PS, Sánchez PJ. Treatment of syphilis in pregnancy and prevention of congenital syphilis. Clin Infect Dis 2002;35(Suppl 2):S200–9. 10.1086/342108
    1. Zhu L, Qin M, Du L, Xie RH, Wong T, Wen SW. Maternal and congenital syphilis in Shanghai, China, 2002 to 2006. Int J Infect Dis 2010;14(Suppl 3):e45–8. 10.1016/j.ijid.2009.09.009
    1. Hawkes S, Matin N, Broutet N, Low N. Effectiveness of interventions to improve screening for syphilis in pregnancy: a systematic review and meta-analysis. Lancet Infect Dis 2011;11:684–91. 10.1016/S1473-3099(11)70104-9
    1. Hollier LM, Harstad TW, Sanchez PJ, Twickler DM, Wendel GD Jr. Fetal syphilis: clinical and laboratory characteristics. Obstet Gynecol 2001;97:947–53.
    1. Rac MW, Bryant SN, McIntire DD, et al. Progression of ultrasound findings of fetal syphilis after maternal treatment. Am J Obstet Gynecol 2014;211:426.e1–6. 10.1016/j.ajog.2014.05.049
    1. Zhou P, Gu Z, Xu J, Wang X, Liao K. A study evaluating ceftriaxone as a treatment agent for primary and secondary syphilis in pregnancy. Sex Transm Dis 2005;32:495–8. 10.1097/
    1. Katanami Y, Hashimoto T, Takaya S, et al. Amoxicillin and ceftriaxone as treatment alternatives to penicillin for maternal syphilis. Emerg Infect Dis 2017;23:827–9. 10.3201/eid2305.161936
    1. Kestenbaum LA, Ebberson J, Zorc JJ, Hodinka RL, Shah SS. Defining cerebrospinal fluid white blood cell count reference values in neonates and young infants. Pediatrics 2010;125:257–64. 10.1542/peds.2009-1181
    1. Shah SS, Ebberson J, Kestenbaum LA, Hodinka RL, Zorc JJ. Age-specific reference values for cerebrospinal fluid protein concentration in neonates and young infants. J Hosp Med 2011;6:22–7. 10.1002/jhm.711
    1. Thomson J, Sucharew H, Cruz AT, et al.; Pediatric Emergency Medicine Collaborative Research Committee (PEM CRC) HSV Study Group. Cerebrospinal fluid reference values for young infants undergoing lumbar puncture. Pediatrics 2018;141:e20173405. 10.1542/peds.2017-3405
    1. Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red book: 2018 report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.
    1. Macy E, Contreras R. Adverse reactions associated with oral and parenteral use of cephalosporins: a retrospective population-based analysis. J Allergy Clin Immunol 2015;135:745–52.e5. 10.1016/j.jaci.2014.07.062
    1. Macy E, Vyles D. Who needs penicillin allergy testing? Ann Allergy Asthma Immunol 2018;121:523–9. 10.1016/j.anai.2018.07.041
    1. Annè S, Reisman RE. Risk of administering cephalosporin antibiotics to patients with histories of penicillin allergy. Ann Allergy Asthma Immunol 1995;74:167–70.
    1. Albin S, Agarwal S. Prevalence and characteristics of reported penicillin allergy in an urban outpatient adult population. Allergy Asthma Proc 2014;35:489–94. 10.2500/aap.2014.35.3791
    1. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet 2019;393:183–98. 10.1016/S0140-6736(18)32218-9
    1. Macy E, Poon K-Y T. Self-reported antibiotic allergy incidence and prevalence: age and sex effects. Am J Med 2009;122:778.e1–7. 10.1016/j.amjmed.2009.01.034
    1. Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy: a review. JAMA 2019;321:188–99. 10.1001/jama.2018.19283
    1. Gadde J, Spence M, Wheeler B, Adkinson NF Jr. Clinical experience with penicillin skin testing in a large inner-city STD clinic. JAMA 1993;270:2456–63. 10.1001/jama.1993.03510200062033
    1. Macy E, Ngor EW. Safely diagnosing clinically significant penicillin allergy using only penicilloyl-poly-lysine, penicillin, and oral amoxicillin. J Allergy Clin Immunol Pract 2013;1:258–63. 10.1016/j.jaip.2013.02.002
    1. Jares EJ, Sánchez-Borges M, Cardona-Villa R, et al.; Latin America Drug Allergy Interest Group. Multinational experience with hypersensitivity drug reactions in Latin America. Ann Allergy Asthma Immunol 2014;113:282–9. 10.1016/j.anai.2014.06.019
    1. Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin “allergy” in hospitalized patients: A cohort study. J Allergy Clin Immunol 2014;133:790–6. 10.1016/j.jaci.2013.09.021
    1. Blumenthal KG, Lu N, Zhang Y, Li Y, Walensky RP, Choi HK. Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ 2018;361:k2400. 10.1136/bmj.k2400
    1. Blumenthal KG, Ryan EE, Li Y, Lee H, Kuhlen JL, Shenoy ES. The impact of a reported penicillin allergy on surgical site infection risk. Clin Infect Dis 2018;66:329–36. 10.1093/cid/cix794
    1. Tucker MH, Lomas CM, Ramchandar N, Waldram JD. Amoxicillin challenge without penicillin skin testing in evaluation of penicillin allergy in a cohort of Marine recruits. J Allergy Clin Immunol Pract 2017;5:813–5. 10.1016/j.jaip.2017.01.023
    1. Goldberg A, Confino-Cohen R. Skin testing and oral penicillin challenge in patients with a history of remote penicillin allergy. Ann Allergy Asthma Immunol 2008;100:37–43. 10.1016/S1081-1206(10)60402-4
    1. Iammatteo M, Alvarez Arango S, Ferastraoaru D, et al. Safety and outcomes of oral graded challenges to amoxicillin without prior skin testing. J Allergy Clin Immunol Pract 2019;7:236–43. 10.1016/j.jaip.2018.05.008
    1. Cook DJ, Barbara DW, Singh KE, Dearani JA. Penicillin skin testing in cardiac surgery. J Thorac Cardiovasc Surg 2014;147:1931–5. 10.1016/j.jtcvs.2014.01.019
    1. McDanel DL, Azar AE, Dowden AM, et al. Screening for beta-lactam allergy in joint arthroplasty patients to improve surgical prophylaxis practice. J Arthroplasty 2017;32(9s):S101–8. 10.1016/j.arth.2017.01.012
    1. Trubiano JA, Thursky KA, Stewardson AJ, et al. Impact of an integrated antibiotic allergy testing program on antimicrobial stewardship: a multicenter evaluation. Clin Infect Dis 2017;65:166–74. 10.1093/cid/cix244
    1. Siew LQC, Li PH, Watts TJ, et al. Identifying low-risk beta-lactam allergy patients in a UK tertiary centre. J Allergy Clin Immunol Pract 2019;7:2173–2181.e1. 10.1016/j.jaip.2019.03.015
    1. Chen JR, Tarver SA, Alvarez KS, Tran T, Khan DA. A proactive approach to penicillin allergy testing in hospitalized patients. J Allergy Clin Immunol Pract 2017;5:686–93. 10.1016/j.jaip.2016.09.045
    1. Leis JA, Palmay L, Ho G, et al. Point-of-care β-lactam allergy skin testing by antimicrobial stewardship programs: a pragmatic multicenter prospective evaluation. Clin Infect Dis 2017;65:1059–65. 10.1093/cid/cix512
    1. Banks TA, Tucker M, Macy E. Evaluating penicillin allergies without skin testing. Curr Allergy Asthma Rep 2019;19:27. 10.1007/s11882-019-0854-6
    1. Pham MN, Ho HE, Desai M. Penicillin desensitization: treatment of syphilis in pregnancy in penicillin-allergic patients. Ann Allergy Asthma Immunol 2017;118:537–41. 10.1016/j.anai.2017.03.013
    1. Sogn DD, Evans R 3rd, Shepherd GM, et al. Results of the National Institute of Allergy and Infectious Diseases Collaborative Clinical Trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. Arch Intern Med 1992;152:1025–32. 10.1001/archinte.1992.00400170105020
    1. Solensky R, Jacobs J, Lester M, et al. Penicillin allergy evaluation: a prospective, multicenter, open-label evaluation of a comprehensive penicillin skin test kit. J Allergy Clin Immunol Pract 2019;7:1876–85.e3. 10.1016/j.jaip.2019.02.040
    1. Heil EL, Bork JT, Schmalzle SA, et al. Implementation of an infectious disease fellow-managed penicillin allergy skin testing service. Open Forum Infect Dis 2016;3:ofw155. 10.1093/ofid/ofw155
    1. du Plessis T, Walls G, Jordan A, Holland DJ. Implementation of a pharmacist-led penicillin allergy de-labelling service in a public hospital. J Antimicrob Chemother 2019;74:1438–46. 10.1093/jac/dky575
    1. Macy E, Blumenthal KG. Are cephalosporins safe for use in penicillin allergy without prior allergy evaluation? J Allergy Clin Immunol Pract 2018;6:82–9. 10.1016/j.jaip.2017.07.033
    1. Zagursky RJ, Pichichero ME. Cross-reactivity in β-lactam allergy. J Allergy Clin Immunol Pract 2018;6:72–81.e1. 10.1016/j.jaip.2017.08.027
    1. Blumenthal KG, Shenoy ES, Varughese CA, Hurwitz S, Hooper DC, Banerji A. Impact of a clinical guideline for prescribing antibiotics to inpatients reporting penicillin or cephalosporin allergy. Ann Allergy Asthma Immunol 2015;115:294–300.e2. 10.1016/j.anai.2015.05.011
    1. Kuruvilla M, Wolf F, Sexton M, Wiley Z, Thomas J. Perioperative use of cefazolin without preliminary skin testing in patients with reported penicillin allergy. Surgery 2019;165:486–96. 10.1016/j.surg.2018.05.054
    1. Lee P, Shanson D. Results of a UK survey of fatal anaphylaxis after oral amoxicillin. J Antimicrob Chemother 2007;60:1172–3. 10.1093/jac/dkm315
    1. Blumenthal KG, Shenoy ES, Wolfson AR, et al. Addressing inpatient beta-lactam allergies: a multihospital implementation. J Allergy Clin Immunol Pract 2017;5:616–25.e7. 10.1016/j.jaip.2017.02.019
    1. Mustafa SS, Conn K, Ramsey A. Comparing direct challenge to penicillin skin testing for the outpatient evaluation of penicillin allergy: a randomized controlled trial. J Allergy Clin Immunol Pract 2019;7:2163–70. 10.1016/j.jaip.2019.05.037
    1. Chastain DB, Hutzley VJ, Parekh J, Alegro JVG. Antimicrobial desensitization: a review of published protocols. Pharmacy (Basel) 2019;7:112. 10.3390/pharmacy7030112
    1. Wendel GD Jr, Stark BJ, Jamison RB, Molina RD, Sullivan TJ. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med 1985;312:1229–32. 10.1056/NEJM198505093121905
    1. Borish L, Tamir R, Rosenwasser LJ. Intravenous desensitization to beta-lactam antibiotics. J Allergy Clin Immunol 1987;80:314–9. 10.1016/0091-6749(87)90037-6
    1. Legere HJ 3rd, Palis RI, Rodriguez Bouza T, Uluer AZ, Castells MC. A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros 2009;8:418–24. 10.1016/j.jcf.2009.08.002
    1. Manhart LE, Holmes KK, Hughes JP, Houston LS, Totten PA. Mycoplasma genitalium among young adults in the United States: an emerging sexually transmitted infection. Am J Public Health 2007;97:1118–25. 10.2105/AJPH.2005.074062
    1. Ross JDC, Jensen JS. Mycoplasma genitalium as a sexually transmitted infection: implications for screening, testing, and treatment. Sex Transm Infect 2006;82:269–71. 10.1136/sti.2005.017368
    1. Taylor-Robinson D, Gilroy CB, Thomas BJ, Hay PE. Mycoplasma genitalium in chronic non-gonococcal urethritis. Int J STD AIDS 2004;15:21–5. 10.1258/095646204322637209
    1. Dupin N, Bijaoui G, Schwarzinger M, et al. Detection and quantification of Mycoplasma genitalium in male patients with urethritis. Clin Infect Dis 2003;37:602–5. 10.1086/376990
    1. Krieger JN, Riley DE, Roberts MC, Berger RE. Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis. J Clin Microbiol 1996;34:3120–8. 10.1128/JCM.34.12.3120-3128.1996
    1. le Roux MC, Hoosen AA. Quantitative real-time polymerase chain reaction for the diagnosis of Mycoplasma genitalium infection in South African men with and without symptoms of urethritis. Sex Transm Dis 2017;44:17–20. 10.1097/OLQ.0000000000000540
    1. Bachmann LH, Kirkcaldy RD, Geisler WM, et al.; the MAGNUM Laboratory Working Group. Prevalence of Mycoplasma genitalium infection, antimicrobial resistance mutations and symptom resolution following treatment of urethritis. Clin Infect Dis 2020;71:e624–32. 10.1093/cid/ciaa293
    1. Nye MB, Schwebke JR, Body BA. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol 2009;200:188.e1–7. 10.1016/j.ajog.2008.10.005
    1. Bradshaw CS, Tabrizi SN, Read TR, et al. Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with orogenital exposure. J Infect Dis 2006;193:336–45. 10.1086/499434
    1. Dombrowski JC, Harrington RD, Golden MR. Evidence for the long-term stability of HIV transmission-associated sexual behavior after HIV diagnosis. Sex Transm Dis 2013;40:41–5. 10.1097/OLQ.0b013e3182753327
    1. Rane VS, Fairley CK, Weerakoon A, et al. Characteristics of acute nongonococcal urethritis in men differ by sexual preference. J Clin Microbiol 2014;52:2971–6. 10.1128/JCM.00899-14
    1. Pond MJ, Nori AV, Witney AA, Lopeman RC, Butcher PD, Sadiq ST. High prevalence of antibiotic-resistant Mycoplasma genitalium in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. Clin Infect Dis 2014;58:631–7. 10.1093/cid/cit752
    1. Khatib N, Bradbury C, Chalker V, et al. Prevalence of Trichomonas vaginalis, Mycoplasma genitalium and Ureaplasma urealyticum in men with urethritis attending an urban sexual health clinic. Int J STD AIDS 2015;26:388–92. 10.1177/0956462414539464
    1. Cox C, McKenna JP, Watt AP, Coyle PV. Ureaplasma parvum and Mycoplasma genitalium are found to be significantly associated with microscopy-confirmed urethritis in a routine genitourinary medicine setting. Int J STD AIDS 2016;27:861–7. 10.1177/0956462415597620
    1. Li Y, Su X, Le W, et al. Mycoplasma genitalium in symptomatic male urethritis: macrolide use is associated with increased resistance. Clin Infect Dis 2020;70:805–10. 10.1093/cid/ciz294
    1. Ito S, Hanaoka N, Shimuta K, et al. Male non-gonococcal urethritis: from microbiological etiologies to demographic and clinical features. Int J Urol 2016;23:325–31. 10.1111/iju.13044
    1. Horner P, Donders G, Cusini M, Gomberg M, Jensen JS, Unemo M. Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women?—A position statement from the European STI Guidelines Editorial Board. J Eur Acad Dermatol Venereol 2018;32:1845–51. 10.1111/jdv.15146
    1. van der Veer C, van Rooijen MS, Himschoot M, de Vries HJ, Bruisten SM. Trichomonas vaginalis and Mycoplasma genitalium: age-specific prevalence and disease burden in men attending a sexually transmitted infections clinic in Amsterdam, the Netherlands. Sex Transm Infect 2016;92:83–5. 10.1136/sextrans-2015-052118
    1. Seike K, Maeda S, Kubota Y, Tamaki M, Yasuda M, Deguchi T. Prevalence and morbidity of urethral Trichomonas vaginalis in Japanese men with or without urethritis. Sex Transm Infect 2013;89:528–30. 10.1136/sextrans-2012-050702
    1. Napierala M, Munson E, Wenten D, et al. Detection of Mycoplasma genitalium from male primary urine specimens: an epidemiologic dichotomy with Trichomonas vaginalis. Diagn Microbiol Infect Dis 2015;82:194–8. 10.1016/j.diagmicrobio.2015.03.016
    1. Sviben M, Missoni EM, Meštrović T, Vojnović G, Galinović GM. Epidemiology and laboratory characteristics of Trichomonas vaginalis infection in Croatian men with and without urethritis syndrome: a case-control study. Sex Transm Infect 2015;91:360–4. 10.1136/sextrans-2014-051771
    1. Rietmeijer CA, Mungati M, Machiha A, et al. The etiology of male urethral discharge in Zimbabwe: results from the Zimbabwe STI Etiology Study. Sex Transm Dis 2018;45:56–60. 10.1097/OLQ.0000000000000696
    1. Bazan JA, Peterson AS, Kirkcaldy RD, et al. Notes from the field: increase in Neisseria meningitidis-associated urethritis among men at two sentinel clinics—Columbus, Ohio, and Oakland County, Michigan, 2015. MMWR Morb Mortal Wkly Rep 2016;65:550–2. 10.15585/mmwr.mm6521a5
    1. Jannic A, Mammeri H, Larcher L, et al. Orogenital transmission of Neisseria meningitidis causing acute urethritis in men who have sex with men. Emerg Infect Dis 2019;25:175–6. 10.3201/eid2501.171102
    1. Hayakawa K, Itoda I, Shimuta K, Takahashi H, Ohnishi M. Urethritis caused by novel Neisseria meningitidis serogroup W in man who has sex with men, Japan. Emerg Infect Dis 2014;20:1585–7. 10.3201/eid2009.140349
    1. Bazan JA, Tzeng YL, Stephens DS, et al. Repeat episodes of symptomatic urethritis due to a uropathogenic meningococcal clade. Sex Transm Dis 2020;47:e1–4. 10.1097/OLQ.0000000000001079
    1. Ong JJ, Morton AN, Henzell HR, et al. Clinical characteristics of herpes simplex virus urethritis compared with chlamydial urethritis among men. Sex Transm Dis 2017;44:121–5. 10.1097/OLQ.0000000000000547
    1. Avolio M, De Rosa R, Modolo ML, Stano P, Camporese A. When should adenoviral non-gonococcal urethritis be suspected? Two case reports. New Microbiol 2014;37:109–12.
    1. You C, Hamasuna R, Ogawa M, et al. The first report: an analysis of bacterial flora of the first voided urine specimens of patients with male urethritis using the 16S ribosomal RNA gene-based clone library method. Microb Pathog 2016;95:95–100. 10.1016/j.micpath.2016.02.022
    1. Deguchi T, Ito S, Hatazaki K, et al. Antimicrobial susceptibility of Haemophilus influenzae strains isolated from the urethra of men with acute urethritis and/or epididymitis. J Infect Chemother 2017;23:804–7. 10.1016/j.jiac.2017.05.009
    1. Ito S, Hatazaki K, Shimuta K, et al. Haemophilus influenzae isolated from men with acute urethritis: its pathogenic roles, responses to antimicrobial chemotherapies, and antimicrobial susceptibilities. Sex Transm Dis 2017;44:205–10. 10.1097/OLQ.0000000000000573
    1. Horie K, Ito S, Hatazaki K, et al. ‘Haemophilus quentini’ in the urethra of men complaining of urethritis symptoms. J Infect Chemother 2018;24:71–4. 10.1016/j.jiac.2017.08.007
    1. Frølund M, Falk L, Ahrens P, Jensen JS. Detection of ureaplasmas and bacterial vaginosis associated bacteria and their association with non-gonococcal urethritis in men. PLoS One 2019;14:e0214425. 10.1371/journal.pone.0214425
    1. Deza G, Martin-Ezquerra G, Gómez J, Villar-García J, Supervia A, Pujol RM. Isolation of Haemophilus influenzae and Haemophilus parainfluenzae in urethral exudates from men with acute urethritis: a descriptive study of 52 cases. Sex Transm Infect 2016;92:29–31. 10.1136/sextrans-2015-052135
    1. Magdaleno-Tapial J, Valenzuela-Oñate C, Giacaman-von der Weth MM, et al. Haemophilus species isolated in urethral exudates as a possible causative agent in acute urethritis: a study of 38 cases. Actas Dermosifiliogr 2019;110:38–42. 10.1016/j.adengl.2018.11.011
    1. Abdolrasouli A, Roushan A. Corynebacterium propinquum associated with acute, nongonococcal urethritis. Sex Transm Dis 2013;40:829–31. 10.1097/OLQ.0000000000000027
    1. Ongrádi J, Stercz B, Kövesdi V, Nagy K, Chatlynne L. Isolation of Kurthia gibsonii from non-gonorrheal urethritis: implications for the pathomechanism upon surveying the literature. Acta Microbiol Immunol Hung 2014;61:79–87. 10.1556/AMicr.61.2014.1.8
    1. Gherardi G, Di Bonaventura G, Pompilio A, Savini V. Corynebacterium glucuronolyticum causing genitourinary tract infection: case report and review of the literature. IDCases 2015;2:56–8. 10.1016/j.idcr.2015.03.001
    1. Meštrović T. A microbial game of whack-a-mole: clinical case series of the urethral uncloaking phenomenon caused by Corynebacterium glucuronolyticum in men treated for Chlamydia trachomatis urethritis. Infection 2019;47:121–4. 10.1007/s15010-018-1211-8
    1. Frikh M, El Yaagoubi I, Lemnouer A, Elouennass M. Urethritis due to corynebacterium striatum: an emerging germ. Tunis Med 2015;93:43–4.
    1. Babaeer AA, Nader C, Iacoviello V, Tomera K. Necrotizing urethritis due to Aerococcus urinae. Case Rep Urol 2015;2015:136147. 10.1155/2015/136147
    1. Grandolfo M, Vestita M, Bonamonte D, Filoni A. Acute urethritis and balonoposthitis associated to Neisseria elongata. Sex Transm Dis 2016;43:778–9. 10.1097/OLQ.0000000000000532
    1. Frølund M, Lidbrink P, Wikström A, Cowan S, Ahrens P, Jensen JS. Urethritis-associated pathogens in urine from men with non-gonococcal urethritis: a case-control study. Acta Derm Venereol 2016;96:689–94. 10.2340/00015555-2314
    1. Chambers LC, Morgan JL, Lowens MS, et al. Cross-sectional study of urethral exposures at last sexual episode associated with non-gonococcal urethritis among STD clinic patients. Sex Transm Infect 2019;95:212–8. 10.1136/sextrans-2018-053634
    1. Manhart LE, Khosropour CM, Liu C, et al. Bacterial vaginosis-associated bacteria in men: association of Leptotrichia/Sneathia spp. with nongonococcal urethritis. Sex Transm Dis 2013;40:944–9. 10.1097/OLQ.0000000000000054
    1. Ashraf J, Radford AR, Turner A, Subramaniam R. Preliminary experience with instillation of triamcinolone acetonide into the urethra for idiopathic urethritis: a prospective pilot study. J Laparoendosc Adv Surg Tech A 2017;27:1217–21. 10.1089/lap.2017.0064
    1. Taylor SN, DiCarlo RP, Martin DH. Comparison of methylene blue/gentian violet stain to Gram’s stain for the rapid diagnosis of gonococcal urethritis in men. Sex Transm Dis 2011;38:995–6. 10.1097/OLQ.0b013e318225f7c2
    1. Rietmeijer CA, Mettenbrink CJ. Recalibrating the Gram stain diagnosis of male urethritis in the era of nucleic acid amplification testing. Sex Transm Dis 2012;39:18–20. 10.1097/OLQ.0b013e3182354da3
    1. Geisler WM, Yu S, Hook EW 3rd. Chlamydial and gonococcal infection in men without polymorphonuclear leukocytes on Gram stain: implications for diagnostic approach and management. Sex Transm Dis 2005;32:630–4. 10.1097/01.olq.0000175390.45315.a1
    1. Gottesman T, Yossepowitch O, Samra Z, Rosenberg S, Dan M. Prevalence of Mycoplasma genitalium in men with urethritis and in high risk asymptomatic males in Tel Aviv: a prospective study. Int J STD AIDS 2017;28:127–32. 10.1177/0956462416630675
    1. Kim HJ, Park JK, Park SC, et al. The prevalence of causative organisms of community-acquired urethritis in an age group at high risk for sexually transmitted infections in Korean soldiers. J R Army Med Corps 2017;163:20–2. 10.1136/jramc-2015-000488
    1. Libois A, Hallin M, Crucitti T, Delforge M, De Wit S. Prevalence of Mycoplasma genitalium in men with urethritis in a large public hospital in Brussels, Belgium: an observational, cross-sectional study. PLoS One 2018;13:e0196217. 10.1371/journal.pone.0196217
    1. Bachmann LH, Manhart LE, Martin DH, et al. Advances in the understanding and treatment of male urethritis. Clin Infect Dis 2015;61(Suppl 8):S763–9. 10.1093/cid/civ755
    1. Samaraweera GR, Garcia K, Druce J, et al. Characteristics of adenovirus urethritis among heterosexual men and men who have sex with men: a review of clinical cases. Sex Transm Infect 2016;92:172–4. 10.1136/sextrans-2015-052243
    1. Horner P, Blee K, O’Mahony C, Muir P, Evans C, Radcliffe K; Clinical Effectiveness Group of the British Association for Sexual Health and HIV. 2015 UK National Guideline on the management of non-gonococcal urethritis. Int J STD AIDS 2016;27:85–96. 10.1177/0956462415586675
    1. Sarier M, Sepin N, Duman I, et al. Microscopy of Gram-stained urethral smear in the diagnosis of urethritis: which threshold value should be selected? Andrologia 2018;50:e13143. 10.1111/and.13143
    1. Sarier M, Kukul E. Classification of non-gonococcal urethritis: a review. Int Urol Nephrol 2019;51:901–7. 10.1007/s11255-019-02140-2
    1. Kong FY, Tabrizi SN, Law M, et al. Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. Clin Infect Dis 2014;59:193–205. 10.1093/cid/ciu220
    1. Páez-Canro C, Alzate JP, González LM, Rubio-Romero JA, Lethaby A, Gaitán HG. Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. Cochrane Database Syst Rev 2019;1:CD010871. 10.1002/14651858.CD010871.pub2
    1. McIver R, Jalocon D, McNulty A, et al. Men who have sex with men with Mycoplasma genitalium-positive nongonococcal urethritis are more likely to have macrolide resistant strains than men with only female partners: a prospective study. Sex Transm Dis 2019;46:513–7. 10.1097/OLQ.0000000000001009
    1. Lau A, Bradshaw CS, Lewis D, et al. The efficacy of azithromycin for the treatment of genital Mycoplasma genitalium: a systematic review and meta-analysis. Clin Infect Dis 2015;61:1389–99. 10.1093/cid/civ644
    1. Horner P. Mycoplasma genitalium nongonococcal urethritis is likely to increase in men who have sex with men who practice unsafe sex: what should we do? Sex Transm Dis 2019;46:518–20. 10.1097/OLQ.0000000000001030
    1. Hosenfeld CB, Workowski KA, Berman S, et al. Repeat infection with Chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis 2009;36:478–89. 10.1097/OLQ.0b013e3181a2a933
    1. Fung M, Scott KC, Kent CK, Klausner JD. Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting. Sex Transm Infect 2007;83:304–9. 10.1136/sti.2006.024059
    1. Kissinger PJ, White S, Manhart LE, et al. Azithromycin treatment failure for Chlamydia trachomatis among heterosexual men with nongonococcal urethritis. Sex Transm Dis 2016;43:599–602. 10.1097/OLQ.0000000000000489
    1. Schwebke JR, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens—a randomized clinical trial. Clin Infect Dis 2011;52:163–70. 10.1093/cid/ciq074
    1. Manhart LE, Khosropour CM, Gillespie CW, Lowens MS, Golden MR, Totten PA. O02.3 Treatment outcomes for persistent Mycoplasma genitalium-associated NGU: evidence of moxifloxacin treatment failures. Sex Transm Infect 2013;89(Suppl 1):A29. 10.1136/sextrans-2013-051184.0091
    1. Romano SS, Jensen JS, Lowens MS, et al. Long duration of asymptomatic Mycoplasma genitalium infection after syndromic treatment for nongonococcal urethritis. Clin Infect Dis 2019;69:113–20. 10.1093/cid/ciy843
    1. Read TRH, Fairley CK, Murray GL, et al. Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation. Clin Infect Dis 2019;68:554–60. 10.1093/cid/ciy477
    1. Dowe G, Smikle M, King SD, Baum M, Chout R, Williams Y. Symptomatic and asymptomatic chlamydial non-gonococcal urethritis in Jamaica: the potential for HIV transmission. Int J STD AIDS 2000;11:187–90. 10.1258/0956462001915507
    1. Lusk MJ, Garden FL, Rawlinson WD, Naing ZW, Cumming RG, Konecny P. Cervicitis aetiology and case definition: a study in Australian women attending sexually transmitted infection clinics. Sex Transm Infect 2016;92:175–81. 10.1136/sextrans-2015-052332
    1. Lusk MJ, Konecny P. Cervicitis: a review. Curr Opin Infect Dis 2008;21:49–55.
    1. Marrazzo JM, Martin DH. Management of women with cervicitis. Clin Infect Dis 2007;44(Suppl 3):S102–10. 10.1086/511423
    1. Manavi K, Young H, Clutterbuck D. Sensitivity of microscopy for the rapid diagnosis of gonorrhoea in men and women and the role of gonorrhoea serovars. Int J STD AIDS 2003;14:390–4. 10.1258/095646203765371277
    1. Lillis RA, Martin DH, Nsuami MJ. Mycoplasma genitalium infections in women attending a sexually transmitted disease clinic in New Orleans. Clin Infect Dis 2019;69:459–65. 10.1093/cid/ciy922
    1. Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis 2015;61:418–26. 10.1093/cid/civ312
    1. Oliphant J, Azariah S. Cervicitis: limited clinical utility for the detection of Mycoplasma genitalium in a cross-sectional study of women attending a New Zealand sexual health clinic. Sex Health 2013;10:263–7. 10.1071/SH12168
    1. Sethi S, Rajkumari N, Dhaliwal L, Roy A. P3.294 Association of Mycoplasma genitalium with cervicitis in North Indian women attending gynecologic clinics. Sex Transm Infect 2013;89(Suppl 1):A240–1. 10.1136/sextrans-2013-051184.0749
    1. Taylor SN, Lensing S, Schwebke J, et al. Prevalence and treatment outcome of cervicitis of unknown etiology. Sex Transm Dis 2013;40:379–85. 10.1097/OLQ.0b013e31828bfcb1
    1. Mobley VL, Hobbs MM, Lau K, Weinbaum BS, Getman DK, Seña AC. Mycoplasma genitalium infection in women attending a sexually transmitted infection clinic: diagnostic specimen type, coinfections, and predictors. Sex Transm Dis 2012;39:706–9. 10.1097/OLQ.0b013e318255de03
    1. Marrazzo JM, Wiesenfeld HC, Murray PJ, et al. Risk factors for cervicitis among women with bacterial vaginosis. J Infect Dis 2006;193:617–24. 10.1086/500149
    1. Gaydos C, Maldeis NE, Hardick A, Hardick J, Quinn TC. Mycoplasma genitalium as a contributor to the multiple etiologies of cervicitis in women attending sexually transmitted disease clinics. Sex Transm Dis 2009;36:598–606. 10.1097/OLQ.0b013e3181b01948
    1. Clark LR, Atendido M. Group B streptococcal vaginitis in postpubertal adolescent girls. J Adolesc Health 2005;36:437–40. 10.1016/j.jadohealth.2004.03.009
    1. Hester EE, Middleman AB. A clinical conundrum: chronic cervicitis. J Pediatr Adolesc Gynecol 2019;32:342–4. 10.1016/j.jpag.2018.12.004
    1. Liu L, Cao G, Zhao Z, Zhao F, Huang Y. High bacterial loads of Ureaplasma may be associated with non-specific cervicitis. Scand J Infect Dis 2014;46:637–41. 10.3109/00365548.2014.922696
    1. Leli C, Mencacci A, Latino MA, et al. Prevalence of cervical colonization by Ureaplasma parvum, Ureaplasma urealyticum, Mycoplasma hominis and Mycoplasma genitalium in childbearing age women by a commercially available multiplex real-time PCR: an Italian observational multicentre study. J Microbiol Immunol Infect 2018;51:220–5. 10.1016/j.jmii.2017.05.004
    1. Manhart LE. Has the time come to systematically test for Mycoplasma genitalium? Sex Transm Dis 2009;36:607–8. 10.1097/OLQ.0b013e3181b9d825
    1. Liu HL, Chen CM, Pai LW, Hwu YJ, Lee HM, Chung YC. Comorbidity profiles among women with postcoital bleeding: a nationwide health insurance database. Arch Gynecol Obstet 2017;295:935–41. 10.1007/s00404-017-4327-7
    1. Coleman JS, Hitti J, Bukusi EA, et al. Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. AIDS 2007;21:755–9. 10.1097/QAD.0b013e328012b838
    1. Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis 2008;35:946–59. 10.1097/OLQ.0b013e3181812d15
    1. McClelland RS, Wang CC, Mandaliya K, et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001;15:105–10. 10.1097/00002030-200101050-00015
    1. Gatski M, Martin DH, Theall K, et al. Mycoplasma genitalium infection among HIV-positive women: prevalence, risk factors and association with vaginal shedding. Int J STD AIDS 2011;22:155–9. 10.1258/ijsa.2010.010320
    1. Gitau RW, Graham SM, Masese LN, et al. Effect of acquisition and treatment of cervical infections on HIV-1 shedding in women on antiretroviral therapy. AIDS 2010;24:2733–7. 10.1097/QAD.0b013e32833f9f43
    1. Kreisel KM, Weston EJ, St Cyr SB, Spicknall IH. Estimates of the prevalence and incidence of chlamydia and gonorrhea among US men and women, 2018. Sex Transm Dis 2021;48:222–31. 10.1097/OLQ.0000000000001382
    1. Aghaizu A, Reid F, Kerry S, et al. Frequency and risk factors for incident and redetected Chlamydia trachomatis infection in sexually active, young, multi-ethnic women: a community based cohort study. Sex Transm Infect 2014;90:524–8. 10.1136/sextrans-2014-051607
    1. Scholes D, Satterwhite CL, Yu O, Fine D, Weinstock H, Berman S. Long-term trends in Chlamydia trachomatis infections and related outcomes in a U.S. managed care population. Sex Transm Dis 2012;39:81–8. 10.1097/OLQ.0b013e31823e3009
    1. Kamwendo F, Forslin L, Bodin L, Danielsson D. Decreasing incidences of gonorrhea- and chlamydia-associated acute pelvic inflammatory disease. A 25-year study from an urban area of central Sweden. Sex Transm Dis 1996;23:384–91. 10.1097/00007435-199609000-00007
    1. Rietmeijer CA, Hopkins E, Geisler WM, Orr DP, Kent CK. Chlamydia trachomatis positivity rates among men tested in selected venues in the United States: a review of the recent literature. Sex Transm Dis 2008;35(Suppl):S8–18. 10.1097/OLQ.0b013e31816938ba
    1. Gift TL, Blake DR, Gaydos CA, Marrazzo JM. The cost-effectiveness of screening men for Chlamydia trachomatis: a review of the literature. Sex Transm Dis 2008;35(Suppl):S51–60. 10.1097/OLQ.0b013e3181723dba
    1. Gift TL, Gaydos CA, Kent CK, et al. The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women. Sex Transm Dis 2008;35(Suppl):S66–75. 10.1097/OLQ.0b013e31818b64ac
    1. Gopalappa C, Huang YL, Gift TL, Owusu-Edusei K, Taylor M, Gales V. Cost-effectiveness of screening men in Maricopa County jails for chlamydia and gonorrhea to avert infections in women. Sex Transm Dis 2013;40:776–83. 10.1097/OLQ.0000000000000023
    1. Masek BJ, Arora N, Quinn N, et al. Performance of three nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of self-collected vaginal swabs obtained via an Internet-based screening program. J Clin Microbiol 2009;47:1663–7. 10.1128/JCM.02387-08
    1. Knox J, Tabrizi SN, Miller P, et al. Evaluation of self-collected samples in contrast to practitioner-collected samples for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis by polymerase chain reaction among women living in remote areas. Sex Transm Dis 2002;29:647–54. 10.1097/00007435-200211000-00006
    1. Schachter J, Chernesky MA, Willis DE, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis 2005;32:725–8. 10.1097/01.olq.0000190092.59482.96
    1. Doshi JS, Power J, Allen E. Acceptability of chlamydia screening using self-taken vaginal swabs. Int J STD AIDS 2008;19:507–9. 10.1258/ijsa.2008.008056
    1. Chernesky MA, Jang D, Portillo E, et al. Self-collected swabs of the urinary meatus diagnose more Chlamydia trachomatis and Neisseria gonorrhoeae infections than first catch urine from men. Sex Transm Infect 2013;89:102–4. 10.1136/sextrans-2012-050573
    1. Dize L, Barnes P Jr, Barnes M, et al. Performance of self-collected penile-meatal swabs compared to clinician-collected urethral swabs for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium by nucleic acid amplification assays. Diagn Microbiol Infect Dis 2016;86:131–5. 10.1016/j.diagmicrobio.2016.07.018
    1. Berry L, Stanley B. Comparison of self-collected meatal swabs with urine specimens for the diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men. J Med Microbiol 2017;66:134–6. 10.1099/jmm.0.000428
    1. Chernesky M, Freund GG, Hook E 3rd, Leone P, D’Ascoli P, Martens M. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae infections in North American women by testing SurePath liquid-based Pap specimens in APTIMA assays. J Clin Microbiol 2007;45:2434–8. 10.1128/JCM.00013-07
    1. Schachter J, Moncada J, Liska S, Shayevich C, Klausner JD. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis 2008;35:637–42. 10.1097/OLQ.0b013e31817bdd7e
    1. Mimiaga MJ, Mayer KH, Reisner SL, et al. Asymptomatic gonorrhea and chlamydial infections detected by nucleic acid amplification tests among Boston area men who have sex with men. Sex Transm Dis 2008;35:495–8. 10.1097/OLQ.0b013e31816471ae
    1. Bachmann LH, Johnson RE, Cheng H, Markowitz LE, Papp JR, Hook EW 3rd. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae oropharyngeal infections. J Clin Microbiol 2009;47:902–7. 10.1128/JCM.01581-08
    1. Bachmann LH, Johnson RE, Cheng H, et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol 2010;48:1827–32. 10.1128/JCM.02398-09
    1. Cosentino LA, Danby CS, Rabe LK, et al. Use of nucleic acid amplification testing for diagnosis of extragenital sexually transmitted infections. J Clin Microbiol 2017;55:2801–7. 10.1128/JCM.00616-17
    1. Food and Drug Administration. Microbiology Devices Panel of the Medical Devices Advisory Committee meeting annoucement [Internet]. Silver Spring, MD: US Department of Agriculture, Food and Drug Administration; 2019.
    1. Sexton ME, Baker JJ, Nakagawa K, et al. How reliable is self-testing for gonorrhea and chlamydia among men who have sex with men? J Fam Pract 2013;62:70–8.
    1. Herbst de Cortina S, Bristow CC, Joseph Davey D, Klausner JD. A systematic review of point of care testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. Infect Dis Obstet Gynecol 2016;2016:4386127. Epub May 26, 2016. 10.1155/2016/4386127
    1. Rivard KR, Dumkow LE, Draper HM, Brandt KL, Whalen DW, Egwuatu NE. Impact of rapid diagnostic testing for chlamydia and gonorrhea on appropriate antimicrobial utilization in the emergency department. Diagn Microbiol Infect Dis 2017;87:175–9. 10.1016/j.diagmicrobio.2016.10.019
    1. Wingrove I, McOwan A, Nwokolo N, Whitlock G. Diagnostics within the clinic to test for gonorrhoea and chlamydia reduces the time to treatment: a service evaluation. Sex Transm Infect 2014;90:474. 10.1136/sextrans-2014-051580
    1. Geisler WM, Wang C, Morrison SG, Black CM, Bandea CI, Hook EW 3rd. The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sex Transm Dis 2008;35:119–23. 10.1097/OLQ.0b013e318151497d
    1. Dukers-Muijrers NHTM, Wolffs PFG, De Vries H, et al. Treatment effectiveness of azithromycin and doxycycline in uncomplicated rectal and vaginal Chlamydia trachomatis infections in women: a multicentre observational study (FemCure). Clin Infect Dis 2019;69:1946–54. 10.1093/cid/ciz050
    1. Dombrowski JC, Wierzbicki MR, Newman LM, et al. Doxycycline versus azithromycin for the treatment of rectal chlamydia in men who have sex with men: a randomized controlled trial. Clin Infect Dis 2021;ciab153. 10.1093/cid/ciab153
    1. Dukers-Muijrers NH, Schachter J, van Liere GA, Wolffs PF, Hoebe CJ. What is needed to guide testing for anorectal and pharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae in women and men? Evidence and opinion. BMC Infect Dis 2015;15:533. 10.1186/s12879-015-1280-6
    1. Marcus JL, Kohn RP, Barry PM, Philip SS, Bernstein KT. Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the female oropharynx to the male urethra. Sex Transm Dis 2011;38:372–3. 10.1097/OLQ.0b013e3182029008
    1. Manavi K, Hettiarachchi N, Hodson J. Comparison of doxycycline with azithromycin in treatment of pharyngeal chlamydia infection. Int J STD AIDS 2016;27:1303–8. 10.1177/0956462415614723
    1. Rank RG, Yeruva L. An alternative scenario to explain rectal positivity in Chlamydia-infected individuals. Clin Infect Dis 2015;60:1585–6. 10.1093/cid/civ079
    1. Geisler WM, Koltun WD, Abdelsayed N, et al. Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital Chlamydia trachomatis infection: a randomized, double-blind, double-dummy, active-controlled, multicenter trial. Clin Infect Dis 2012;55:82–8. 10.1093/cid/cis291
    1. Renault CA, Israelski DM, Levy V, Fujikawa BK, Kellogg TA, Klausner JD. Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection. Sex Health 2011;8:69–73. 10.1071/SH10030
    1. Lazenby GB, Korte JE, Tillman S, Brown FK, Soper DE. A recommendation for timing of repeat Chlamydia trachomatis test following infection and treatment in pregnant and nonpregnant women. Int J STD AIDS 2017;28:902–9. 10.1177/0956462416680438
    1. Dunne EF, Chapin JB, Rietmeijer CA, et al. Rate and predictors of repeat Chlamydia trachomatis infection among men. Sex Transm Dis 2008;35(Suppl):S40–4. 10.1097/OLQ.0b013e31817247b2
    1. Kjaer HO, Dimcevski G, Hoff G, Olesen F, Ostergaard L. Recurrence of urogenital Chlamydia trachomatis infection evaluated by mailed samples obtained at home: 24 weeks’ prospective follow up study. Sex Transm Infect 2000;76:169–72. 10.1136/sti.76.3.169
    1. Whittington WL, Kent C, Kissinger P, et al. Determinants of persistent and recurrent Chlamydia trachomatis infection in young women: results of a multicenter cohort study. Sex Transm Dis 2001;28:117–23. 10.1097/00007435-200102000-00011
    1. Kapil R, Press CG, Hwang ML, Brown L, Geisler WM. Investigating the epidemiology of repeat Chlamydia trachomatis detection after treatment by using C. trachomatis OmpA genotyping. J Clin Microbiol 2015;53:546–9. 10.1128/JCM.02483-14
    1. Jacobson GF, Autry AM, Kirby RS, Liverman EM, Motley RU. A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy. Am J Obstet Gynecol 2001;184:1352–6. 10.1067/mob.2001.115050
    1. Kacmar J, Cheh E, Montagno A, Peipert JF. A randomized trial of azithromycin versus amoxicillin for the treatment of Chlamydia trachomatis in pregnancy. Infect Dis Obstet Gynecol 2001;9:197–202. 10.1155/S1064744901000321
    1. Rahangdale L, Guerry S, Bauer HM, et al. An observational cohort study of Chlamydia trachomatis treatment in pregnancy. Sex Transm Dis 2006;33:106–10. 10.1097/01.olq.0000187226.32145.ea
    1. Aggarwal A, Spitzer RF, Caccia N, Stephens D, Johnstone J, Allen L. Repeat screening for sexually transmitted infection in adolescent obstetric patients. J Obstet Gynaecol Can 2010;32:956–61. 10.1016/S1701-2163(16)34683-7
    1. Phillips Campbell R, Kintner J, Whittimore J, Schoborg RV. Chlamydia muridarum enters a viable but non-infectious state in amoxicillin-treated BALB/c mice. Microbes Infect 2012;14:1177–85. 10.1016/j.micinf.2012.07.017
    1. Wyrick PB. Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis 2010;201(Suppl 2):S88–95. 10.1086/652394
    1. Fan H, Li L, Wijlaars L, Gilbert RE. Associations between use of macrolide antibiotics during pregnancy and adverse child outcomes: a systematic review and meta-analysis. PLoS One 2019;14:e0212212. 10.1371/journal.pone.0212212
    1. Fan H, Gilbert R, O’Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ 2020;368:m331. Erratum in: BMJ 2020;368:m766. 10.1136/bmj.m331
    1. Mallah N, Tohidinik HR, Etminan M, Figueiras A, Takkouche B. Prenatal exposure to macrolides and risk of congenital malformations: a meta-analysis. Drug Saf 2020;43:211–21. 10.1007/s40264-019-00884-5
    1. Hammerschlag MR, Cummings C, Roblin PM, Williams TH, Delke I. Efficacy of neonatal ocular prophylaxis for the prevention of chlamydial and gonococcal conjunctivitis. N Engl J Med 1989;320:769–72. 10.1056/NEJM198903233201204
    1. Zikic A, Schünemann H, Wi T, Lincetto O, Broutet N, Santesso N. Treatment of neonatal chlamydial conjunctivitis: a systematic review and meta-analysis. J Pediatric Infect Dis Soc 2018;7:e107–15. 10.1093/jpids/piy060
    1. Hammerschlag MR, Chandler JW, Alexander ER, English M, Koutsky L. Longitudinal studies on chlamydial infections in the first year of life. Pediatr Infect Dis 1982;1:395–401. 10.1097/00006454-198211000-00007
    1. Beem MO, Saxon E, Tipple MA. Treatment of chlamydial pneumonia of infancy. Pediatrics 1979;63:198–203.
    1. Brownell AD, Shapiro RA, Hammerschlag MR. Caution is required when using non-Food and Drug Administration-cleared assays to diagnose sexually transmitted infections in children. J Pediatr 2019;206:280–2. 10.1016/j.jpeds.2018.10.038
    1. Kreisel KM, Spicknall IH, Gargano JW, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2018. Sex Transm Dis 2021;48:208–14. 10.1097/OLQ.0000000000001355
    1. Lunny C, Taylor D, Hoang L, et al. Self-collected versus clinician-collected sampling for chlamydia and gonorrhea screening: a systemic review and meta-analysis. PLoS One 2015;10:e0132776. 10.1371/journal.pone.0132776
    1. Schick V, Van Der Pol B, Dodge B, Baldwin A, Fortenberry JD. A mixed methods approach to assess the likelihood of testing for STI using self-collected samples among behaviourally bisexual women. Sex Transm Infect 2015;91:329–33. 10.1136/sextrans-2014-051842
    1. Mustanski B, Feinstein BA, Madkins K, Sullivan P, Swann G. Prevalence and risk factors for rectal and urethral sexually transmitted infections from self-collected samples among young men who have sex with men participating in the Keep It Up! 2.0 randomized controlled trial. Sex Transm Dis 2017;44:483–8. 10.1097/OLQ.0000000000000636
    1. Salow KR, Cohen AC, Bristow CC, McGrath MR, Klausner JD. Comparing mail-in self-collected specimens sent via United States Postal Service versus clinic-collected specimens for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in extra-genital sites. PLoS One 2017;12:e0189515. 10.1371/journal.pone.0189515
    1. Drake C, Barenfanger J, Lawhorn J, Verhulst S. Comparison of Easy-Flow Copan Liquid Stuart’s and Starplex Swab transport systems for recovery of fastidious aerobic bacteria. J Clin Microbiol 2005;43:1301–3. 10.1128/JCM.43.3.1301-1303.2005
    1. Wade JJ, Graver MA. Survival of six auxotypes of Neisseria gonorrhoeae in transport media. J Clin Microbiol 2003;41:1720–1. 10.1128/JCM.41.4.1720-1721.2003
    1. Arbique JC, Forward KR, LeBlanc J. Evaluation of four commercial transport media for the survival of Neisseria gonorrhoeae. Diagn Microbiol Infect Dis 2000;36:163–8. 10.1016/S0732-8893(99)00134-0
    1. Hook EW 3rd, Kirkcaldy RD. A brief history of evolving diagnostics and therapy for gonorrhea: lessons learned. Clin Infect Dis 2018;67:1294–9. 10.1093/cid/ciy271
    1. Unemo M, Shafer WM. Future treatment of gonorrhea—novel emerging drugs are essential and in progress? Expert Opin Emerg Drugs 2015;20:357–60. 10.1517/14728214.2015.1039981
    1. Sánchez-Busó L, Golparian D, Corander J, et al. The impact of antimicrobials on gonococcal evolution. Nat Microbiol 2019;4:1941–50. 10.1038/s41564-019-0501-y
    1. Schwarcz SK, Zenilman JM, Schnell D, et al. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. The Gonococcal Isolate Surveillance Project. JAMA 1990;264:1413–7. 10.1001/jama.1990.03450110059027
    1. CDC. Update to CDC’s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007;56:332–6.
    1. CDC. Sexually transmitted disease surveillance 2013. Atlanta, GA: US Department of Health and Human Services, CDC; 2014.
    1. Muratani T, Akasaka S, Kobayashi T, et al. Outbreak of cefozopran (penicillin, oral cephems, and aztreonam)-resistant Neisseria gonorrhoeae in Japan. Antimicrob Agents Chemother 2001;45:3603–6. 10.1128/AAC.45.12.3603-3606.2001
    1. Yokoi S, Deguchi T, Ozawa T, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007;13:1275–7.
    1. Lo JY, Ho KM, Leung AO, et al. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother 2008;52:3564–7. 10.1128/AAC.00198-08
    1. Deguchi T, Yasuda M, Yokoi S, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother 2003;9:35–9. 10.1007/s10156-002-0204-8
    1. Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 2011;16:19792.
    1. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010;15:19721. 10.2807/ese.15.47.19721-en
    1. Unemo M, Golparian D, Potočnik M, Jeverica S. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill 2012;17:20200.
    1. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011;16:19833.
    1. Forsyth S, Penney P, Rooney G. Cefixime-resistant Neisseria gonorrhoeae in the UK: a time to reflect on practice and recommendations. Int J STD AIDS 2011;22:296–7. 10.1258/ijsa.2009.009191
    1. Lewis DA, Sriruttan C, Müller EE, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 2013;68:1267–70. 10.1093/jac/dkt034
    1. Ota KV, Fisman DN, Tamari IE, et al. Incidence and treatment outcomes of pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis infections in men who have sex with men: a 13-year retrospective cohort study. Clin Infect Dis 2009;48:1237–43. 10.1086/597586
    1. Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013;309:163–70. 10.1001/jama.2012.176575
    1. Chen MY, Stevens K, Tideman R, et al. Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother 2013;68:1445–7. 10.1093/jac/dkt017
    1. Tapsall J, Read P, Carmody C, et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009;58:683–7. 10.1099/jmm.0.007641-0
    1. Ohnishi M, Saika T, Hoshina S, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 2011;17:148–9. 10.3201/eid1701.100397
    1. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012;56:1273–80. 10.1128/AAC.05760-11
    1. CDC. Update to CDC’s sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012;61:590–4.
    1. Wind CM, de Vries E, Schim van der Loeff MF, et al. Decreased azithromycin susceptibility of Neisseria gonorrhoeae isolates in patients recently treated with azithromycin. Clin Infect Dis 2017;65:37–45. 10.1093/cid/cix249
    1. Kong FYS, Horner P, Unemo M, Hocking JS. Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review. J Antimicrob Chemother 2019;74:1157–66. 10.1093/jac/dky548
    1. CDC. Antibiotic resistance threats in the United States, 2019. Atlanta, GA: US Department of Health and Human Services, CDC; 2019.
    1. St Cyr S, Barbee L, Workowski KA, et al. Update to CDC’s treatment guidelines for gonococcal infection, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1911–6. 10.15585/mmwr.mm6950a6
    1. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. Clinical and Laboratory Standards Institute document M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
    1. CDC. Cephalosporin-resistant Neisseria gonorrhoeae public health response plan. Atlanta, GA: US Department of Health and Human Services, CDC; 2012.
    1. Poncin T, Merimeche M, Braille A, et al. Two cases of multidrug-resistant Neisseria gonorrhoeae related to travel in south-eastern Asia, France, June 2019. Euro Surveill 2019;24:1900528. 10.2807/1560-7917.ES.2019.24.36.1900528
    1. Carnicer-Pont D, Smithson A, Fina-Homar E, Bastida MT; Gonococcus Antimicrobial Resistance Surveillance Working Group. First cases of Neisseria gonorrhoeae resistant to ceftriaxone in Catalonia, Spain, May 2011. Enferm Infecc Microbiol Clin 2012;30:218–9. 10.1016/j.eimc.2011.11.010
    1. Cámara J, Serra J, Ayats J, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 2012;67:1858–60. 10.1093/jac/dks162
    1. Eyre DW, Sanderson ND, Lord E, et al. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Euro Surveill 2018;23:1800323. 10.2807/1560-7917.ES.2018.23.27.1800323
    1. Fifer H, Hughes G, Whiley D, Lahra MM. Lessons learnt from ceftriaxone-resistant gonorrhoea in the UK and Australia. Lancet Infect Dis 2020;20:276–8. 10.1016/S1473-3099(20)30055-4
    1. Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother 2010;65:2141–8. 10.1093/jac/dkq289
    1. Connolly KL, Eakin AE, Gomez C, Osborn BL, Unemo M, Jerse AE. Pharmacokinetic data are predictive of in vivo efficacy for cefixime and ceftriaxone against susceptible and resistant Neisseria gonorrhoeae strains in the gonorrhea mouse model. Antimicrob Agents Chemother 2019;63:e01644-18. 10.1128/AAC.01644-18
    1. Blondeau JM, Hansen G, Metzler K, Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother 2004;16(Suppl 3):1–19. 10.1080/1120009X.2004.11782371
    1. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995;20(Suppl 1):S47–65. 10.1093/clinids/20.Supplement_1.S47
    1. Unemo M, Golparian D, Eyre DW. Antimicrobial resistance in Neisseria gonorrhoeae and treatment of gonorrhea. Methods Mol Biol 2019;1997:37–58. 10.1007/978-1-4939-9496-0_3
    1. Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis 2014;59:1083–91. 10.1093/cid/ciu521
    1. Ross JDC, Brittain C, Cole M, et al.; G-ToG trial team. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial. Lancet 2019;393:2511–20. 10.1016/S0140-6736(18)32817-4
    1. Singh V, Bala M, Bhargava A, Kakran M, Bhatnagar R. In vitro efficacy of 21 dual antimicrobial combinations comprising novel and currently recommended combinations for treatment of drug resistant gonorrhoea in future era. PLoS One 2018;13:e0193678. 10.1371/journal.pone.0193678
    1. Mayer KH, Klausner JD, Handsfield HH. Intersecting epidemics and educable moments: sexually transmitted disease risk assessment and screening in men who have sex with men. Sex Transm Dis 2001;28:464–7. 10.1097/00007435-200108000-00008
    1. Linhart Y, Shohat T, Amitai Z, et al. Sexually transmitted infections among brothel-based sex workers in Tel-Aviv area, Israel: high prevalence of pharyngeal gonorrhoea. Int J STD AIDS 2008;19:656–9. 10.1258/ijsa.2008.008127
    1. Johnson Jones ML, Chapin-Bardales J, Bizune D, et al.; National HIV Behavioral Surveillance Sexually Transmitted Infection Study Group. Extragenital chlamydia and gonorrhea among community venue-attending men who have sex with men—five cities, United States, 2017. MMWR Morb Mortal Wkly Rep 2019;68:321–5. 10.15585/mmwr.mm6814a1
    1. Chow EP, Williamson DA, Fortune R, et al. Prevalence of genital and oropharyngeal chlamydia and gonorrhoea among female sex workers in Melbourne, Australia, 2015–2017: need for oropharyngeal testing. Sex Transm Infect 2019;95:398–401. 10.1136/sextrans-2018-053957
    1. Cornelisse VJ, Williamson D, Zhang L, et al. Evidence for a new paradigm of gonorrhoea transmission: cross-sectional analysis of Neisseria gonorrhoeae infections by anatomical site in both partners in 60 male couples. Sex Transm Infect 2019;95:437–42. 10.1136/sextrans-2018-053803
    1. Kissinger PJ, Reilly K, Taylor SN, Leichliter JS, Rosenthal S, Martin DH. Early repeat Chlamydia trachomatis and Neisseria gonorrhoeae infections among heterosexual men. Sex Transm Dis 2009;36:498–500. 10.1097/OLQ.0b013e3181a4d147
    1. Berenger BM, Demczuk W, Gratrix J, Pabbaraju K, Smyczek P, Martin I. Genetic characterization and enhanced surveillance of ceftriaxone-resistant Neisseria gonorrhoeae strain, Alberta, Canada, 2018. Emerg Infect Dis 2019;25:1660–7. 10.3201/eid2509.190407
    1. Rob F, Klubalová B, Nyčová E, Hercogová J, Unemo M. Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial. Clin Microbiol Infect 2020;26:207–12. 10.1016/j.cmi.2019.08.004
    1. Romano A, Gaeta F, Valluzzi RL, Caruso C, Rumi G, Bousquet PJ. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Allergy Clin Immunol 2010;126:994–9. 10.1016/j.jaci.2010.06.052
    1. American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice. Committee opinion No. 717: sulfonamides, nitrofurantoin, and risk of birth defects. Obstet Gynecol 2017;130:e150–2. 10.1097/AOG.0000000000002300
    1. Haimovici R, Roussel TJ. Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftriaxone. Am J Ophthalmol 1989;107:511–4. 10.1016/0002-9394(89)90495-9
    1. Bleich AT, Sheffield JS, Wendel GD Jr, Sigman A, Cunningham FG. Disseminated gonococcal infection in women. Obstet Gynecol 2012;119:597–602. 10.1097/AOG.0b013e318244eda9
    1. Belkacem A, Caumes E, Ouanich J, et al.; Working Group FRA-DGI. Changing patterns of disseminated gonococcal infection in France: cross-sectional data 2009–2011. Sex Transm Infect 2013;89:613–5. 10.1136/sextrans-2013-051119
    1. Birrell JM, Gunathilake M, Singleton S, Williams S, Krause V. Characteristics and impact of disseminated gonococcal infection in the “Top End” of Australia. Am J Trop Med Hyg 2019;101:753–60. 10.4269/ajtmh.19-0288
    1. Crew PE, Abara WE, McCulley L, et al. Disseminated gonococcal infections in patients receiving eculizumab: a case series. Clin Infect Dis 2019;69:596–600. 10.1093/cid/ciy958
    1. Curry SJ, Krist AH, Owens DK, et al.; US Preventive Services Task Force. Ocular prophylaxis for gonococcal ophthalmia neonatorum: US Preventive Services Task Force reaffirmation recommendation statement. JAMA 2019;321:394–8. 10.1001/jama.2018.21367
    1. Kreisel K, Weston E, Braxton J, Llata E, Torrone E. Keeping an eye on chlamydia and gonorrhea conjunctivitis in infants in the United States, 2010–2015. Sex Transm Dis 2017;44:356–8. 10.1097/OLQ.0000000000000613
    1. Scott WJ, Eck CD. Povidone-iodine and ophthalmia neonatorum. Ophthalmology 2012;119:653–4. 10.1016/j.ophtha.2011.11.037
    1. David M, Rumelt S, Weintraub Z. Efficacy comparison between povidone iodine 2.5% and tetracycline 1% in prevention of ophthalmia neonatorum. Ophthalmology 2011;118:1454–8. 10.1016/j.ophtha.2010.12.003
    1. Binenbaum G, Bruno CJ, Forbes BJ, et al. Periocular ulcerative dermatitis associated with gentamicin ointment prophylaxis in newborns. J Pediatr 2010;156:320–1. 10.1016/j.jpeds.2009.11.060
    1. Nathawad R, Mendez H, Ahmad A, et al. Severe ocular reactions after neonatal ocular prophylaxis with gentamicin ophthalmic ointment. Pediatr Infect Dis J 2011;30:175–6. 10.1097/INF.0b013e3181f6c2e5
    1. Taylor-Robinson D, Jensen JS. Mycoplasma genitalium: from chrysalis to multicolored butterfly. Clin Microbiol Rev 2011;24:498–514. 10.1128/CMR.00006-11
    1. Seña AC, Lensing S, Rompalo A, et al. Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis infections in men with nongonococcal urethritis: predictors and persistence after therapy. J Infect Dis 2012;206:357–65. 10.1093/infdis/jis356
    1. Huppert JS, Mortensen JE, Reed JL, Kahn JA, Rich KD, Hobbs MM. Mycoplasma genitalium detected by transcription-mediated amplification is associated with Chlamydia trachomatis in adolescent women. Sex Transm Dis 2008;35:250–4. 10.1097/OLQ.0b013e31815abac6
    1. Mena L, Wang X, Mroczkowski TF, Martin DH. Mycoplasma genitalium infections in asymptomatic men and men with urethritis attending a sexually transmitted diseases clinic in New Orleans. Clin Infect Dis 2002;35:1167–73. 10.1086/343829
    1. Falk L. The overall agreement of proposed definitions of mucopurulent cervicitis in women at high risk of Chlamydia infection. Acta Derm Venereol 2010;90:506–11. 10.2340/00015555-0924
    1. Anagrius C, Loré B, Jensen JS. Mycoplasma genitalium: prevalence, clinical significance, and transmission. Sex Transm Infect 2005;81:458–62. 10.1136/sti.2004.012062
    1. Manhart LE, Critchlow CW, Holmes KK, et al. Mucopurulent cervicitis and Mycoplasma genitalium. J Infect Dis 2003;187:650–7. 10.1086/367992
    1. Lusk MJ, Konecny P, Naing ZW, Garden FL, Cumming RG, Rawlinson WD. Mycoplasma genitalium is associated with cervicitis and HIV infection in an urban Australian STI clinic population. Sex Transm Infect 2011;87:107–9. 10.1136/sti.2010.045138
    1. Dehon PM, McGowin CL. The immunopathogenesis of Mycoplasma genitalium infections in women: a narrative review. Sex Transm Dis 2017;44:428–32. 10.1097/OLQ.0000000000000621
    1. Bjartling C, Osser S, Persson K. The association between Mycoplasma genitalium and pelvic inflammatory disease after termination of pregnancy. BJOG 2010;117:361–4. 10.1111/j.1471-0528.2009.02455.x
    1. Bjartling C, Osser S, Persson K. Mycoplasma genitalium in cervicitis and pelvic inflammatory disease among women at a gynecologic outpatient service. Am J Obstet Gynecol 2012;206:476.e1–8. 10.1016/j.ajog.2012.02.036
    1. Taylor BD, Zheng X, O’Connell CM, Wiesenfeld HC, Hillier SL, Darville T. Risk factors for Mycoplasma genitalium endometritis and incident infection: a secondary data analysis of the T cell Response Against Chlamydia (TRAC) Study. Sex Transm Infect 2018;94:414–20. 10.1136/sextrans-2017-053376
    1. Cohen CR, Mugo NR, Astete SG, et al. Detection of Mycoplasma genitalium in women with laparoscopically diagnosed acute salpingitis. Sex Transm Infect 2005;81:463–6. 10.1136/sti.2005.015701
    1. Haggerty CL, Totten PA, Astete SG, Ness RB. Mycoplasma genitalium among women with nongonococcal, nonchlamydial pelvic inflammatory disease. Infect Dis Obstet Gynecol 2006;2006:30184. 10.1155/IDOG/2006/30184
    1. Short VL, Totten PA, Ness RB, Astete SG, Kelsey SF, Haggerty CL. Clinical presentation of Mycoplasma genitalium infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease. Clin Infect Dis 2009;48:41–7. 10.1086/594123
    1. Simms I, Eastick K, Mallinson H, et al. Associations between Mycoplasma genitalium, Chlamydia trachomatis, and pelvic inflammatory disease. Sex Transm Infect 2003;79:154–6. 10.1136/sti.79.2.154
    1. Oakeshott P, Aghaizu A, Hay P, et al. Is Mycoplasma genitalium in women the “New Chlamydia?” A community-based prospective cohort study. Clin Infect Dis 2010;51:1160–6. 10.1086/656739
    1. Wiesenfeld HC, Hillier SL, Meyn L, et al. Mycoplasma genitalium—is it a pathogen in acute pelvic inflammatory disease (PID)? Sex Transm Infect 2013;89(Suppl 1):A34. 10.1136/sextrans-2013-051184.0106
    1. Møller BR, Taylor-Robinson D, Furr PM, Freundt EA. Acute upper genital-tract disease in female monkeys provoked experimentally by Mycoplasma genitalium. Br J Exp Pathol 1985;66:417–26.
    1. Wiesenfeld HC, Manhart LE. Mycoplasma genitalium in women: current knowledge and research priorities for this recently emerged pathogen. J Infect Dis 2017;216(suppl_2):S389–95.
    1. Clausen HF, Fedder J, Drasbek M, et al. Serological investigation of Mycoplasma genitalium in infertile women. Hum Reprod 2001;16:1866–74. 10.1093/humrep/16.9.1866
    1. Svenstrup HF, Fedder J, Kristoffersen SE, Trolle B, Birkelund S, Christiansen G. Mycoplasma genitalium, Chlamydia trachomatis, and tubal factor infertility—a prospective study. Fertil Steril 2008;90:513–20. 10.1016/j.fertnstert.2006.12.056
    1. Idahl A, Jurstrand M, Olofsson JI, Fredlund H. Mycoplasma genitalium serum antibodies in infertile couples and fertile women. Sex Transm Infect 2015;91:589–91. 10.1136/sextrans-2015-052011
    1. Edwards RK, Ferguson RJ, Reyes L, Brown M, Theriaque DW, Duff P. Assessing the relationship between preterm delivery and various microorganisms recovered from the lower genital tract. J Matern Fetal Neonatal Med 2006;19:357–63. 10.1080/00207170600712071
    1. Vandepitte J, Bukenya J, Hughes P, et al. Clinical characteristics associated with Mycoplasma genitalium infection among women at high risk of HIV and other STI in Uganda. Sex Transm Dis 2012;39:487–91. 10.1097/OLQ.0b013e31824b1cf3
    1. Rowlands S, Danielewski JA, Tabrizi SN, Walker SP, Garland SM. Microbial invasion of the amniotic cavity in midtrimester pregnancies using molecular microbiology. Am J Obstet Gynecol 2017;217:71.e1–5. 10.1016/j.ajog.2017.02.051
    1. Jurstrand M, Jensen JS, Magnuson A, Kamwendo F, Fredlund H. A serological study of the role of Mycoplasma genitalium in pelvic inflammatory disease and ectopic pregnancy. Sex Transm Infect 2007;83:319–23. 10.1136/sti.2007.024752
    1. Ashshi AM, Batwa SA, Kutbi SY, Malibary FA, Batwa M, Refaat B. Prevalence of 7 sexually transmitted organisms by multiplex real-time PCR in Fallopian tube specimens collected from Saudi women with and without ectopic pregnancy. BMC Infect Dis 2015;15:569. 10.1186/s12879-015-1313-1
    1. Bissessor M, Tabrizi SN, Bradshaw CS, et al. The contribution of Mycoplasma genitalium to the aetiology of sexually acquired infectious proctitis in men who have sex with men. Clin Microbiol Infect 2016;22:260–5. 10.1016/j.cmi.2015.11.016
    1. Ong JJ, Aung E, Read TRH, et al. Clinical characteristics of anorectal Mycoplasma genitalium infection and microbial cure in men who have sex with men. Sex Transm Dis 2018;45:522–6. 10.1097/OLQ.0000000000000793
    1. Read TRH, Murray GL, Danielewski JA, et al. symptoms, sites, and significance of Mycoplasma genitalium in men who have sex with men. Emerg Infect Dis 2019;25:719–27. 10.3201/eid2504.181258
    1. Cina M, Baumann L, Egli-Gany D, et al. Mycoplasma genitalium incidence, persistence, concordance between partners and progression: systematic review and meta-analysis. Sex Transm Infect 2019;95:328–35. 10.1136/sextrans-2018-053823
    1. Baumann L, Cina M, Egli-Gany D, et al. Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis. Sex Transm Infect 2018;94:255–62. 10.1136/sextrans-2017-053384
    1. Vandepitte J, Weiss HA, Bukenya J, et al. Association between Mycoplasma genitalium infection and HIV acquisition among female sex workers in Uganda: evidence from a nested case-control study. Sex Transm Infect 2014;90:545–9. 10.1136/sextrans-2013-051467
    1. Ferré VM, Ekouevi DK, Gbeasor-Komlanvi FA, et al. Prevalence of human papillomavirus, human immunodeficiency virus and other sexually transmitted infections among female sex workers in Togo: a national cross-sectional survey. Clin Microbiol Infect 2019;25:1560.e1–7. 10.1016/j.cmi.2019.04.015
    1. Mavedzenge SN, Van Der Pol B, Weiss HA, et al. The association between Mycoplasma genitalium and HIV-1 acquisition in African women. AIDS 2012;26:617–24. 10.1097/QAD.0b013e32834ff690
    1. Salado-Rasmussen K, Jensen JS. Mycoplasma genitalium testing pattern and macrolide resistance: a Danish nationwide retrospective survey. Clin Infect Dis 2014;59:24–30. 10.1093/cid/ciu217
    1. Wold C, Sorthe J, Hartgill U, Olsen AO, Moghaddam A, Reinton N. Identification of macrolide-resistant Mycoplasma genitalium using real-time PCR. J Eur Acad Dermatol Venereol 2015;29:1616–20. 10.1111/jdv.12963
    1. Gesink D, Racey CS, Seah C, et al. Mycoplasma genitalium in Toronto, Ont: estimates of prevalence and macrolide resistance. Can Fam Physician 2016;62:e96–101.
    1. Kristiansen GQ, Lisby JG, Schønning K. 5’ nuclease genotyping assay for identification of macrolide-resistant Mycoplasma genitalium in clinical specimens. J Clin Microbiol 2016;54:1593–7. 10.1128/JCM.00012-16
    1. Braam JF, Slotboom B, Van Marm S, et al. High prevalence of the A2058T macrolide resistance-associated mutation in Mycoplasma genitalium strains from the Netherlands. J Antimicrob Chemother 2017;72:1529–30. 10.1093/jac/dkw584
    1. Murray GL, Bradshaw CS, Bissessor M, et al. Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium. Emerg Infect Dis 2017;23:809–12. 10.3201/eid2305.161745
    1. Chernesky MA, Jang D, Martin I, et al.; Canadian MG Study Group. Mycoplasma genitalium antibiotic resistance-mediating mutations in Canadian women with or without Chlamydia trachomatis infection. Sex Transm Dis 2017;44:433–5. 10.1097/OLQ.0000000000000617
    1. Barberá MJ, Fernández-Huerta M, Jensen JS, Caballero E, Andreu A. Mycoplasma genitalium macrolide and fluoroquinolone resistance: prevalence and risk factors among a 2013–2014 cohort of patients in Barcelona, Spain. Sex Transm Dis 2017;44:457–62. 10.1097/OLQ.0000000000000631
    1. Sweeney EL, Trembizki E, Bletchly C, et al. Levels of Mycoplasma genitalium antimicrobial resistance differ by both region and gender in the state of Queensland, Australia: implications for treatment guidelines. J Clin Microbiol 2019;57:e01555-18. 10.1128/JCM.01555-18
    1. Bissessor M, Tabrizi SN, Twin J, et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis 2015;60:1228–36. 10.1093/cid/ciu1162
    1. Piñeiro L, Idigoras P, de la Caba I, López-Olaizola M, Cilla G. Guided antibiotic therapy for Mycoplasma genitalium infections: analysis of mutations associated with resistance to macrolides and fluoroquinolones [Spanish]. Enferm Infecc Microbiol Clin 2019;37:394–7.
    1. Dionne-Odom J, Geisler WM, Aaron KJ, et al. High prevalence of multidrug-resistant Mycoplasma genitalium in human immunodeficiency virus-infected men who have sex with men in Alabama. Clin Infect Dis 2018;66:796–8. 10.1093/cid/cix853
    1. Pitt R, Fifer H, Woodford N, Alexander S. Detection of markers predictive of macrolide and fluoroquinolone resistance in Mycoplasma genitalium from patients attending sexual health services in England. Sex Transm Infect 2018;94:9–13. 10.1136/sextrans-2017-053164
    1. Unemo M, Salado-Rasmussen K, Hansen M, et al. Clinical and analytical evaluation of the new Aptima Mycoplasma genitalium assay, with data on M. genitalium prevalence and antimicrobial resistance in M. genitalium in Denmark, Norway and Sweden in 2016. Clin Microbiol Infect 2018;24:533–9. 10.1016/j.cmi.2017.09.006
    1. Anderson T, Coughlan E, Werno A. Mycoplasma genitalium macrolide and fluoroquinolone resistance detection and clinical implications in a selected cohort in New Zealand. J Clin Microbiol 2017;55:3242–8. 10.1128/JCM.01087-17
    1. Shimada Y, Deguchi T, Nakane K, et al. Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistance. Int J Antimicrob Agents 2010;36:255–8. 10.1016/j.ijantimicag.2010.05.011
    1. Muller EE, Mahlangu MP, Lewis DA, Kularatne RS. Macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in Johannesburg, South Africa, 2007–2014. BMC Infect Dis 2019;19:148. 10.1186/s12879-019-3797-6
    1. Chambers LC, Jensen JS, Morgan JL, et al. Lack of association between the S83I ParC mutation in Mycoplasma genitalium and treatment outcomes among men who have sex with men with nongonococcal urethritis. Sex Transm Dis 2019;46:805–9. 10.1097/OLQ.0000000000001035
    1. Durukan D, Read TRH, Murray G, et al. Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline-2.5g azithromycin for the treatment of Mycoplasma genitalium infection: efficacy and tolerability. Clin Infect Dis 2020;71:1461–8. 10.1093/cid/ciz1031
    1. Li Y, Le WJ, Li S, Cao YP, Su XH. Meta-analysis of the efficacy of moxifloxacin in treating Mycoplasma genitalium infection. Int J STD AIDS 2017;28:1106–14. 10.1177/0956462416688562
    1. Mondeja BA, Couri J, Rodríguez NM, Blanco O, Fernández C, Jensen JS. Macrolide-resistant Mycoplasma genitalium infections in Cuban patients: an underestimated health problem. BMC Infect Dis 2018;18:601. 10.1186/s12879-018-3523-9
    1. Glaser AM, Geisler WM, Ratliff AE, Xiao L, Waites KB, Gaisa M. Two cases of multidrug-resistant genitourinary Mycoplasma genitalium infection successfully eradicated with minocycline. Int J STD AIDS 2019;30:512–4. 10.1177/0956462418816757
    1. Xiao L, Waites KB, Van Der Pol B, Aaron KJ, Hook EW 3rd, Geisler WM. Mycoplasma genitalium infections with macrolide and fluoroquinolone resistance-associated mutations in heterosexual African American couples in Alabama. Sex Transm Dis 2019;46:18–24. 10.1097/OLQ.0000000000000891
    1. Slifirski JB, Vodstrcil LA, Fairley CK, et al. Mycoplasma genitalium infection in adults reporting sexual contact with infected partners, Australia, 2008–2016. Emerg Infect Dis 2017;23:1826–33. 10.3201/eid2311.170998
    1. Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA 2004;291:1368–79. 10.1001/jama.291.11.1368
    1. Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol 2005;106:1013–23. 10.1097/01.AOG.0000183594.45524.d2
    1. Brotman RM, Klebanoff MA, Nansel TR, et al. Bacterial vaginosis assessed by Gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. J Infect Dis 2010;202:1907–15. 10.1086/657320
    1. Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sex Transm Dis 2019;46:304–11. 10.1097/OLQ.0000000000000972
    1. Kenyon CR, Buyze J, Klebanoff M, Brotman RM. Association between bacterial vaginosis and partner concurrency: a longitudinal study. Sex Transm Infect 2018;94:75–7. 10.1136/sextrans-2016-052652
    1. Sanchez S, Garcia PJ, Thomas KK, Catlin M, Holmes KK. Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol 2004;191:1898–906. 10.1016/j.ajog.2004.06.089
    1. Ness RB, Soper DE, Holley RL, et al.; PID Evaluation and Clinical Health (PEACH) Study Investigators. Douching and endometritis: results from the PID evaluation and clinical health (PEACH) study. Sex Transm Dis 2001;28:240–5. 10.1097/00007435-200104000-00010
    1. Gondwe T, Ness R, Totten PA, et al. Novel bacterial vaginosis-associated organisms mediate the relationship between vaginal douching and pelvic inflammatory disease. Sex Transm Infect 2020;96:439–44. 10.1136/sextrans-2019-054191
    1. Abbai NS, Reddy T, Ramjee G. Prevalent bacterial vaginosis infection—a risk factor for incident sexually transmitted infections in women in Durban, South Africa. Int J STD AIDS 2016;27:1283–8. 10.1177/0956462415616038
    1. Morris BJ, Hankins CA, Banerjee J, et al. Does male circumcision reduce women’s risk of sexually transmitted infections, cervical cancer, and associated conditions? Front Public Health 2019;7:4. 10.3389/fpubh.2019.00004
    1. Srinivasan S, Liu C, Mitchell CM, et al. Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. PLoS One 2010;5:e10197. 10.1371/journal.pone.0010197
    1. Gajer P, Brotman RM, Bai G, et al. Temporal dynamics of the human vaginal microbiota. Sci Transl Med 2012;4:132ra52. 10.1126/scitranslmed.3003605
    1. Fethers KA, Fairley CK, Morton A, et al. Early sexual experiences and risk factors for bacterial vaginosis. J Infect Dis 2009;200:1662–70. 10.1086/648092
    1. Achilles SL, Austin MN, Meyn LA, Mhlanga F, Chirenje ZM, Hillier SL. Impact of contraceptive initiation on vaginal microbiota. Am J Obstet Gynecol 2018;218:622.e1–10. 10.1016/j.ajog.2018.02.017
    1. Vodstrcil LA, Plummer ME, Fairley CK, et al. Combined oral contraceptive pill-exposure alone does not reduce the risk of bacterial vaginosis recurrence in a pilot randomised controlled trial. Sci Rep 2019;9:3555. 10.1038/s41598-019-39879-8
    1. Brooks JP, Edwards DJ, Blithe DL, et al. Effects of combined oral contraceptives, depot medroxyprogesterone acetate and the levonorgestrel-releasing intrauterine system on the vaginal microbiome. Contraception 2017;95:405–13. 10.1016/j.contraception.2016.11.006
    1. Moore KR, Harmon QE, Baird DD. Serum 25-hydroxyvitamin D and risk of self-reported bacterial vaginosis in a prospective cohort study of young African American women. J Womens Health (Larchmt) 2018;27:1278–84. 10.1089/jwh.2017.6804
    1. Lokken EM, Balkus JE, Kiarie J, et al. Association of recent bacterial vaginosis with acquisition of Mycoplasma genitalium. Am J Epidemiol 2017;186:194–201. 10.1093/aje/kwx043
    1. Brusselaers N, Shrestha S, van de Wijgert J, Verstraelen H. Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer: systematic review and meta-analysis. Am J Obstet Gynecol 2019;221:9–18.e8. 10.1016/j.ajog.2018.12.011
    1. Abbai NS, Nyirenda M, Naidoo S, Ramjee G. Prevalent herpes simplex virus-2 increases the risk of incident bacterial vaginosis in women from South Africa. AIDS Behav 2018;22:2172–80. 10.1007/s10461-017-1924-1
    1. Laxmi U, Agrawal S, Raghunandan C, Randhawa VS, Saili A. Association of bacterial vaginosis with adverse fetomaternal outcome in women with spontaneous preterm labor: a prospective cohort study. J Matern Fetal Neonatal Med 2012;25:64–7. 10.3109/14767058.2011.565390
    1. Cherpes TL, Wiesenfeld HC, Melan MA, et al. The associations between pelvic inflammatory disease, Trichomonas vaginalis infection, and positive herpes simplex virus type 2 serology. Sex Transm Dis 2006;33:747–52. 10.1097/01.olq.0000218869.52753.c7
    1. Nelson DB, Hanlon A, Hassan S, et al. Preterm labor and bacterial vaginosis-associated bacteria among urban women. J Perinat Med 2009;37:130–4. 10.1515/JPM.2009.026
    1. Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008;22:1493–501. 10.1097/QAD.0b013e3283021a37
    1. Gosmann C, Anahtar MN, Handley SA, et al. Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. Immunity 2017;46:29–37. 10.1016/j.immuni.2016.12.013
    1. McClelland RS, Lingappa JR, Srinivasan S, et al. Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study. Lancet Infect Dis 2018;18:554–64. 10.1016/S1473-3099(18)30058-6
    1. Johnston C, Magaret A, Srinivasan S, et al. P239 Genital HSV-2 suppression is not associated with alterations in the vaginal microbiome: a one-way, cross-over study. Sex Transm Infect 2019;95(Suppl 1):A148.
    1. Zozaya M, Ferris MJ, Siren JD, et al. Bacterial communities in penile skin, male urethra, and vaginas of heterosexual couples with and without bacterial vaginosis. Microbiome 2016;4:16. 10.1186/s40168-016-0161-6
    1. Liu CM, Hungate BA, Tobian AA, et al. Penile microbiota and female partner bacterial vaginosis in Rakai, Uganda. MBio 2015;6:e00589. 10.1128/mBio.00589-15
    1. Mehta SD. Systematic review of randomized trials of treatment of male sexual partners for improved bacteria vaginosis outcomes in women. Sex Transm Dis 2012;39:822–30. 10.1097/OLQ.0b013e3182631d89
    1. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983;74:14–22. 10.1016/0002-9343(83)91112-9
    1. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 1991;29:297–301. 10.1128/JCM.29.2.297-301.1991
    1. Schwebke JR, Hillier SL, Sobel JD, McGregor JA, Sweet RL. Validity of the vaginal Gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol 1996;88:573–6. 10.1016/0029-7844(96)00233-5
    1. Coleman JS, Gaydos CA. Molecular diagnosis of bacterial vaginosis: an update. J Clin Microbiol 2018;56:e00342-18. 10.1128/JCM.00342-18
    1. Myziuk L, Romanowski B, Johnson SC. BVBlue test for diagnosis of bacterial vaginosis. J Clin Microbiol 2003;41:1925–8. 10.1128/JCM.41.5.1925-1928.2003
    1. Bradshaw CS, Morton AN, Garland SM, Horvath LB, Kuzevska I, Fairley CK. Evaluation of a point-of-care test, BVBlue, and clinical and laboratory criteria for diagnosis of bacterial vaginosis. J Clin Microbiol 2005;43:1304–8. 10.1128/JCM.43.3.1304-1308.2005
    1. West B, Morison L, Schim van der Loeff M, et al. Evaluation of a new rapid diagnostic kit (FemExam) for bacterial vaginosis in patients with vaginal discharge syndrome in The Gambia. Sex Transm Dis 2003;30:483–9. 10.1097/00007435-200306000-00003
    1. Fredricks DN, Fiedler TL, Thomas KK, Oakley BB, Marrazzo JM. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol 2007;45:3270–6. 10.1128/JCM.01272-07
    1. Gaydos CA, Beqaj S, Schwebke JR, et al. Clinical validation of a test for the diagnosis of vaginitis. Obstet Gynecol 2017;130:181–9. 10.1097/AOG.0000000000002090
    1. Cartwright CP, Lembke BD, Ramachandran K, et al. Development and validation of a semiquantitative, multitarget PCR assay for diagnosis of bacterial vaginosis. J Clin Microbiol 2012;50:2321–9. 10.1128/JCM.00506-12
    1. Hilbert DW, Smith WL, Chadwick SG, et al. Development and validation of a highly accurate quantitative real-time PCR assay for diagnosis of bacterial vaginosis. J Clin Microbiol 2016;54:1017–24. Erratum in: J Clin Microbiol 2016;54:1930. 10.1128/JCM.03104-15
    1. Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol 2007;196:517.e1–6. 10.1016/j.ajog.2007.02.048
    1. Fjeld H, Raknes G. Is combining metronidazole and alcohol really hazardous? [Norwegian]. Tidsskr Nor Laegeforen 2014;134:1661–3. 10.4045/tidsskr.14.0081
    1. Hillier SL, Nyirjesy P, Waldbaum AS, et al. Secnidazole treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol 2017;130:379–86. 10.1097/AOG.0000000000002135
    1. Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol 2017;217:678.e1–9. Erratum in: Am J Obstet Gynecol 2018;219;110. 10.1016/j.ajog.2017.08.017
    1. Chavoustie SE, Gersten JK, Samuel MJ, Schwebke JR. A phase 3, multicenter, prospective, open-label study to evaluate the safety of a single dose of secnidazole 2 g for the treatment of women and postmenarchal adolescent girls with bacterial vaginosis. J Womens Health (Larchmt) 2018;27:492–7. 10.1089/jwh.2017.6500
    1. Livengood CH 3rd, Ferris DG, Wiesenfeld HC, et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol 2007;110:302–9. 10.1097/01.AOG.0000275282.60506.3d
    1. Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001;33:1341–6. 10.1086/323034
    1. Chavoustie SE, Jacobs M, Reisman HA, et al. Metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis: a dose-ranging study. J Low Genit Tract Dis 2015;19:129–34. 10.1097/LGT.0000000000000062
    1. Schwebke JR, Marrazzo J, Beelen AP, Sobel JD. A phase 3, multicenter, randomized, double-blind, vehicle-controlled study evaluating the safety and efficacy of metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis. Sex Transm Dis 2015;42:376–81. 10.1097/OLQ.0000000000000300
    1. Faro S, Skokos CK; Clindesse Investigators Group. The efficacy and safety of a single dose of Clindesse vaginal cream versus a seven-dose regimen of Cleocin vaginal cream in patients with bacterial vaginosis. Infect Dis Obstet Gynecol 2005;13:155–60. 10.1080/10647440500148321
    1. Marrazzo JM, Dombrowski JC, Wierzbicki MR, et al. Safety and efficacy of a novel vaginal anti-infective, TOL-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: a randomized, single-blind, phase 2, controlled trial. Clin Infect Dis 2019;68:803–9. 10.1093/cid/ciy554
    1. Antonio MA, Meyn LA, Murray PJ, Busse B, Hillier SL. Vaginal colonization by probiotic Lactobacillus crispatus CTV-05 is decreased by sexual activity and endogenous Lactobacilli. J Infect Dis 2009;199:1506–13. 10.1086/598686
    1. Senok AC, Verstraelen H, Temmerman M, Botta GA. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev 2009;(4):CD006289. 10.1002/14651858.CD006289.pub2
    1. Abad CL, Safdar N. The role of Lactobacillus probiotics in the treatment or prevention of urogenital infections—a systematic review. J Chemother 2009;21:243–52. 10.1179/joc.2009.21.3.243
    1. Mastromarino P, Macchia S, Meggiorini L, et al. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin Microbiol Infect 2009;15:67–74. 10.1111/j.1469-0691.2008.02112.x
    1. Hemmerling A, Harrison W, Schroeder A, et al. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex Transm Dis 2010;37:745–50. 10.1097/OLQ.0b013e3181e50026
    1. Bunge KE, Beigi RH, Meyn LA, Hillier SL. The efficacy of retreatment with the same medication for early treatment failure of bacterial vaginosis. Sex Transm Dis 2009;36:711–3. 10.1097/OLQ.0b013e3181af6cfd
    1. Aguin T, Akins RA, Sobel JD. High-dose vaginal maintenance metronidazole for recurrent bacterial vaginosis: a pilot study. Sex Transm Dis 2014;41:290–1. 10.1097/OLQ.0000000000000123
    1. Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006;194:1283–9. 10.1016/j.ajog.2005.11.041
    1. Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis 2009;36:732–4. 10.1097/OLQ.0b013e3181b08456
    1. McClelland RS, Richardson BA, Hassan WM, et al. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis 2008;197:1361–8. 10.1086/587490
    1. Schwebke J, Carter B, Waldbaum A, et al. Results of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of astodrimer gel for prevention of recurrent bacterial vaginosis. Am J Obstet Gynecol 2019;221:672–3. 10.1016/j.ajog.2019.10.087
    1. Cohen CR, Wierzbicki MR, French AL, et al. Randomized trial of Lactin-V to prevent recurrence of bacterial vaginosis. N Engl J Med 2020;382:1906–15. 10.1056/NEJMoa1915254
    1. Turner AN, Carr Reese P, Fields KS, et al. A blinded, randomized controlled trial of high-dose vitamin D supplementation to reduce recurrence of bacterial vaginosis. Am J Obstet Gynecol 2014;211:479.e1–13. 10.1016/j.ajog.2014.06.023
    1. Plummer EL, Vodstrcil LA, Danielewski JA, et al. Combined oral and topical antimicrobial therapy for male partners of women with bacterial vaginosis: acceptability, tolerability and impact on the genital microbiota of couples—a pilot study. PLoS One 2018;13:e0190199. 10.1371/journal.pone.0190199
    1. Schwebke JR, Lensing SY, Lee J, et al. Treatment of male sexual partners of women with bacterial vaginosis (BV): a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2020; Epub December 31, 2020.
    1. Koumans EH, Kendrick JS; CDC Bacterial Vaginosis Working Group. Preventing adverse sequelae of bacterial vaginosis: a public health program and research agenda. Sex Transm Dis 2001;28:292–7. 10.1097/00007435-200105000-00011
    1. Hauth JC, Goldenberg RL, Andrews WW, DuBard MB, Copper RL. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995;333:1732–6. 10.1056/NEJM199512283332603
    1. Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol 1994;171:345–9. 10.1016/S0002-9378(94)70033-8
    1. Yudin MH, Landers DV, Meyn L, Hillier SL. Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial. Obstet Gynecol 2003;102:527–34.
    1. Ugwumadu A, Reid F, Hay P, Manyonda I. Natural history of bacterial vaginosis and intermediate flora in pregnancy and effect of oral clindamycin. Obstet Gynecol 2004;104:114–9. 10.1097/01.AOG.0000130068.21566.4e
    1. Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995;172:525–9. 10.1016/0002-9378(95)90567-7
    1. Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 1993;82:348–52.
    1. Sheehy O, Santos F, Ferreira E, Berard A. The use of metronidazole during pregnancy: a review of evidence. Curr Drug Saf 2015;10:170–9. 10.2174/157488631002150515124548
    1. Lamont RF, Nhan-Chang CL, Sobel JD, Workowski K, Conde-Agudelo A, Romero R. Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol 2011;205:177–90. 10.1016/j.ajog.2011.03.047
    1. Odendaal HJ, Popov I, Schoeman J, Smith M, Grové D. Preterm labour—is bacterial vaginosis involved? S Afr Med J 2002;92:231–4.
    1. Carey JC, Klebanoff MA, Hauth JC, et al.; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. N Engl J Med 2000;342:534–40. 10.1056/NEJM200002243420802
    1. Vermeulen GM, Bruinse HW. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial. Br J Obstet Gynaecol 1999;106:652–7. 10.1111/j.1471-0528.1999.tb08363.x
    1. McDonald HM, O’Loughlin JA, Vigneswaran R, et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial. Br J Obstet Gynaecol 1997;104:1391–7. 10.1111/j.1471-0528.1997.tb11009.x
    1. Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 2003;361:983–8. 10.1016/S0140-6736(03)12823-1
    1. Subtil D, Brabant G, Tilloy E, et al. Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. Lancet 2018;392:2171–9. 10.1016/S0140-6736(18)31617-9
    1. Erickson SH, Oppenheim GL, Smith GH. Metronidazole in breast milk. Obstet Gynecol 1981;57:48–50.
    1. Passmore CM, McElnay JC, Rainey EA, D’Arcy PF. Metronidazole excretion in human milk and its effect on the suckling neonate. Br J Clin Pharmacol 1988;26:45–51. 10.1111/j.1365-2125.1988.tb03362.x
    1. United Kingdom National Health Service. Medicines Q&A: metronidazole—is it safe to use with breastfeeding? [Internet]. London, England: United Kingdom National Health Service, UK Medicines Information; 2012.
    1. Jamieson DJ, Duerr A, Klein RS, et al. Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol 2001;98:656–63. 10.1097/00006250-200110000-00023
    1. Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ 2019;97:548–562P. 10.2471/BLT.18.228486
    1. Hoots BE, Peterman TA, Torrone EA, Weinstock H, Meites E, Bolan GA. A Trich-y question: should Trichomonas vaginalis infection be reportable? Sex Transm Dis 2013;40:113–6. 10.1097/OLQ.0b013e31827c08c3
    1. Flagg EW, Meites E, Phillips C, Papp J, Torrone EA. Prevalence of Trichomonas vaginalis among civilian, noninstitutionalized male and female population aged 14 to 59 years: United States, 2013 to 2016. Sex Transm Dis 2019;46:e93–6. 10.1097/OLQ.0000000000001013
    1. Daugherty M, Glynn K, Byler T. Prevalence of Trichomonas vaginalis infection among US males, 2013–2016. Clin Infect Dis 2019;68:460–5. 10.1093/cid/ciy499
    1. Alcaide ML, Feaster DJ, Duan R, et al. The incidence of Trichomonas vaginalis infection in women attending nine sexually transmitted diseases clinics in the USA. Sex Transm Infect 2016;92:58–62. 10.1136/sextrans-2015-052010
    1. Muzny CA, Blackburn RJ, Sinsky RJ, Austin EL, Schwebke JR. Added benefit of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among men and women attending a sexually transmitted diseases clinic. Clin Infect Dis 2014;59:834–41. 10.1093/cid/ciu446
    1. Meites E, Llata E, Braxton J, et al. Trichomonas vaginalis in selected U.S. sexually transmitted disease clinics: testing, screening, and prevalence. Sex Transm Dis 2013;40:865–9. 10.1097/OLQ.0000000000000038
    1. Ginocchio CC, Chapin K, Smith JS, et al. Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the Aptima Trichomonas vaginalis nucleic acid amplification assay. J Clin Microbiol 2012;50:2601–8. 10.1128/JCM.00748-12
    1. Shuter J, Bell D, Graham D, Holbrook KA, Bellin EY. Rates of and risk factors for trichomoniasis among pregnant inmates in New York City. Sex Transm Dis 1998;25:303–7. 10.1097/00007435-199807000-00006
    1. Sosman JM, MacGowan RJ, Margolis AD, et al.; Project START Study Group. Screening for sexually transmitted diseases and hepatitis in 18–29-year-old men recently released from prison: feasibility and acceptability. Int J STD AIDS 2005;16:117–22. 10.1258/0956462053057594
    1. Rogers SM, Turner CF, Hobbs M, et al. Epidemiology of undiagnosed trichomoniasis in a probability sample of urban young adults. PLoS One 2014;9:e90548. 10.1371/journal.pone.0090548
    1. Mayer KH, Bush T, Henry K, et al.; SUN Investigators. Ongoing sexually transmitted disease acquisition and risk-taking behavior among US HIV-infected patients in primary care: implications for prevention interventions. Sex Transm Dis 2012;39:1–7. 10.1097/OLQ.0b013e31823b1922
    1. Seña AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis 2007;44:13–22. 10.1086/511144
    1. Kelley CF, Rosenberg ES, OʼHara BM, Sanchez T, del Rio C, Sullivan PS. Prevalence of urethral Trichomonas vaginalis in black and white men who have sex with men. Sex Transm Dis 2012;39:739. 10.1097/OLQ.0b013e318264248b
    1. Sutton M, Sternberg M, Koumans EH, McQuillan G, Berman S, Markowitz L. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001–2004. Clin Infect Dis 2007;45:1319–26. 10.1086/522532
    1. Peterman TA, Tian LH, Metcalf CA, Malotte CK, Paul SM, Douglas JM Jr; RESPECT-2 Study Group. Persistent, undetected Trichomonas vaginalis infections? Clin Infect Dis 2009;48:259–60. 10.1086/595706
    1. Wølner-Hanssen P, Krieger JN, Stevens CE, et al. Clinical manifestations of vaginal trichomoniasis. JAMA 1989;261:571–6. 10.1001/jama.1989.03420040109029
    1. Gray RH, Kigozi G, Serwadda D, et al. The effects of male circumcision on female partners’ genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol 2009;200:42.e1–7. 10.1016/j.ajog.2008.07.069
    1. Sobngwi-Tambekou J, Taljaard D, Nieuwoudt M, Lissouba P, Puren A, Auvert B. Male circumcision and Neisseria gonorrhoeae, Chlamydia trachomatis and Trichomonas vaginalis: observations after a randomised controlled trial for HIV prevention. Sex Transm Infect 2009;85:116–20. 10.1136/sti.2008.032334
    1. Tsai CS, Shepherd BE, Vermund SH. Does douching increase risk for sexually transmitted infections? A prospective study in high-risk adolescents. Am J Obstet Gynecol 2009;200:38.e1–8. 10.1016/j.ajog.2008.06.026
    1. Silver BJ, Guy RJ, Kaldor JM, Jamil MS, Rumbold AR. Trichomonas vaginalis as a cause of perinatal morbidity: a systematic review and meta-analysis. Sex Transm Dis 2014;41:369–76. 10.1097/OLQ.0000000000000134
    1. Yang S, Zhao W, Wang H, Wang Y, Li J, Wu X. Trichomonas vaginalis infection-associated risk of cervical cancer: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2018;228:166–73. 10.1016/j.ejogrb.2018.06.031
    1. Najafi A, Chaechi Nosrati MR, Ghasemi E, et al. Is there association between Trichomonas vaginalis infection and prostate cancer risk?: A systematic review and meta-analysis. Microb Pathog 2019;137:103752. 10.1016/j.micpath.2019.103752
    1. Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001;183:1017–22. 10.1086/319287
    1. Kissinger P, Amedee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis 2009;36:11–6. 10.1097/OLQ.0b013e318186decf
    1. Minkoff H, Grunebaum AN, Schwarz RH, et al. Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am J Obstet Gynecol 1984;150:965–72. 10.1016/0002-9378(84)90392-2
    1. Cotch MF, Pastorek JG 2nd, Nugent RP, et al.; The Vaginal Infections and Prematurity Study Group. Trichomonas vaginalis associated with low birth weight and preterm delivery. Sex Transm Dis 1997;24:353–60. 10.1097/00007435-199707000-00008
    1. Moodley P, Wilkinson D, Connolly C, Moodley J, Sturm AW. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis 2002;34:519–22. 10.1086/338399
    1. Francis SC, Kent CK, Klausner JD, et al. Prevalence of rectal Trichomonas vaginalis and Mycoplasma genitalium in male patients at the San Francisco STD clinic, 2005–2006. Sex Transm Dis 2008;35:797–800. 10.1097/OLQ.0b013e318177ec39
    1. Hollman D, Coupey SM, Fox AS, Herold BC. Screening for Trichomonas vaginalis in high-risk adolescent females with a new transcription-mediated nucleic acid amplification test (NAAT): associations with ethnicity, symptoms, and prior and current STIs. J Pediatr Adolesc Gynecol 2010;23:312–6. 10.1016/j.jpag.2010.03.004
    1. Roth AM, Williams JA, Ly R, et al. Changing sexually transmitted infection screening protocol will result in improved case finding for Trichomonas vaginalis among high-risk female populations. Sex Transm Dis 2011;38:398–400. 10.1097/OLQ.0b013e318203e3ce
    1. Hobbs MM, Seña AC. Modern diagnosis of Trichomonas vaginalis infection. Sex Transm Infect 2013;89:434–8. 10.1136/sextrans-2013-051057
    1. Kingston MA, Bansal D, Carlin EM. ‘Shelf life’ of Trichomonas vaginalis. Int J STD AIDS 2003;14:28–9. 10.1258/095646203321043228
    1. Schwebke JR, Hobbs MM, Taylor SN, et al. Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial. J Clin Microbiol 2011;49:4106–11. 10.1128/JCM.01291-11
    1. Huppert JS, Mortensen JE, Reed JL, et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis 2007;45:194–8. 10.1086/518851
    1. Van Der Pol B, Williams JA, Taylor SN, et al. Detection of Trichomonas vaginalis DNA by use of self-obtained vaginal swabs with the BD ProbeTec Qx assay on the BD Viper system. J Clin Microbiol 2014;52:885–9. 10.1128/JCM.02966-13
    1. Van Der Pol B, Williams JA, Fuller D, Taylor SN, Hook EW 3rd. Combined testing for chlamydia, gonorrhea, and trichomonas by use of the BD Max CT/GC/TV assay with genitourinary specimen types. J Clin Microbiol 2016;55:155–64. 10.1128/JCM.01766-16
    1. Schwebke JR, Gaydos CA, Davis T, et al. Clinical evaluation of the Cepheid Xpert TV Assay for detection of Trichomonas vaginalis with prospectively collected specimens from men and women. J Clin Microbiol 2018;56:e01091-17. 10.1128/JCM.01091-17
    1. Campbell L, Woods V, Lloyd T, Elsayed S, Church DL. Evaluation of the OSOM Trichomonas rapid test versus wet preparation examination for detection of Trichomonas vaginalis vaginitis in specimens from women with a low prevalence of infection. J Clin Microbiol 2008;46:3467–9. 10.1128/JCM.00671-08
    1. Huppert JS, Hesse E, Kim G, et al. Adolescent women can perform a point-of-care test for trichomoniasis as accurately as clinicians. Sex Transm Infect 2010;86:514–9. 10.1136/sti.2009.042168
    1. Sheele JM, Crandall CJ, Arko BL, et al. The OSOM® Trichomonas Test is unable to accurately diagnose Trichomonas vaginalis from urine in men. Am J Emerg Med 2019;37:1002–3. 10.1016/j.ajem.2018.10.022
    1. Gaydos CA, Schwebke J, Dombrowski J, et al. Clinical performance of the Solana® Point-of-Care Trichomonas Assay from clinician-collected vaginal swabs and urine specimens from symptomatic and asymptomatic women. Expert Rev Mol Diagn 2017;17:303–6. 10.1080/14737159.2017.1282823
    1. Gaydos CA, Hobbs M, Marrazzo J, et al. Rapid diagnosis of Trichomonas vaginalis by testing vaginal swabs in an isothermal helicase-dependent AmpliVue Assay. Sex Transm Dis 2016;43:369–73. 10.1097/OLQ.0000000000000447
    1. Patil MJ, Nagamoti JM, Metgud SC. Diagnosis of Trichomonas vaginalis from vaginal specimens by wet mount microscopy, In Pouch TV culture system, and PCR. J Glob Infect Dis 2012;4:22–5. 10.4103/0974-777X.93756
    1. Lawing LF, Hedges SR, Schwebke JR. Detection of trichomonosis in vaginal and urine specimens from women by culture and PCR. J Clin Microbiol 2000;38:3585–8. 10.1128/JCM.38.10.3585-3588.2000
    1. Mohamed OA, Cohen CR, Kungu D, et al. Urine proves a poor specimen for culture of Trichomonas vaginalis in women. Sex Transm Infect 2001;77:78–9. 10.1136/sti.77.1.78
    1. Rivers CA, Muzny CA, Schwebke JR. Diagnostic rates differ on the basis of the number of read days with the use of the InPouch culture system for Trichomonas vaginalis screening. J Clin Microbiol 2013;51:3875–6. 10.1128/JCM.02006-13
    1. Audisio T, Pigini T, de Riutort SV, et al. Validity of the Papanicolaou smear in the diagnosis of Candida spp., Trichomonas vaginalis, and bacterial vaginosis. J Low Genit Tract Dis 2001;5:223–5.
    1. Loo SK, Tang WY, Lo KK. Clinical significance of Trichomonas vaginalis detected in Papanicolaou smear: a survey in female Social Hygiene Clinic. Hong Kong Med J 2009;15:90–3.
    1. Howe K, Kissinger PJ. Single-dose compared with multidose metronidazole for the treatment of trichomoniasis in women: a meta-analysis. Sex Transm Dis 2017;44:29–34. 10.1097/OLQ.0000000000000537
    1. Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr 2010;55:565–71. 10.1097/QAI.0b013e3181eda955
    1. Wood BA, Monro AM. Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses. Br J Vener Dis 1975;51:51–3. 10.1136/sti.51.1.51
    1. Viitanen J, Haataja H, Männistö PT. Concentrations of metronidazole and tinidazole in male genital tissues. Antimicrob Agents Chemother 1985;28:812–4. 10.1128/AAC.28.6.812
    1. Gabriel G, Robertson E, Thin RN. Single dose treatment of trichomoniasis. J Int Med Res 1982;10:129–30. 10.1177/030006058201000212
    1. Mati JK, Wallace RJ. The treatment of trichomonal vaginitis using a single dose of tinidazole by mouth. East Afr Med J 1974;51:883–8.
    1. Anjaeyulu R, Gupte SA, Desai DB. Single-dose treatment of trichomonal vaginitis: a comparison of tinidazole and metronidazole. J Int Med Res 1977;5:438–41.
    1. Apte VV, Packard RS. Tinidazole in the treatment of trichomoniasis, giardiasis and amoebiasis. Report of a multicentre study. Drugs 1978;15(Suppl 1):43–8. 10.2165/00003495-197800151-00009
    1. O-Prasertsawat P, Jetsawangsri T. Split-dose metronidazole or single-dose tinidazole for the treatment of vaginal trichomoniasis. Sex Transm Dis 1992;19:295–7. 10.1097/00007435-199209000-00011
    1. Kawamura N. Metronidazole and tinidazole in a single large dose for treating urogenital infections with Trichomonas vaginalis in men. Br J Vener Dis 1978;54:81–3. 10.1136/sti.54.2.81
    1. Forna F, Gülmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev 2003;(2):CD000218.
    1. Cu-Uvin S, Ko H, Jamieson DJ, et al.; HIV Epidemiology Research Study (HERS) Group. Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis 2002;34:1406–11. 10.1086/340264
    1. Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother 2006;50:4209–10. 10.1128/AAC.00814-06
    1. Van Der Pol B, Williams JA, Orr DP, Batteiger BE, Fortenberry JD. Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women. J Infect Dis 2005;192:2039–44. 10.1086/498217
    1. Kirkcaldy RD, Augostini P, Asbel LE, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009–2010. Emerg Infect Dis 2012;18:939–43. 10.3201/eid1806.111590
    1. Crowell AL, Sanders-Lewis KA, Secor WE. In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob Agents Chemother 2003;47:1407–9. 10.1128/AAC.47.4.1407-1409.2003
    1. Muzny CA, Mena L, Lillis RA, et al. A comparison of 2 g single-dose versus 7-day 500 mg twice daily metronidazole for the treatment trichomoniasis in women by selected clinical factors. Am J Obstet Gynecol 2019;221:669. 10.1016/j.ajog.2019.10.079
    1. Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001;33:1341–6. 10.1086/323034
    1. Nyirjesy P, Gilbert J, Mulcahy LJ. Resistant trichomoniasis: successful treatment with combination therapy. Sex Transm Dis 2011;38:962–3. 10.1097/OLQ.0b013e31822037e4
    1. Muzny C, Barnes A, Mena L. Symptomatic Trichomonas vaginalis infection in the setting of severe nitroimidazole allergy: successful treatment with boric acid. Sex Health 2012;9:389–91. 10.1071/SH11114
    1. Aggarwal A, Shier RM. Recalcitrant Trichomonas vaginalis infections successfully treated with vaginal acidification. J Obstet Gynaecol Can 2008;30:55–8. 10.1016/S1701-2163(16)32714-1
    1. Dan M, Sobel JD. Failure of nitazoxanide to cure trichomoniasis in three women. Sex Transm Dis 2007;34:813–4. 10.1097/NMD.0b013e31802f5d9a
    1. Seña AC, Bachmann LH, Hobbs MM. Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations. Expert Rev Anti Infect Ther 2014;12:673–85. 10.1586/14787210.2014.887440
    1. Helms DJ, Mosure DJ, Secor WE, Workowski KA. Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol 2008;198:370.e1–7. 10.1016/j.ajog.2007.10.795
    1. Gendelman SR, Pien LC, Gutta RC, Abouhassan SR. Modified oral metronidazole desensitization protocol. Allergy Rhinol (Providence) 2014;5:66–9. 10.2500/ar.2014.5.0080
    1. Nyirjesy P, Sobel JD, Weitz MV, Leaman DJ, Gelone SP. Difficult-to-treat trichomoniasis: results with paromomycin cream. Clin Infect Dis 1998;26:986–8. 10.1086/513951
    1. Klebanoff MA, Carey JC, Hauth JC, et al.; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001;345:487–93. 10.1056/NEJMoa003329
    1. Stringer E, Read JS, Hoffman I, Valentine M, Aboud S, Goldenberg RL. Treatment of trichomoniasis in pregnancy in sub-Saharan Africa does not appear to be associated with low birth weight or preterm birth. S Afr Med J 2010;100:58–64.
    1. Caro-Patón T, Carvajal A, Martin de Diego I, Martin-Arias LH, Alvarez Requejo A, Rodríguez Pinilla E. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 1997;44:179–82. 10.1046/j.1365-2125.1997.00660.x
    1. Gülmezoglu AM. Interventions for trichomoniasis in pregnancy. Cochrane Database Syst Rev 2002;(3):CD000220.
    1. Goldenberg RL, Mwatha A, Read JS, et al.; Hptn024 Team. The HPTN 024 Study: the efficacy of antibiotics to prevent chorioamnionitis and preterm birth. Am J Obstet Gynecol 2006;194:650–61. 10.1016/j.ajog.2006.01.004
    1. Mann JR, McDermott S, Zhou L, Barnes TL, Hardin J. Treatment of trichomoniasis in pregnancy and preterm birth: an observational study. J Womens Health (Larchmt) 2009;18:493–7. 10.1089/jwh.2008.0964
    1. Carter JE, Whithaus KC. Neonatal respiratory tract involvement by Trichomonas vaginalis: a case report and review of the literature. Am J Trop Med Hyg 2008;78:17–9. 10.4269/ajtmh.2008.78.17
    1. Trintis J, Epie N, Boss R, Riedel S. Neonatal Trichomonas vaginalis infection: a case report and review of literature. Int J STD AIDS 2010;21:606–7. 10.1258/ijsa.2010.010174
    1. Miller M, Liao Y, Wagner M, Korves C. HIV, the clustering of sexually transmitted infections, and sex risk among African American women who use drugs. Sex Transm Dis 2008;35:696–702. 10.1097/OLQ.0b013e31816b1fb8
    1. Anderson BL, Firnhaber C, Liu T, et al. Effect of trichomoniasis therapy on genital HIV viral burden among African women. Sex Transm Dis 2012;39:638–42. 10.1097/OLQ.0b013e31825725ad
    1. Masese LN, Graham SM, Gitau R, et al. A prospective study of vaginal trichomoniasis and HIV-1 shedding in women on antiretroviral therapy. BMC Infect Dis 2011;11:307. 10.1186/1471-2334-11-307
    1. Balkus JE, Richardson BA, Mochache V, et al. A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women. Sex Transm Dis 2013;40:499–505. 10.1097/OLQ.0b013e31828fce34
    1. Gumbo FZ, Duri K, Kandawasvika GQ, et al. Risk factors of HIV vertical transmission in a cohort of women under a PMTCT program at three peri-urban clinics in a resource-poor setting. J Perinatol 2010;30:717–23. 10.1038/jp.2010.31
    1. Brüggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009;48:1441–58. 10.1086/598327
    1. Shahid Z, Sobel JD. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagn Microbiol Infect Dis 2009;64:354–6. 10.1016/j.diagmicrobio.2009.03.021
    1. Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol 2012;120:1407–14. 10.1097/AOG.0b013e31827307b2
    1. Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis 2018;18:e339–47. 10.1016/S1473-3099(18)30103-8
    1. Crouss T, Sobel JD, Smith K, Nyirjesy P. Long-term outcomes of women with recurrent vulvovaginal candidiasis after a course of maintenance antifungal therapy. J Low Genit Tract Dis 2018;22:382–6. 10.1097/LGT.0000000000000413
    1. Kennedy MA, Sobel JD. Vulvovaginal candidiasis caused by non-albicans Candida species: new insights. Curr Infect Dis Rep 2010;12:465–70. 10.1007/s11908-010-0137-9
    1. Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003;189:1297–300. 10.1067/S0002-9378(03)00726-9
    1. Mølgaard-Nielsen D, Svanström H, Melbye M, Hviid A, Pasternak B. Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth. JAMA 2016;315:58–67. 10.1001/jama.2015.17844
    1. Bérard A, Sheehy O, Zhao JP, et al. Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies. CMAJ 2019;191:E179–87. 10.1503/cmaj.180963
    1. Ohmit SE, Sobel JD, Schuman P, et al.; HIV Epidemiology Research Study (HERS) Group. Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003;188:118–27. 10.1086/375746
    1. Duerr A, Heilig CM, Meikle SF, et al.; HER Study Group. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: risk factors and severity. Obstet Gynecol 2003;101:548–56. 10.1097/00006250-200303000-00022
    1. Vazquez JA, Peng G, Sobel JD, et al. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis 2001;33:1069–75. 10.1086/322641
    1. Darville T; Pelvic Inflammatory Disease Workshop Proceedings Committee. Pelvic inflammatory disease: identifying research gaps—proceedings of a workshop sponsored by Department of Health and Human Services/National Institutes of Health/National Institute of Allergy and Infectious Diseases, November 3–4, 2011. Sex Transm Dis 2013;40:761–7. 10.1097/OLQ.0000000000000028
    1. Wiesenfeld HC, Sweet RL, Ness RB, Krohn MA, Amortegui AJ, Hillier SL. Comparison of acute and subclinical pelvic inflammatory disease. Sex Transm Dis 2005;32:400–5. 10.1097/01.olq.0000154508.26532.6a
    1. Wiesenfeld HC, Hillier SL, Meyn LA, Amortegui AJ, Sweet RL. Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol 2012;120:37–43. 10.1097/AOG.0b013e31825a6bc9
    1. Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–37. 10.1067/mob.2002.121625
    1. Burnett AM, Anderson CP, Zwank MD. Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis. Am J Emerg Med 2012;30:1114–7. 10.1016/j.ajem.2011.07.014
    1. Wiesenfeld HC, Meyn LA, Darville T, Macio IS, Hillier SL. A randomized controlled trial of ceftriaxone and doxycycline, with or without metronidazole, for the treatment of acute pelvic inflammatory disease. Clin Infect Dis 2021;72:1181–9. 10.1093/cid/ciaa101
    1. Ness RB, Kip KE, Hillier SL, et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol 2005;162:585–90. 10.1093/aje/kwi243
    1. Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996;334:1362–6. 10.1056/NEJM199605233342103
    1. Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (Prevention of Pelvic Infection) trial. BMJ 2010;340:c1642. 10.1136/bmj.c1642
    1. Peipert JF, Ness RB, Blume J, et al.; Pelvic Inflammatory Disease Evaluation and Clinical Health Study Investigators. Clinical predictors of endometritis in women with symptoms and signs of pelvic inflammatory disease. Am J Obstet Gynecol 2001;184:856–64. 10.1067/mob.2001.113847
    1. Gaitán H, Angel E, Diaz R, Parada A, Sanchez L, Vargas C. Accuracy of five different diagnostic techniques in mild-to-moderate pelvic inflammatory disease. Infect Dis Obstet Gynecol 2002;10:171–80. 10.1155/S1064744902000194
    1. Vicetti Miguel RD, Chivukula M, Krishnamurti U, et al. Limitations of the criteria used to diagnose histologic endometritis in epidemiologic pelvic inflammatory disease research. Pathol Res Pract 2011;207:680–5. 10.1016/j.prp.2011.08.007
    1. Jacobson L, Weström L. Objectivized diagnosis of acute pelvic inflammatory disease. Diagnostic and prognostic value of routine laparoscopy. Am J Obstet Gynecol 1969;105:1088–98. 10.1016/0002-9378(69)90132-X
    1. Sellors J, Mahony J, Goldsmith C, et al. The accuracy of clinical findings and laparoscopy in pelvic inflammatory disease. Am J Obstet Gynecol 1991;164:113–20. 10.1016/0002-9378(91)90639-9
    1. Bevan CD, Johal BJ, Mumtaz G, Ridgway GL, Siddle NC. Clinical, laparoscopic and microbiological findings in acute salpingitis: report on a United Kingdom cohort. Br J Obstet Gynaecol 1995;102:407–14. 10.1111/j.1471-0528.1995.tb11294.x
    1. Jaiyeoba O, Soper DE. A practical approach to the diagnosis of pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011;2011:753037. 10.1155/2011/753037
    1. Sweet RL. Treatment of acute pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011;2011:561909. 10.1155/2011/561909
    1. Smith KJ, Ness RB, Wiesenfeld HC, Roberts MS. Cost-effectiveness of alternative outpatient pelvic inflammatory disease treatment strategies. Sex Transm Dis 2007;34:960–6. 10.1097/01.olq.0000225321.61049.13
    1. Petrina MAB, Cosentino LA, Wiesenfeld HC, Darville T, Hillier SL. Susceptibility of endometrial isolates recovered from women with clinical pelvic inflammatory disease or histological endometritis to antimicrobial agents. Anaerobe 2019;56:61–5. 10.1016/j.anaerobe.2019.02.005
    1. Haggerty CL, Ness RB, Amortegui A, et al. Endometritis does not predict reproductive morbidity after pelvic inflammatory disease. Am J Obstet Gynecol 2003;188:141–8. 10.1067/mob.2003.87
    1. Haggerty CL, Totten PA, Tang G, et al. Identification of novel microbes associated with pelvic inflammatory disease and infertility. Sex Transm Infect 2016;92:441–6. 10.1136/sextrans-2015-052285
    1. Ness RB, Randall H, Richter HE, et al.; Pelvic Inflammatory Disease Evaluation and Clinical Health Study Investigators. Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease. Am J Public Health 2004;94:1327–9. 10.2105/AJPH.94.8.1327
    1. McGregor JA, Crombleholme WR, Newton E, Sweet RL, Tuomala R, Gibbs RS. Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis. Obstet Gynecol 1994;83:998–1004. 10.1097/00006250-199406000-00020
    1. Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res 2003;31:45–54. 10.1177/147323000303100108
    1. Heystek M, Ross JD; PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009;20:690–5. 10.1258/ijsa.2008.008495
    1. Boothby M, Page J, Pryor R, Ross JD. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. Int J STD AIDS 2010;21:195–7. 10.1258/ijsa.2009.009374
    1. Judlin P, Liao Q, Liu Z, Reimnitz P, Hampel B, Arvis P. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010;117:1475–84. 10.1111/j.1471-0528.2010.02687.x
    1. Korn AP. Pelvic inflammatory disease in women infected with HIV. AIDS Patient Care STDS 1998;12:431–4. 10.1089/apc.1998.12.431
    1. Irwin KL, Moorman AC, O’Sullivan MJ, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol 2000;95:525–34.
    1. Bukusi EA, Cohen CR, Stevens CE, et al. Effects of human immunodeficiency virus 1 infection on microbial origins of pelvic inflammatory disease and on efficacy of ambulatory oral therapy. Am J Obstet Gynecol 1999;181:1374–81. 10.1016/S0002-9378(99)70378-9
    1. Mugo NR, Kiehlbauch JA, Nguti R, et al. Effect of human immunodeficiency virus-1 infection on treatment outcome of acute salpingitis. Obstet Gynecol 2006;107:807–12. 10.1097/01.AOG.0000207597.70524.e8
    1. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000;356:1013–9. 10.1016/S0140-6736(00)02699-4
    1. Viberga I, Odlind V, Lazdane G, Kroica J, Berglund L, Olofsson S. Microbiology profile in women with pelvic inflammatory disease in relation to IUD use. Infect Dis Obstet Gynecol 2005;13:183–90. 10.1155/2005/376830
    1. Jatlaoui TC, Riley HEM, Curtis KM. The safety of intrauterine devices among young women: a systematic review. Contraception 2017;95:17–39. 10.1016/j.contraception.2016.10.006
    1. Chen MJ, Kim CR, Whitehouse KC, Berry-Bibee E, Gaffield ME. Development, updates, and future directions of the World Health Organization Selected Practice Recommendations for Contraceptive Use. Int J Gynaecol Obstet 2017;136:113–9. 10.1002/ijgo.12064
    1. Tepper NK, Steenland MW, Gaffield ME, Marchbanks PA, Curtis KM. Retention of intrauterine devices in women who acquire pelvic inflammatory disease: a systematic review. Contraception 2013;87:655–60. 10.1016/j.contraception.2012.08.011
    1. Louette A, Krahn J, Caine V, Ha S, Lau TTY, Singh AE. Treatment of acute epididymitis: a systematic review and discussion of the implications for treatment based on etiology. Sex Transm Dis 2018;45:e104–8. 10.1097/OLQ.0000000000000901
    1. Pilatz A, Hossain H, Kaiser R, et al. Acute epididymitis revisited: impact of molecular diagnostics on etiology and contemporary guideline recommendations. Eur Urol 2015;68:428–35. 10.1016/j.eururo.2014.12.005
    1. Hongo H, Kikuchi E, Matsumoto K, et al. Novel algorithm for management of acute epididymitis. Int J Urol 2017;24:82–7. 10.1111/iju.13236
    1. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324:17–27. 10.1016/j.virol.2004.03.033
    1. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158–71. 10.1093/oxfordjournals.aje.a010166
    1. Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis 2014;41:660–4. 10.1097/OLQ.0000000000000193
    1. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204. 10.1016/S1470-2045(05)70086-3
    1. Senkomago V, Henley SJ, Thomas CC, Mix JM, Markowitz LE, Saraiya M. Human papillomavirus-attributable cancers—United States, 2012–2016. MMWR Morb Mortal Wkly Rep 2019;68:724–8. 10.15585/mmwr.mm6833a3
    1. Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine 2012;30:6016–9. 10.1016/j.vaccine.2012.07.056
    1. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis 2013;208:385–93. 10.1093/infdis/jit192
    1. Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003–2010: potential impact of human papillomavirus vaccination. Am J Public Health 2013;103:1428–35. 10.2105/AJPH.2012.301182
    1. McClung NM, Lewis RM, Gargano JW, Querec T, Unger ER, Markowitz LE. Declines in vaccine-type human papillomavirus prevalence in females across racial/ethnic groups: data from a national survey. J Adolesc Health 2019;65:715–22. 10.1016/j.jadohealth.2019.07.003
    1. Drolet M, Bénard É, Pérez N, et al.; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019;394:497–509. 10.1016/S0140-6736(19)30298-3
    1. Mayhew A, Mullins TL, Ding L, et al. Risk perceptions and subsequent sexual behaviors after HPV vaccination in adolescents. Pediatrics 2014;133:404–11. 10.1542/peds.2013-2822
    1. Brouwer AF, Delinger RL, Eisenberg MC, et al. HPV vaccination has not increased sexual activity or accelerated sexual debut in a college-aged cohort of men and women. BMC Public Health 2019;19:821. 10.1186/s12889-019-7134-1
    1. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009;199:805–14. 10.1086/597071
    1. Flagg EW, Torrone EA. Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006–2014. Am J Public Health 2018;108:112–9. 10.2105/AJPH.2017.304119
    1. Hariri S, Schuler MS, Naleway AL, et al. Human papillomavirus vaccine effectiveness against incident genital warts among female health-plan enrollees, United States. Am J Epidemiol 2018;187:298–305. 10.1093/aje/kwx253
    1. Wangu Z, Hsu KK. Impact of HPV vaccination on anogenital warts and respiratory papillomatosis. Hum Vaccin Immunother 2016;12:1357–62. 10.1080/21645515.2016.1172754
    1. Swedish KA, Goldstone SE. Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men. PLoS One 2014;9:e93393. 10.1371/journal.pone.0093393
    1. Sandø N, Kofoed K, Zachariae C, Fouchard J. A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women—an ecological study. Acta Derm Venereol 2014;94:288–92. 10.2340/00015555-1721
    1. Herweijer E, Ploner A, Sparén P. Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden. Vaccine 2018;36:1917–20. 10.1016/j.vaccine.2018.02.097
    1. Harrison C, Britt H, Garland S, et al. Decreased management of genital warts in young women in Australian general practice post introduction of national HPV vaccination program: results from a nationally representative cross-sectional general practice study. PLoS One 2014;9:e105967. 10.1371/journal.pone.0105967
    1. Canvin M, Sinka K, Hughes G, Mesher D. Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. Sex Transm Infect 2017;93:125–8. 10.1136/sextrans-2016-052626
    1. Chow EP, Read TR, Wigan R, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2015;91:214–9. 10.1136/sextrans-2014-051813
    1. Petrosky EY, Liu G, Hariri S, Markowitz LE. Human papillomavirus vaccination and age at first sexual activity, National Health and Nutrition Examination Survey. Clin Pediatr (Phila) 2017;56:363–70. 10.1177/0009922816660541
    1. Gotovtseva EP, Kapadia AS, Smolensky MH, Lairson DR. Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis. Sex Transm Dis 2008;35:346–51. 10.1097/OLQ.0b013e31815ea8d1
    1. Baker DA, Ferris DG, Martens MG, et al. Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies. Infect Dis Obstet Gynecol 2011;2011:806105. 10.1155/2011/806105
    1. Mashiah J, Brenner S. Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. Clin Exp Dermatol 2008;33:74–6.
    1. Domingues E, Chaney KC, Scharf MJ, Wiss K. Imiquimod reactivation of lichen planus. Cutis 2012;89:276–7, 283.
    1. Patel U, Mark NM, Machler BC, Levine VJ. Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism. Br J Dermatol 2011;164:670–2. 10.1111/j.1365-2133.2010.10124.x
    1. Kumar B, Narang T. Local and systemic adverse effects to topical imiquimod due to systemic immune stimulation. Sex Transm Infect 2011;87:432. 10.1136/sextrans-2011-050025
    1. Stockfleth E, Beti H, Orasan R, et al. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol 2008;158:1329–38. 10.1111/j.1365-2133.2008.08520.x
    1. Gross G, Meyer KG, Pres H, Thielert C, Tawfik H, Mescheder A. A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. J Eur Acad Dermatol Venereol 2007;21:1404–12. 10.1111/j.1468-3083.2007.02441.x
    1. Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 2008;111:1371–9. 10.1097/AOG.0b013e3181719b60
    1. National Institute for Occupational Safety and Health. Control of smoke from laser/electric surgical procedures. Washington, DC: US Department of Health and Human Services, CDC, National Institute for Occupational Safety and Health; 1996.
    1. Filley CM, Graff-Richard NR, Lacy JR, Heitner MA, Earnest MP. Neurologic manifestations of podophyllin toxicity. Neurology 1982;32:308–11. 10.1212/WNL.32.3.308
    1. Conard PF, Hanna N, Rosenblum M, Gross JB. Delayed recognition of podophyllum toxicity in a patient receiving epidural morphine. Anesth Analg 1990;71:191–3. 10.1213/00000539-199008000-00013
    1. Karol MD, Conner CS, Watanabe AS, Murphrey KJ. Podophyllum: suspected teratogenicity from topical application. Clin Toxicol 1980;16:283–6. 10.3109/15563658008989950
    1. Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003;101:645–52.
    1. Dolev JC, Maurer T, Springer G, et al. Incidence and risk factors for verrucae in women. AIDS 2008;22:1213–9. 10.1097/QAD.0b013e3283021aa3
    1. Silverberg MJ, Ahdieh L, Munoz A, et al. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis 2002;29:427–35. 10.1097/00007435-200208000-00001
    1. De Panfilis G, Melzani G, Mori G, Ghidini A, Graifemberghi S. Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls. Sex Transm Dis 2002;29:121–5. 10.1097/00007435-200203000-00001
    1. Conley LJ, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002;359:108–13. 10.1016/S0140-6736(02)07368-3
    1. Schlecht HP, Fugelso DK, Murphy RK, et al. Frequency of occult high-grade squamous intraepithelial neoplasia and invasive cancer within anal condylomata in men who have sex with men. Clin Infect Dis 2010;51:107–10. 10.1086/653426
    1. Maniar KP, Ronnett BM, Vang R, Yemelyanova A. Coexisting high-grade vulvar intraepithelial neoplasia (VIN) and condyloma acuminatum: independent lesions due to different HPV types occurring in immunocompromised patients. Am J Surg Pathol 2013;37:53–60. 10.1097/PAS.0b013e318263cda6
    1. Massad LS, Xie X, Darragh T, et al.; Women’s Interagency HIV Study Collaborative Study Group. Genital warts and vulvar intraepithelial neoplasia: natural history and effects of treatment and human immunodeficiency virus infection. Obstet Gynecol 2011;118:831–9. 10.1097/AOG.0b013e31821a0f4d
    1. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30(Suppl 5):F12–23. 10.1016/j.vaccine.2012.07.055
    1. Darragh TM, Colgan TJ, Cox JT, et al.; Members of LAST Project Work Groups. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med 2012;136:1266–97. 10.5858/arpa.LGT200570
    1. Committee on Practice Bulletins—Gynecology. Practice Bulletin No. 168 Summary: Cervical cancer screening and prevention. Obstet Gynecol 2016;128:923–5. 10.1097/AOG.0000000000001699
    1. Perkins RB, Guido RL, Saraiya M, et al. Summary of current guidelines for cervical cancer screening and management of abnormal test results: 2016–2020. J Womens Health (Larchmt) 2021;30:5–13. 10.1089/jwh.2020.8918
    1. Kim JJ, Burger EA, Regan C, Sy S. Screening for cervical cancer in primary care: a decision analysis for the US Preventive Services Task Force. JAMA 2018;320:706–14. 10.1001/jama.2017.19872
    1. Sawaya GF, Sanstead E, Alarid-Escudero F, et al. Estimated quality of life and economic outcomes associated with 12 cervical cancer screening strategies: a cost-effectiveness analysis. JAMA Intern Med 2019;179:867–78. 10.1001/jamainternmed.2019.0299
    1. Saslow D, Solomon D, Lawson HW, et al.; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62:147–72. 10.3322/caac.21139
    1. Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 131: Screening for cervical cancer. Obstet Gynecol 2012;120:1222–38. 10.1097/AOG.0b013e318277c92a
    1. Meyerson BE, Sayegh MA, Davis A, et al. Cervical cancer screening in a sexually transmitted disease clinic: screening adoption experiences from a midwestern clinic. Am J Public Health 2015;105(Suppl 2):e8–14. 10.2105/AJPH.2014.302272
    1. Perkins RB, Guido RS, Castle PE, et al.; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2020;24:102–31. 10.1097/LGT.0000000000000525
    1. Saraiya M, Lee NC, Blackman D, Smith MJ, Morrow B, McKenna MA. Self-reported Papanicolaou smears and hysterectomies among women in the United States. Obstet Gynecol 2001;98:269–78.
    1. Sirovich BE, Welch HG. Cervical cancer screening among women without a cervix. JAMA 2004;291:2990–3. 10.1001/jama.291.24.2990
    1. Stokes-Lampard H, Wilson S, Waddell C, Ryan A, Holder R, Kehoe S. Vaginal vault smears after hysterectomy for reasons other than malignancy: a systematic review of the literature. BJOG 2006;113:1354–65. 10.1111/j.1471-0528.2006.01099.x
    1. Arbyn M, Herbert A, Schenck U, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 2007;18:133–9. 10.1111/j.1365-2303.2007.00464.x
    1. Daley E, Perrin K, Vamos C, et al. Confusion about Pap smears: lack of knowledge among high-risk women. J Womens Health (Larchmt) 2013;22:67–74. 10.1089/jwh.2012.3667
    1. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015;15:565–80. 10.1016/S1473-3099(14)71073-4
    1. Ogbechie OA, Hacker MR, Dodge LE, Patil MM, Ricciotti HA. Confusion regarding cervical cancer screening and chlamydia screening among sexually active young women. Sex Transm Infect 2012;88:35–7. 10.1136/sextrans-2011-050289
    1. Dunne EF, Friedman A, Datta SD, Markowitz LE, Workowski KA. Updates on human papillomavirus and genital warts and counseling messages from the 2010 Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis 2011;53(Suppl 3):S143–52. 10.1093/cid/cir703
    1. Fry AM, Ferries-Rowe EA, Learman LA, Haas DM. Pap smear versus speculum examination: can we teach providers to educate patients? J Womens Health (Larchmt) 2010;19:1715–9. 10.1089/jwh.2009.1862
    1. Adab P, Marshall T, Rouse A, Randhawa B, Sangha H, Bhangoo N. Randomised controlled trial of the effect of evidence based information on women’s willingness to participate in cervical cancer screening. J Epidemiol Community Health 2003;57:589–93. 10.1136/jech.57.8.589
    1. Drolet M, Brisson M, Maunsell E, et al. The psychosocial impact of an abnormal cervical smear result. Psychooncology 2012;21:1071–81. 10.1002/pon.2003
    1. McCaffery KJ, Irwig L, Turner R, et al. Psychosocial outcomes of three triage methods for the management of borderline abnormal cervical smears: an open randomised trial. BMJ 2010;340(feb23 1):b4491. 10.1136/bmj.b4491
    1. Daley EM, Perrin KM, McDermott RJ, et al. The psychosocial burden of HPV: a mixed-method study of knowledge, attitudes and behaviors among HPV+ women. J Health Psychol 2010;15:279–90. 10.1177/1359105309351249
    1. Pirotta M, Ung L, Stein A, et al. The psychosocial burden of human papillomavirus related disease and screening interventions. Sex Transm Infect 2009;85:508–13. 10.1136/sti.2009.037028
    1. Lin L, Benard VB, Greek A, Roland KB, Hawkins NA, Saraiya M. Communication practices about HPV testing among providers in Federally Qualified Health Centers. Prev Med Rep 2015;2:436–9. 10.1016/j.pmedr.2015.05.006
    1. Kapeu AS, Luostarinen T, Jellum E, et al. Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am J Epidemiol 2009;169:480–8.10.1093/aje/kwn354
    1. Plummer M, Herrero R, Franceschi S, et al.; IARC Multi-centre Cervical Cancer Study Group. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 2003;14:805–14. 10.1023/B:CACO.0000003811.98261.3e
    1. de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol 2018;47:2–13. 10.1016/j.bpobgyn.2017.08.015
    1. Louie KS, Castellsague X, de Sanjose S, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Smoking and passive smoking in cervical cancer risk: pooled analysis of couples from the IARC multicentric case-control studies. Cancer Epidemiol Biomarkers Prev 2011;20:1379–90. 10.1158/1055-9965.EPI-11-0284
    1. Nelson HD, Cantor A, Wagner J, et al. Effectiveness of patient navigation to increase cancer screening in populations adversely affected by health disparities: a meta-analysis. J Gen Intern Med 2020;35:3026–35. 10.1007/s11606-020-06020-9
    1. Stillson T, Knight AL, Elswick RK Jr. The effectiveness and safety of two cervical cytologic techniques during pregnancy. J Fam Pract 1997;45:159–63.
    1. Foster JC, Smith HL. Use of the Cytobrush for Papanicolaou smear screens in pregnant women. J Nurse Midwifery 1996;41:211–7. 10.1016/0091-2182(96)00013-4
    1. Paraiso MF, Brady K, Helmchen R, Roat TW. Evaluation of the endocervical Cytobrush and Cervex-Brush in pregnant women. Obstet Gynecol 1994;84:539–43.
    1. Silverberg MJ, Leyden WA, Chi A, et al. Human immunodeficiency virus (HIV)- and non-HIV-associated immunosuppression and risk of cervical neoplasia. Obstet Gynecol 2018;131:47–55. 10.1097/AOG.0000000000002371
    1. Videla S, Tarrats A, Ornelas A, et al. Incidence of cervical high-grade squamous intraepithelial lesions in HIV-1-infected women with no history of cervical pathology: up to 17 years of follow-up. Int J STD AIDS 2019;30:56–63. 10.1177/0956462418792653
    1. Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS 2018;32:795–808. 10.1097/QAD.0000000000001765
    1. Sawaya GF, Lamar R, Perkins RB. Managing minimally abnormal cervical cancer screening test results. JAMA 2020;324:1557. 10.1001/jama.2020.12488
    1. Silverberg MJ, Lau B, Justice AC, et al.; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012;54:1026–34. 10.1093/cid/cir1012
    1. Tomassi MJ, Abbas MA, Klaristenfeld DD. Expectant management surveillance for patients at risk for invasive squamous cell carcinoma of the anus: a large US healthcare system experience. Int J Colorectal Dis 2019;34:47–54. 10.1007/s00384-018-3167-7
    1. Colón-López V, Shiels MS, Machin M, et al. Anal cancer risk among people with HIV infection in the United States. J Clin Oncol 2018;36:68–75. 10.1200/JCO.2017.74.9291
    1. Machalek DA, Grulich AE, Jin F, Templeton DJ, Poynten IM. The epidemiology and natural history of anal human papillomavirus infection in men who have sex with men. Sex Health 2012;9:527–37. 10.1071/SH12043
    1. Deshmukh AA, Suk R, Shiels MS, et al. Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001–2015. J Natl Cancer Inst 2020;112:829–38. 10.1093/jnci/djz219
    1. Edgren G, Sparén P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol 2007;8:311–6. 10.1016/S1470-2045(07)70043-8
    1. Chaturvedi AK, Engels EA, Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 2007;99:1634–43. 10.1093/jnci/djm201
    1. Suk R, Mahale P, Sonawane K, et al. Trends in risks for second primary cancers associated with index human papillomavirus-associated cancers. JAMA Netw Open 2018;1:e181999. 10.1001/jamanetworkopen.2018.1999
    1. Hillman RJ, Berry-Lawhorn JM, Ong JJ, et al.; International Anal Neoplasia Society. International Anal Neoplasia Society guidelines for the practice of digital anal rectal examination. J Low Genit Tract Dis 2019;23:138–46. 10.1097/LGT.0000000000000458
    1. Ong JJ, Grulich A, Walker S, et al. Baseline findings from the Anal Cancer Examination (ACE) study: screening using digital ano-rectal examination in HIV-positive men who have sex with men. J Med Screen 2016;23:70–6. 10.1177/0969141315604658
    1. Read TR, Vodstrcil L, Grulich AE, et al. Acceptability of digital anal cancer screening examinations in HIV-positive homosexual men. HIV Med 2013;14:491–6. 10.1111/hiv.12035
    1. Jin F, Grulich AE, Poynten IM, et al.; SPANC Study Team. The performance of anal cytology as a screening test for anal HSILs in homosexual men. Cancer Cytopathol 2016;124:415–24. 10.1002/cncy.21702
    1. Silva M, Peixoto A, Sarmento JA, Coelho R, Macedo G. Anal cytology, histopathology and anoscopy in an anal dysplasia screening program: is anal cytology enough? Rev Esp Enferm Dig 2018;110:109–14. 10.17235/reed.2018.5678/2018
    1. Iribarren Díaz M, Ocampo Hermida A, González-Carreró Fojón J, et al. Preliminary results of a screening program for anal cancer and its precursors for HIV-infected men who have sex with men in Vigo-Spain [Spanish]. Rev Esp Enferm Dig 2017;109:242–9. 10.17235/reed.2017.4274/2016
    1. Burgos J, Hernández-Losa J, Landolfi S, et al. The role of oncogenic human papillomavirus determination for diagnosis of high-grade anal intraepithelial neoplasia in HIV-infected MSM. AIDS 2017;31:2227–33. 10.1097/QAD.0000000000001605
    1. Cheng SH, Wang CC, Chang SL, Chu FY, Hsueh YM. Oncogenic human papillomavirus is not helpful for cytology screening of the precursor lesions of anal cancers in Taiwanese men who are infected with human immunodeficiency virus. Int J Clin Oncol 2015;20:943–51. 10.1007/s10147-015-0804-9
    1. Hidalgo-Tenorio C, Rivero-Rodriguez M, Gil-Anguita C, et al. The role of polymerase chain reaction of high-risk human papilloma virus in the screening of high-grade squamous intraepithelial lesions in the anal mucosa of human immunodeficiency virus-positive males having sex with males. PLoS One 2015;10:e0123590. 10.1371/journal.pone.0123590
    1. Richel O, de Vries HJ, van Noesel CJ, Dijkgraaf MG, Prins JM. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncol 2013;14:346–53. 10.1016/S1470-2045(13)70067-6
    1. Goldstone SE, Johnstone AA, Moshier EL. Long-term outcome of ablation of anal high-grade squamous intraepithelial lesions: recurrence and incidence of cancer. Dis Colon Rectum 2014;57:316–23. 10.1097/DCR.0000000000000058
    1. Tong WW, Shepherd K, Garland S, et al.; Study of the Prevention of Anal Cancer (SPANC) team. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions. J Infect Dis 2015;211:405–15. 10.1093/infdis/jiu461
    1. Tong WW, Jin F, McHugh LC, et al. Progression to and spontaneous regression of high-grade anal squamous intraepithelial lesions in HIV-infected and uninfected men. AIDS 2013;27:2233–43. 10.1097/QAD.0b013e3283633111
    1. Shin EC, Jeong SH. Natural history, clinical manifestations, and pathogenesis of hepatitis A. Cold Spring Harb Perspect Med 2018;8:a031708. 10.1101/cshperspect.a031708
    1. Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep 2020;69(No. RR-5). 10.15585/mmwr.rr6905a1
    1. Foster MA, Hofmeister MG, Kupronis BA, et al. Increase in hepatitis A virus infections—United States, 2013–2018. MMWR Morb Mortal Wkly Rep 2019;68:413–5. 10.15585/mmwr.mm6818a2
    1. Bower WA, Nainan OV, Han X, Margolis HS. Duration of viremia in hepatitis A virus infection. J Infect Dis 2000;182:12–7. 10.1086/315701
    1. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, André FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995;171(Suppl 1):S44–9. 10.1093/infdis/171.Supplement_1.S44
    1. Sharapov UM, Bulkow LR, Negus SE, et al. Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up. Hepatology 2012;56:516–22. 10.1002/hep.25687
    1. Mosites E, Gounder P, Snowball M, et al. Hepatitis A vaccine immune response 22 years after vaccination. J Med Virol 2018;90:1418–22. 10.1002/jmv.25197
    1. Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N. Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine 2015;33:5723–7. 10.1016/j.vaccine.2015.07.008
    1. Hens N, Habteab Ghebretinsae A, Hardt K, Van Damme P, Van Herck K. Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine 2014;32:1507–13. 10.1016/j.vaccine.2013.10.088
    1. Mosites E, Seeman S, Negus S, et al. Immunogenicity of the hepatitis A vaccine 20 years after infant immunization. Vaccine 2020;38:4940–3. 10.1016/j.vaccine.2020.05.069
    1. Yin S, Barker L, Ly KN, et al. Susceptibility to hepatitis A virus infection in the United States, 2007–2016. Clin Infect Dis 2020;71:e571–9. 10.1093/cid/ciaa298
    1. Moro PL, Arana J, Marquez PL, et al. Is there any harm in administering extra-doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007–2017. Vaccine 2019;37:3730–4. 10.1016/j.vaccine.2019.04.088
    1. Winokur PL, Stapleton JT. Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 1992;14:580–6. 10.1093/clinids/14.2.580
    1. Alter HJ, Purcell RH, Gerin JL, et al. Transmission of hepatitis B to chimpanzees by hepatitis B surface antigen-positive saliva and semen. Infect Immun 1977;16:928–33. 10.1128/IAI.16.3.928-933.1977
    1. Villarejos VM, Visoná KA, Gutiérrez A, Rodríguez A. Role of saliva, urine and feces in the transmission of type B hepatitis. N Engl J Med 1974;291:1375–8. 10.1056/NEJM197412262912602
    1. Busch K, Thimme R. Natural history of chronic hepatitis B virus infection. Med Microbiol Immunol (Berl) 2015;204:5–10. 10.1007/s00430-014-0369-7
    1. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995;20:992–1000. 10.1093/clinids/20.4.992
    1. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005;34:1329–39. 10.1093/ije/dyi206
    1. Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998–2008. Ann Intern Med 2009;150:33–9. 10.7326/0003-4819-150-1-200901060-00007
    1. Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet 1989;1:889–93. 10.1016/S0140-6736(89)92876-6
    1. Martinson FE, Weigle KA, Royce RA, Weber DJ, Suchindran CM, Lemon SM. Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana. Am J Epidemiol 1998;147:478–87. 10.1093/oxfordjournals.aje.a009474
    1. CDC. Healthcare-associated hepatitis B and C outbreaks (≥2 cases) reported to the CDC 2008–2019. Atlanta, GA: US Department of Health and Human Services, CDC; 2019.
    1. Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep 2018;67:455–8. 10.15585/mmwr.mm6715a5
    1. Lu PJ, Byrd KK, Murphy TV, Weinbaum C. Hepatitis B vaccination coverage among high-risk adults 18–49 years, U.S., 2009. Vaccine 2011;29:7049–57. 10.1016/j.vaccine.2011.07.030
    1. Williams WW, Lu PJ, O’Halloran A, et al. Surveillance of vaccination coverage among adult populations—United States, 2015. MMWR Surveill Summ 2017;66(No. SS-11). 10.15585/mmwr.ss6611a1
    1. CDC. Hepatitis B vaccination coverage among adults—United States, 2004. MMWR Morb Mortal Wkly Rep 2006;55:509–11.
    1. MacKellar DA, Valleroy LA, Secura GM, et al.; Young Men’s Survey Study Group. Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health 2001;91:965–71. 10.2105/AJPH.91.6.965
    1. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67:1560–99. 10.1002/hep.29800
    1. Ezeanolue E, Harriman K, Hunter P, Kroger A, Pellegrini C. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP) [Internet]. Atlanta, GA: US Department of Health and Human Services, CDC, Advisory Committee on Immunization Practices; 2020.
    1. Bruce MG, Bruden D, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis 2016;214:16–22. 10.1093/infdis/jiv748
    1. McMahon BJ, Bulkow LR, Singleton RJ, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 2011;54:801–7. 10.1002/hep.24442
    1. Simons BC, Spradling PR, Bruden DJ, et al. A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen. J Infect Dis 2016;214:273–80. 10.1093/infdis/jiw142
    1. Bohlke K, Davis RL, Marcy SM, et al.; Vaccine Safety Datalink Team. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003;112:815–20. 10.1542/peds.112.4.815
    1. André FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989;87(3A):14S–20. 10.1016/0002-9343(89)90525-1
    1. Abara WE, Qaseem A, Schillie S, McMahon BJ, Harris AM; High Value Care Task Force of the American College of Physicians and the Centers for Disease Control and Prevention. Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med 2017;167:794–804. 10.7326/M17-1106
    1. Minuk GY, Bohme CE, Bowen TJ, et al. Efficacy of commercial condoms in the prevention of hepatitis B virus infection. Gastroenterology 1987;93:710–4. 10.1016/0016-5085(87)90431-8
    1. Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013–2016. Hepatology 2019;69:1020–31. 10.1002/hep.30297
    1. Lockart I, Matthews GV, Danta M. Sexually transmitted hepatitis C infection: the evolving epidemic in HIV-positive and HIV-negative MSM. Curr Opin Infect Dis 2019;32:31–7. 10.1097/QCO.0000000000000515
    1. Terrault NA, Dodge JL, Murphy EL, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology 2013;57:881–9. 10.1002/hep.26164
    1. Price JC, McKinney JE, Crouch PC, et al. Sexually acquired hepatitis C infection in HIV-uninfected men who have sex with men using preexposure prophylaxis against HIV. J Infect Dis 2019;219:1373–6. 10.1093/infdis/jiy670
    1. Tohme RA, Holmberg SD. Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clin Infect Dis 2012;54:1167–78. 10.1093/cid/cir991
    1. Brettler DB, Mannucci PM, Gringeri A, et al. The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study. Blood 1992;80:540–3. 10.1182/blood.V80.2.540.540
    1. Kao JH, Hwang YT, Chen PJ, et al. Transmission of hepatitis C virus between spouses: the important role of exposure duration. Am J Gastroenterol 1996;91:2087–90.
    1. Fierer DS, Mullen MP, Dieterich DT, Isabel Fiel M, Branch AD. Early-onset liver fibrosis due to primary hepatitis C virus infection is higher over time in HIV-infected men. Clin Infect Dis 2012;55:887–8, author reply 888–9. 10.1093/cid/cis538
    1. van de Laar TJ, van der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007;196:230–8. 10.1086/518796
    1. Nijmeijer BM, Koopsen J, Schinkel J, Prins M, Geijtenbeek TB. Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men. J Int AIDS Soc 2019;22(Suppl 6):e25348. 10.1002/jia2.25348
    1. Todesco E, Day N, Amiel C, et al. High clustering of acute HCV infections and high rate of associated STIs among Parisian HIV-positive male patients. Int J Antimicrob Agents 2019;53:678–81. 10.1016/j.ijantimicag.2019.02.002
    1. Jin F, Matthews GV, Grulich AE. Sexual transmission of hepatitis C virus among gay and bisexual men: a systematic review. Sex Health 2017;14:28–41. 10.1071/SH16141
    1. Hegazi A, Lee MJ, Whittaker W, et al. Chemsex and the city: sexualised substance use in gay bisexual and other men who have sex with men attending sexual health clinics. Int J STD AIDS 2017;28:362–6. Erratum in: Int J STD AIDS 2017;28:423. 10.1177/0956462416651229
    1. Page EE, Nelson M. Hepatitis C and sex. Clin Med (Lond) 2016;16:189–92. 10.7861/clinmedicine.16-2-189
    1. Apers L, Vanden Berghe W, De Wit S, et al. Risk factors for HCV acquisition among HIV-positive MSM in Belgium. J Acquir Immune Defic Syndr 2015;68:585–93. 10.1097/QAI.0000000000000528
    1. Daskalopoulou M, Rodger AJ, Phillips AN, et al.; ASTRA Study Group. Condomless sex in HIV-diagnosed men who have sex with men in the UK: prevalence, correlates, and implications for HIV transmission. Sex Transm Infect 2017;93:590–8. 10.1136/sextrans-2016-053029
    1. Vanhommerig JW, Lambers FA, Schinkel J, et al.; MOSAIC (MSM Observational Study of Acute Infection With Hepatitis C) Study Group. Risk factors for sexual transmission of hepatitis C virus among human immunodeficiency virus-infected men who have sex with men: a case-control study. Open Forum Infect Dis 2015;2:ofv115. 10.1093/ofid/ofv115
    1. Turner SS, Gianella S, Yip MJ, et al. Shedding of hepatitis C virus in semen of human immunodeficiency virus-infected men. Open Forum Infect Dis 2016;3:ofw057.
    1. Foster AL, Gaisa MM, Hijdra RM, et al. Shedding of hepatitis C virus into the rectum of HIV-infected men who have sex with men. Clin Infect Dis 2017;64:284–8. 10.1093/cid/ciw740
    1. Hammer GP, Kellogg TA, McFarland WC, et al. Low incidence and prevalence of hepatitis C virus infection among sexually active non-intravenous drug-using adults, San Francisco, 1997–2000. Sex Transm Dis 2003;30:919–24. 10.1097/01.OLQ.0000091152.31366.E6
    1. Roy KM, Goldberg DJ, Hutchinson S, Cameron SO, Wilson K, MacDonald L. Hepatitis C virus among self declared non-injecting sexual partners of injecting drug users. J Med Virol 2004;74:62–6. 10.1002/jmv.20146
    1. Mele A, Stroffolini T, Tosti ME, et al. Heterosexual transmission of hepatitis C in Italy. J Med Virol 1999;57:111–3. 10.1002/(SICI)1096-9071(199902)57:2<111::AID-JMV4>;2-C
    1. Rauch A, Rickenbach M, Weber R, et al.; Swiss HIV Cohort Study. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005;41:395–402. 10.1086/431486
    1. Browne R, Asboe D, Gilleece Y, et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? Sex Transm Infect 2004;80:326–7. 10.1136/sti.2003.008532
    1. Danta M, Brown D, Bhagani S, et al.; HIV and Acute HCV (HAAC) group. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007;21:983–91. 10.1097/QAD.0b013e3281053a0c
    1. Ghosn J, Pierre-François S, Thibault V, et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med 2004;5:303–6. 10.1111/j.1468-1293.2004.00225.x
    1. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009;136:1609–17. 10.1053/j.gastro.2009.02.006
    1. Hoornenborg E, Achterbergh RCA, Schim van der Loeff MF, et al.; Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Initiative, MOSAIC study group. MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection. AIDS 2017;31:1603–10. 10.1097/QAD.0000000000001522
    1. Gras J, Mahjoub N, Charreau I, et al.; IPERGAY Study Group. Early diagnosis and risk factors of acute hepatitis C in high-risk MSM on preexposure prophylaxis. AIDS 2020;34:47–52. 10.1097/QAD.0000000000002364
    1. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26(Suppl 1):15S–20S. 10.1002/hep.510260703
    1. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology 2001;33:321–7. 10.1053/jhep.2001.22112
    1. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992;327:1899–905. 10.1056/NEJM199212313272702
    1. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325:98–104. 10.1056/NEJM199107113250205
    1. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000;132:296–305. 10.7326/0003-4819-132-4-200002150-00008
    1. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005;9:383–98, vi. 10.1016/j.cld.2005.05.003
    1. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61(Suppl):S58–68. 10.1016/j.jhep.2014.07.012
    1. Zou S, Stramer SL, Dodd RY. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfus Med Rev 2012;26:119–28. 10.1016/j.tmrv.2011.07.007
    1. Bixler D, Annambholta P, Abara WE, et al. Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014–2017. Am J Transplant 2019;19:2570–82. 10.1111/ajt.15352
    1. CDC. Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013;62:362–5.
    1. Marincovich B, Castilla J, del Romero J, et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect 2003;79:160–2. 10.1136/sti.79.2.160
    1. Tahan V, Karaca C, Yildirim B, et al. Sexual transmission of HCV between spouses. Am J Gastroenterol 2005;100:821–4. 10.1111/j.1572-0241.2005.40879.x
    1. Vandelli C, Renzo F, Romanò L, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol 2004;99:855–9. 10.1111/j.1572-0241.2004.04150.x
    1. Fierer DS, Uriel AJ, Carriero DC, et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis 2008;198:683–6. 10.1086/590430
    1. Cottrell EB, Chou R, Wasson N, Rahman B, Guise JM. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013;158:109–13. 10.7326/0003-4819-158-2-201301150-00575
    1. Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005;192:1880–9. 10.1086/497701
    1. Barbosa C, Fraser H, Hoerger TJ, et al. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs. Addiction 2019;114:2267–78. 10.1111/add.14731
    1. Lambers FA, Prins M, Thomas X, et al.; MOSAIC (MSM Observational Study of Acute Infection with hepatitis C) study group. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS 2011;25:F21–7. 10.1097/QAD.0b013e32834bac44
    1. Martin TC, Singh GJ, McClure M, Nelson M. HCV reinfection among HIV-positive men who have sex with men: a pragmatic approach. Hepatology 2015;61:1437. 10.1002/hep.27391
    1. Ingiliz P, Martin TC, Rodger A, et al.; NEAT study group. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol 2017;66:282–7. 10.1016/j.jhep.2016.09.004
    1. Briat A, Dulioust E, Galimand J, et al. Hepatitis C virus in the semen of men coinfected with HIV-1: prevalence and origin. AIDS 2005;19:1827–35. 10.1097/01.aids.0000189847.98569.2d
    1. Bissessor M, Fairley CK, Read T, Denham I, Bradshaw C, Chen M. The etiology of infectious proctitis in men who have sex with men differs according to HIV status. Sex Transm Dis 2013;40:768–70. 10.1097/OLQ.0000000000000022
    1. Gutierrez-Fernandez J, Medina V, Hidalgo-Tenorio C, Abad R. Two cases of Neisseria meningitidis proctitis in HIV-positive men who have sex with men. Emerg Infect Dis 2017;23:542–3. 10.3201/eid2303.161039
    1. Levy I, Gefen-Halevi S, Nissan I, et al. Delayed diagnosis of colorectal sexually transmitted diseases due to their resemblance to inflammatory bowel diseases. Int J Infect Dis 2018;75:34–8. 10.1016/j.ijid.2018.08.004
    1. Lebari D. Syphilis presenting as colorectal cancer [Abstract 34216]. Sex Transm Dis 2014;41(Suppl 1):S4.
    1. Hines JZ, Pinsent T, Rees K, et al. Notes from the field: shigellosis outbreak among men who have sex with men and homeless persons—Oregon, 2015–2016. MMWR Morb Mortal Wkly Rep 2016;65:812–3. 10.15585/mmwr.mm6531a5
    1. Marchand-Senécal X, Bekal S, Pilon PA, Sylvestre JL, Gaudreau C. Campylobacter fetus cluster among men who have sex with men, Montreal, Quebec, Canada, 2014–2016. Clin Infect Dis 2017;65:1751–3. 10.1093/cid/cix610
    1. Klausner JD, Kohn R, Kent C. Etiology of clinical proctitis among men who have sex with men. Clin Infect Dis 2004;38:300–2. 10.1086/380838
    1. Stoner BP, Cohen SE. Lymphogranuloma venereum 2015: clinical presentation, diagnosis, and treatment. Clin Infect Dis 2015;61(Suppl 8):S865–73. 10.1093/cid/civ756
    1. Mohrmann G, Noah C, Sabranski M, Sahly H, Stellbrink HJ. Ongoing epidemic of lymphogranuloma venereum in HIV-positive men who have sex with men: how symptoms should guide treatment. J Int AIDS Soc 2014;17(Suppl 3):19657. 10.7448/IAS.17.4.19657
    1. Hoffmann C, Sahly H, Jessen A, et al. High rates of quinolone-resistant strains of Shigella sonnei in HIV-infected MSM. Infection 2013;41:999–1003. 10.1007/s15010-013-0501-4
    1. Heiman KE, Karlsson M, Grass J, et al.; CDC. Notes from the field: Shigella with decreased susceptibility to azithromycin among men who have sex with men—United States, 2002–2013. MMWR Morb Mortal Wkly Rep 2014;63:132–3.
    1. Galiczynski EM Jr, Elston DM. What’s eating you? Pubic lice (Pthirus pubis). Cutis 2008;81:109–14.
    1. Meinking TL, Serrano L, Hard B, et al. Comparative in vitro pediculicidal efficacy of treatments in a resistant head lice population in the United States. Arch Dermatol 2002;138:220–4. 10.1001/archderm.138.2.220
    1. Yoon KS, Gao JR, Lee SH, Clark JM, Brown L, Taplin D. Permethrin-resistant human head lice, Pediculus capitis, and their treatment. Arch Dermatol 2003;139:994–1000. 10.1001/archderm.139.8.994
    1. Burkhart CG, Burkhart CN. Oral ivermectin for Phthirus pubis. J Am Acad Dermatol 2004;51:1037–8. 10.1016/j.jaad.2004.04.041
    1. Scott GR, Chosidow O; IUSTI/WHO. European guideline for the management of pediculosis pubis, 2010. Int J STD AIDS 2011;22:304–5. 10.1258/ijsa.2011.011114
    1. Goldust M, Rezaee E, Raghifar R, Hemayat S. Comparing the efficacy of oral ivermectin vs malathion 0.5% lotion for the treatment of scabies. Skinmed 2014;12:284–7.
    1. Veraldi S, Schianchi R, Ramoni S, Nazzaro G. Pubic hair removal and Phthirus pubis infestation. Int J STD AIDS 2018;29:103–4. 10.1177/0956462417740292
    1. Leung AKC, Lam JM, Leong KF. Scabies: a neglected global disease. Curr Pediatr Rev 2020;16:33–42. 10.2174/1573396315666190717114131
    1. Engelman D, Cantey PT, Marks M, et al. The public health control of scabies: priorities for research and action. Lancet 2019;394:81–92. 10.1016/S0140-6736(19)31136-5
    1. Shimose L, Munoz-Price LS. Diagnosis, prevention, and treatment of scabies. Curr Infect Dis Rep 2013;15:426–31. 10.1007/s11908-013-0354-0
    1. Walter B, Heukelbach J, Fengler G, Worth C, Hengge U, Feldmeier H. Comparison of dermoscopy, skin scraping, and the adhesive tape test for the diagnosis of scabies in a resource-poor setting. Arch Dermatol 2011;147:468–73. 10.1001/archdermatol.2011.51
    1. Micali G, Lacarrubba F, Verzì AE, Chosidow O, Schwartz RA. Scabies: advances in noninvasive diagnosis. PLoS Negl Trop Dis 2016;10:e0004691. 10.1371/journal.pntd.0004691
    1. Strong M, Johnstone P. Interventions for treating scabies. Cochrane Database Syst Rev 2007;(3):CD000320.
    1. Abdel-Raheem TA, Méabed EM, Nasef GA, Abdel Wahed WY, Rohaim RM. Efficacy, acceptability and cost effectiveness of four therapeutic agents for treatment of scabies. J Dermatolog Treat 2016;27:473–9. 10.3109/09546634.2016.1151855
    1. Alipour H, Goldust M. The efficacy of oral ivermectin vs. sulfur 10% ointment for the treatment of scabies. Ann Parasitol 2015;61:79–84.
    1. Al Jaff DAA, Amin MHM. Comparison of the effectiveness of sulphur ointment, permethrin and oral ivermectin in treatment of scabies. Res J Pharm Biol Chem Sci 2018;9:670–6.
    1. Goldust M, Rezaee E, Raghifar R, Hemayat S. Treatment of scabies: the topical ivermectin vs. permethrin 2.5% cream. Ann Parasitol 2013;59:79–84.
    1. Ahmad HM, Abdel-Azim ES, Abdel-Aziz RT. Clinical efficacy and safety of topical versus oral ivermectin in treatment of uncomplicated scabies. Dermatol Ther (Heidelb) 2016;29:58–63. 10.1111/dth.12310
    1. Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. N Engl J Med 2010;362:717–25. 10.1056/NEJMct0910329
    1. Chiu S, Argaez C. Ivermectin for parasitic skin infections of scabies: a review of comparative clinical effectiveness, cost-effectiveness, and guidelines. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2019.
    1. Nolan K, Kamrath J, Levitt J. Lindane toxicity: a comprehensive review of the medical literature. Pediatr Dermatol 2012;29:141–6. 10.1111/j.1525-1470.2011.01519.x
    1. Mounsey KE, Holt DC, McCarthy J, Currie BJ, Walton SF. Scabies: molecular perspectives and therapeutic implications in the face of emerging drug resistance. Future Microbiol 2008;3:57–66. 10.2217/17460913.3.1.57
    1. Mounsey KE, Holt DC, McCarthy JS, Currie BJ, Walton SF. Longitudinal evidence of increasing in vitro tolerance of scabies mites to ivermectin in scabies-endemic communities. Arch Dermatol 2009;145:840–1. 10.1001/archdermatol.2009.125
    1. Mounsey KE, McCarthy JS, Walton SF. Scratching the itch: new tools to advance understanding of scabies. Trends Parasitol 2013;29:35–42. 10.1016/j.pt.2012.09.006
    1. van der Linden N, van Gool K, Gardner K, et al. A systematic review of scabies transmission models and data to evaluate the cost-effectiveness of scabies interventions. PLoS Negl Trop Dis 2019;13:e0007182. 10.1371/journal.pntd.0007182
    1. Roberts LJ, Huffam SE, Walton SF, Currie BJ. Crusted scabies: clinical and immunological findings in seventy-eight patients and a review of the literature. J Infect 2005;50:375–81. 10.1016/j.jinf.2004.08.033
    1. Ortega-Loayza AG, McCall CO, Nunley JR. Crusted scabies and multiple dosages of ivermectin. J Drugs Dermatol 2013;12:584–5.
    1. Bouvresse S, Chosidow O. Scabies in healthcare settings. Curr Opin Infect Dis 2010;23:111–8. 10.1097/QCO.0b013e328336821b
    1. Marotta M, Toni F, Dallolio L, Toni G, Leoni E. Management of a family outbreak of scabies with high risk of spread to other community and hospital facilities. Am J Infect Control 2018;46:808–13. 10.1016/j.ajic.2017.12.004
    1. Romani L, Whitfeld MJ, Koroivueta J, et al. Mass drug administration for scabies control in a population with endemic disease. N Engl J Med 2015;373:2305–13. 10.1056/NEJMoa1500987
    1. Ackerman DR, Sugar NF, Fine DN, Eckert LO. Sexual assault victims: factors associated with follow-up care. Am J Obstet Gynecol 2006;194:1653–9. 10.1016/j.ajog.2006.03.014
    1. Parekh V, Beaumont Brown C. Follow up of patients who have been recently sexually assaulted. Sex Transm Infect 2003;79:349. 10.1136/sti.79.4.349-a
    1. Vrees RA. Evaluation and management of female victims of sexual assault. Obstet Gynecol Surv 2017;72:39–53. 10.1097/OGX.0000000000000390
    1. Unger ER, Fajman NN, Maloney EM, et al. Anogenital human papillomavirus in sexually abused and nonabused children: a multicenter study. Pediatrics 2011;128:e658–65. 10.1542/peds.2010-2247
    1. Kreimer AR, Rodriguez AC, Hildesheim A, et al.; CVT Vaccine Group. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011;103:1444–51. 10.1093/jnci/djr319
    1. Claydon E, Murphy S, Osborne EM, Kitchen V, Smith JR, Harris JR. Rape and HIV. Int J STD AIDS 1991;2:200–1. 10.1177/095646249100200310
    1. Murphy S, Kitchen V, Harris JR, Forster SM. Rape and subsequent seroconversion to HIV. BMJ 1989;299:718. 10.1136/bmj.299.6701.718
    1. Cardo DM, Culver DH, Ciesielski CA, et al.; CDC Needlestick Surveillance Group. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997;337:1485–90. 10.1056/NEJM199711203372101
    1. Kuhar DT, Henderson DK, Struble KA, et al.; US Public Health Service Working Group. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol 2013;34:875–92. 10.1086/672271
    1. Du Mont J, Myhr TL, Husson H, Macdonald S, Rachlis A, Loutfy MR. HIV postexposure prophylaxis use among Ontario female adolescent sexual assault victims: a prospective analysis. Sex Transm Dis 2008;35:973–8.
    1. Neu N, Heffernan-Vacca S, Millery M, Stimell M, Brown J. Postexposure prophylaxis for HIV in children and adolescents after sexual assault: a prospective observational study in an urban medical center. Sex Transm Dis 2007;34:65–8. 10.1097/01.olq.0000225329.07765.d8
    1. Loutfy MR, Macdonald S, Myhr T, et al. Prospective cohort study of HIV post-exposure prophylaxis for sexual assault survivors. Antivir Ther 2008;13:87–95.
    1. Inciarte A, Leal L, Masfarre L, et al.; Sexual Assault Victims Study Group. Post-exposure prophylaxis for HIV infection in sexual assault victims. HIV Med 2020;21:43–52. 10.1111/hiv.12797
    1. Announcement: Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV—United States, 2016. MMWR Morb Mortal Wkly Rep 2016;65:458. 10.15585/mmwr.mm6517a5
    1. Ford N, Venter F, Irvine C, Beanland RL, Shubber Z. Starter packs versus full prescription of antiretroviral drugs for postexposure prophylaxis: a systematic review. Clin Infect Dis 2015;60(Suppl 3):S182–6. 10.1093/cid/civ093
    1. Jenny C, Crawford-Jakubiak JE; Committee on Child Abuse and Neglect; American Academy of Pediatrics. The evaluation of children in the primary care setting when sexual abuse is suspected. Pediatrics 2013;132:e558–67. 10.1542/peds.2013-1741
    1. Girardet RG, Lahoti S, Howard LA, et al. Epidemiology of sexually transmitted infections in suspected child victims of sexual assault. Pediatrics 2009;124:79–86. 10.1542/peds.2008-2947
    1. Black CM, Driebe EM, Howard LA, et al. Multicenter study of nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in children being evaluated for sexual abuse. Pediatr Infect Dis J 2009;28:608–13. 10.1097/INF.0b013e31819b592e
    1. Trotman GE, Young-Anderson C, Deye KP. Acute sexual assault in the pediatric and adolescent population. J Pediatr Adolesc Gynecol 2016;29:518–26. 10.1016/j.jpag.2015.05.001
    1. Schwandt A, Williams C, Beigi RH. Perinatal transmission of Trichomonas vaginalis: a case report. J Reprod Med 2008;53:59–61.
    1. Bell TA, Stamm WE, Wang SP, Kuo CC, Holmes KK, Grayston JT. Chronic Chlamydia trachomatis infections in infants. JAMA 1992;267:400–2. 10.1001/jama.1992.03480030078041
    1. Adachi K, Nielsen-Saines K, Klausner JD. Chlamydia trachomatis infection in pregnancy: the global challenge of preventing adverse pregnancy and infant outcomes in sub-Saharan Africa and Asia. BioMed Res Int 2016;2016:9315757. 10.1155/2016/9315757
    1. Schachter J, Grossman M, Sweet RL, Holt J, Jordan C, Bishop E. Prospective study of perinatal transmission of Chlamydia trachomatis. JAMA 1986;255:3374–7. 10.1001/jama.1986.03370240044034
    1. Smith EM, Swarnavel S, Ritchie JM, Wang D, Haugen TH, Turek LP. Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents. Pediatr Infect Dis J 2007;26:836–40. 10.1097/INF.0b013e318124a4ae
    1. Sabeena S, Bhat P, Kamath V, Arunkumar G. Possible non-sexual modes of transmission of human papilloma virus. J Obstet Gynaecol Res 2017;43:429–35. 10.1111/jog.13248
    1. Adams JA, Farst KJ, Kellogg ND. Interpretation of medical findings in suspected child sexual abuse: an update for 2018. J Pediatr Adolesc Gynecol 2018;31:225–31. 10.1016/j.jpag.2017.12.011
    1. Kellogg ND, Melville JD, Lukefahr JL, Nienow SM, Russell EL. Genital and extragenital gonorrhea and chlamydia in children and adolescents evaluated for sexual abuse. Pediatr Emerg Care 2018;34:761–6. 10.1097/PEC.0000000000001014
    1. Gavril AR, Kellogg ND, Nair P. Value of follow-up examinations of children and adolescents evaluated for sexual abuse and assault. Pediatrics 2012;129:282–9. 10.1542/peds.2011-0804
    1. Bandea CI, Joseph K, Secor EW, et al. Development of PCR assays for detection of Trichomonas vaginalis in urine specimens. J Clin Microbiol 2013;51:1298–300. 10.1128/JCM.03101-12
    1. Gallion HR, Dupree LJ, Scott TA, Arnold DH. Diagnosis of Trichomonas vaginalis in female children and adolescents evaluated for possible sexual abuse: a comparison of the InPouch TV culture method and wet mount microscopy. J Pediatr Adolesc Gynecol 2009;22:300–5. 10.1016/j.jpag.2008.12.006
    1. Lalor K, McElvaney R. Child sexual abuse, links to later sexual exploitation/high-risk sexual behavior, and prevention/treatment programs. Trauma Violence Abuse 2010;11:159–77. 10.1177/1524838010378299
    1. Girardet RG, Lemme S, Biason TA, Bolton K, Lahoti S. HIV post-exposure prophylaxis in children and adolescents presenting for reported sexual assault. Child Abuse Negl 2009;33:173–8. 10.1016/j.chiabu.2008.05.010
    1. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Washington, DC: US Department of Health and Human Services, National Institutes of Health, AIDSinfo; 2020.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe